Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 1262 articles:
HTML format



Single Articles


    June 2024
  1. VOORDES G, Davison B, Biegus J, Edwards C, et al
    Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF.
    Eur J Heart Fail. 2024 Jun 14. doi: 10.1002/ejhf.3336.
    PubMed     Abstract available


  2. CARRETE A, Codina P, Bayes-Genis A
    Influence of temperature on haemodynamic changes in heart failure: A CardioMEMS pulmonary artery monitoring analysis.
    Eur J Heart Fail. 2024 Jun 14. doi: 10.1002/ejhf.3331.
    PubMed    


  3. PITT B, Rossignol P
    When chronic kidney disease (CKD) intersects with heart failure: Insights and implications of the identification of KDIGO-defined CKD in 1.4 million U.S. Veterans with heart failure.
    Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3298.
    PubMed    


  4. CHOI KH, Kang D, Park H, Park TK, et al
    In-hospital and long-term outcomes of cardiogenic shock complicating myocardial infarction versus heart failure.
    Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3333.
    PubMed     Abstract available


  5. ADAMOPOULOS S, Bonios M, Ben Gal T, Gustafsson F, et al
    Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
    Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3323.
    PubMed     Abstract available


  6. MONZO L, Kovar J, Borlaug BA, Benes J, et al
    Circulating beta-hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact.
    Eur J Heart Fail. 2024 Jun 10. doi: 10.1002/ejhf.3324.
    PubMed     Abstract available


  7. ANKER SD, Friede T, von Bardeleben RS, Butler J, et al
    Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.
    Eur J Heart Fail. 2024 Jun 7. doi: 10.1002/ejhf.3286.
    PubMed     Abstract available


  8. NAITO A, Kagami K, Yuasa N, Harada T, et al
    Prognostic utility of cardiopulmonary exercise testing with simultaneous exercise echocardiography in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Jun 6. doi: 10.1002/ejhf.3334.
    PubMed     Abstract available


  9. HARADA T, Naser JA, Tada A, Doi S, et al
    Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation.
    Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3322.
    PubMed     Abstract available


  10. VON STEIN P, Iliadis C
    EXPANDing horizons: Optimizing heart failure management following transcatheter edge-to-edge repair of mitral regurgitation.
    Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3327.
    PubMed    


  11. PASCUAL-FIGAL D, Nunez Villota J, Perez-Martinez MT, Gonzalez-Juanatey JR, et al
    Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA).
    Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3300.
    PubMed     Abstract available


  12. CANNATA A, Mizani MA, Bromage DI, Piper SE, et al
    A nationwide, population-based study on specialized care for acute heart failure throughout the COVID-19 pandemic.
    Eur J Heart Fail. 2024 Jun 4. doi: 10.1002/ejhf.3306.
    PubMed     Abstract available


  13. ALLACH Y, Barry-Loncq de Jong M, Clephas PRD, van Gent MWF, et al
    Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.
    Eur J Heart Fail. 2024 Jun 2. doi: 10.1002/ejhf.3303.
    PubMed     Abstract available


    May 2024
  14. CISNEROS-BARROSO E, Rossello X
    Sodium-glucose cotransporter 2 inhibitors in acute and chronic coronary syndrome with and without heart failure.
    Eur J Heart Fail. 2024 May 29. doi: 10.1002/ejhf.3321.
    PubMed    


  15. PAGNESI M, Serafini L, Chiarito M, Stolfo D, et al
    Impact of malnutrition in patients with severe heart failure.
    Eur J Heart Fail. 2024 May 29. doi: 10.1002/ejhf.3285.
    PubMed     Abstract available


  16. PABON MA, Vaduganathan M, Lam CSP
    Is the optimal dose of heart failure medical therapy different in women and men?
    Eur J Heart Fail. 2024 May 27. doi: 10.1002/ejhf.3320.
    PubMed    


  17. LAM CSP, Kober L, Kuwahara K, Lund LH, et al
    Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
    Eur J Heart Fail. 2024 May 23. doi: 10.1002/ejhf.3294.
    PubMed     Abstract available


  18. ROSANO GMC, Stolfo D, Anderson L, Abdelhamid M, et al
    Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2024 May 23. doi: 10.1002/ejhf.3284.
    PubMed     Abstract available


  19. SAVARESE G, Lindberg F, Cannata A, Chioncel O, et al
    How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2024 May 22. doi: 10.1002/ejhf.3295.
    PubMed     Abstract available


  20. BUTLER J, Arshad MS, Khan MS
    Role of anti-obesity drugs in heart failure regardless of ejection fraction.
    Eur J Heart Fail. 2024 May 16. doi: 10.1002/ejhf.3224.
    PubMed    


  21. PECK KH, Dulay MS, Hameed S, Rosano G, et al
    Intentional weight loss in overweight and obese patients with heart failure: A systematic review.
    Eur J Heart Fail. 2024 May 16. doi: 10.1002/ejhf.3270.
    PubMed     Abstract available


  22. KITTIPIBUL V, Mentz RJ, Clare RM, Wojdyla DM, et al
    On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
    Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3293.
    PubMed     Abstract available


  23. LASSEN MCH, Ostrominski JW, Inzucchi SE, Claggett BL, et al
    Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
    Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3269.
    PubMed     Abstract available


  24. VADUGANATHAN M, Claggett BL, Lam CSP, Pitt B, et al
    Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
    Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3253.
    PubMed     Abstract available


  25. VILLASCHI A, Chiarito M, Pagnesi M, Stolfo D, et al
    Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry.
    Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3234.
    PubMed     Abstract available


  26. CURTAIN JP, Talebi A, McIntosh A, McConnachie A, et al
    Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF.
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3290.
    PubMed     Abstract available


  27. ESQUIVEL GAYTAN A, Bomer N, Grote Beverborg N, van der Meer P, et al
    404-error "Disease not found": Unleashing the translational potential of -omics approaches beyond traditional disease classification in heart failure research.
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3268.
    PubMed     Abstract available


  28. PANICHELLA G, Tomasoni D, Aimo A
    Insulin-like growth factor binding protein-7 in heart failure: The challenge of moving from risk prediction to a biomarker-guided management.
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3287.
    PubMed    


  29. RICCARDI M, Borlaug BA, Inciardi RM
    Mitral regurgitation and heart failure with preserved ejection fraction: Should we treat the muscle, the valve, or both?
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3288.
    PubMed    


  30. VERBRUGGE FH
    Pushing the limits of natriuresis for poor kidneys in acute heart failure?
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3278.
    PubMed    


  31. ASSMUS B, Sossalla S
    What we claim to do and what we really do - a discrepancy in heart failure treatment.
    Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3279.
    PubMed    


  32. MALGIE J, Wilde MI, Clephas PRD, Emans ME, et al
    Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study.
    Eur J Heart Fail. 2024 May 12. doi: 10.1002/ejhf.3267.
    PubMed     Abstract available


  33. KARACAN MN, Doi SN, Yafasova A, Thune JJ, et al
    New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
    Eur J Heart Fail. 2024 May 11. doi: 10.1002/ejhf.3239.
    PubMed     Abstract available


  34. SOLOMON SD, Ostrominski JW, Vaduganathan M, Claggett B, et al
    Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
    Eur J Heart Fail. 2024 May 11. doi: 10.1002/ejhf.3266.
    PubMed     Abstract available


  35. PACKER M
    Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron-deficient heart failure.
    Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3238.
    PubMed     Abstract available


  36. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure.
    Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3237.
    PubMed     Abstract available


  37. ABDIN A, Kulenthiran S
    Improvements in quality of heart failure randomized controlled trials: Progress and persisting challenges!
    Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3289.
    PubMed    


  38. KESSLER M, Rottbauer W, von Bardeleben RS, Grasso C, et al
    Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge-to-edge repair: Results from the EXPAND study.
    Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3250.
    PubMed     Abstract available


  39. MEBAZAA A, Davison BA, Biegus J, Edwards C, et al
    Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study.
    Eur J Heart Fail. 2024 May 9. doi: 10.1002/ejhf.3265.
    PubMed     Abstract available


  40. SALAH HM, Fudim M
    Guideline-directed medical therapy in patients with heart failure with preserved ejection fraction and polypharmacy: Do not be afraid.
    Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3283.
    PubMed    


  41. WANG N, Rueter P, Ng M, Chandramohan S, et al
    Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3271.
    PubMed     Abstract available


  42. PANICHELLA G, Tomasoni D, Aimo A
    Metabolomics to predict heart failure development: A new frontier?
    Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3281.
    PubMed    



  43. Correction to "Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction".
    Eur J Heart Fail. 2024 May 7. doi: 10.1002/ejhf.3282.
    PubMed    


  44. YANG M, Kondo T, Talebi A, Jhund PS, et al
    Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
    Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3263.
    PubMed     Abstract available


  45. STOLZ L, Hausleiter J
    Under pressure: Advances in device-based heart failure therapy for patients with preserved or mildly reduced ejection fraction.
    Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3277.
    PubMed    


  46. ZAHIR ANJUM D, Strange JE, Fosbol E, Garred CH, et al
    Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study.
    Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3249.
    PubMed     Abstract available


  47. WOLSK E
    Is it worth tying the knot? The lifelong commitment between heart failure patients and pulmonary artery pressure monitoring.
    Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3275.
    PubMed    


  48. PATEL SS, Raman VK, Zhang S, Deedwania P, et al
    Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.
    Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3210.
    PubMed     Abstract available


  49. FUJIMOTO Y, Matsue Y
    Seeking ways to address non-cardiovascular death in patients with heart failure.
    Eur J Heart Fail. 2024 May 2. doi: 10.1002/ejhf.3280.
    PubMed    


  50. FERRARI A, Stolfo D, Uijl A, Orsini N, et al
    Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2024 May 2. doi: 10.1002/ejhf.3272.
    PubMed     Abstract available


    April 2024
  51. LIN YC, Sung YH, Tsai CH
    Letter regarding the article 'Use of natriuretic peptides and echocardiography for diagnosing heart failure'.
    Eur J Heart Fail. 2024 Apr 30. doi: 10.1002/ejhf.3273.
    PubMed    


  52. RAKISHEVA A, Sliwa K, Bauersachs J, Van Linthout S, et al
    Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3246.
    PubMed     Abstract available


  53. ARMENTARO G, Cassano V, Condoleo V, Magurno M, et al
    Association of sodium-glucose cotransporter 2 inhibitors with changes in comprehensive geriatric assessment in elderly diabetic patients with heart failure: Data from MAGIC-HF.
    Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3262.
    PubMed    


  54. RAO VN, Kozaily E, Tedford RJ
    Letting go of restraint: Tricuspid valve intervention in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3254.
    PubMed    


  55. HALAVINA K, Bartko PE, Nitsche C
    Obese or lean: Whom to prescribe sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3261.
    PubMed    


  56. NUNEZ E, Santas E, Merenciano H, Lorenzo-Hernandez M, et al
    Differential sex-related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study.
    Eur J Heart Fail. 2024 Apr 28. doi: 10.1002/ejhf.3252.
    PubMed     Abstract available


  57. GORTER TM, Hoendermis ES, van Veldhuisen DJ
    Interatrial shunting as a treatment for heart failure: Where do we stand?
    Eur J Heart Fail. 2024 Apr 25. doi: 10.1002/ejhf.3251.
    PubMed    


  58. GRASSI G, Dell'Oro R, Quarti-Trevano F
    Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes.
    Eur J Heart Fail. 2024 Apr 25. doi: 10.1002/ejhf.3258.
    PubMed    


  59. PAGNESI M, Adamo M, Metra M
    Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?
    Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3257.
    PubMed    


  60. LIEN T, Srikanth K, Ambrosy AP
    Follow the EMPULSE: In-hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3256.
    PubMed    


  61. ANKER SD, Friede T, von Bardeleben RS, Butler J, et al
    Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design.
    Eur J Heart Fail. 2024 Apr 23. doi: 10.1002/ejhf.3247.
    PubMed     Abstract available


  62. AMERI P, Mercurio V, Pollesello P, Anker MS, et al
    A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
    Eur J Heart Fail. 2024 Apr 19. doi: 10.1002/ejhf.3236.
    PubMed     Abstract available


  63. DHONT S, van den Acker G, van Loon T, Verbrugge FH, et al
    Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium.
    Eur J Heart Fail. 2024 Apr 17. doi: 10.1002/ejhf.3231.
    PubMed     Abstract available


  64. JALLOH MB, Bot VA, Borjaille CZ, Thabane L, et al
    Reporting quality of heart failure randomized controlled trials 2000-2020: Temporal trends in adherence to CONSORT criteria.
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3229.
    PubMed     Abstract available


  65. PORCARI A, Fontana M
    The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium-glucose cotransporter 2 inhibitors?
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3245.
    PubMed    


  66. OEXNER RR, Ahn H, Theofilatos K, Shah RA, et al
    Serum metabolomics improves risk stratification for incident heart failure.
    Eur J Heart Fail. 2024 Apr 16. doi: 10.1002/ejhf.3226.
    PubMed     Abstract available


  67. MULLENS W, Damman K, Dhont S, Banerjee D, et al
    Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3244.
    PubMed     Abstract available


  68. SETTERGREN C, Benson L, Shahim A, Dahlstrom U, et al
    Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3230.
    PubMed     Abstract available


  69. HEIDECKER B, Pagnesi M, Luscher TF
    Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3209.
    PubMed    


  70. LI J, Chen Y, Wang Y, Liu X, et al
    Impact of guideline-directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3208.
    PubMed     Abstract available


  71. ZILE MR, Lindenfeld J, Weaver FA, Zannad F, et al
    Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3232.
    PubMed     Abstract available


  72. PASCUAL-FIGAL DA, Hernandez-Vicente A, Pastor-Perez F, Martinez-Selles M, et al
    N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3222.
    PubMed     Abstract available


  73. BEAVERS CJ, Bhatt DL, Gotter G
    Reply to 'The pharmacist ally in heart failure: Useful when involved'.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3242.
    PubMed    


  74. UREY MA, Hibbert B, Jorde U, Eckman P, et al
    Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3241.
    PubMed     Abstract available


  75. FERREIRA JP, Packer M, Sattar N, Butler J, et al
    Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
    Eur J Heart Fail. 2024 Apr 8. doi: 10.1002/ejhf.3227.
    PubMed     Abstract available


  76. BHATT AS, Vaduganathan M, Jena BP, Suminska S, et al
    Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction.
    Eur J Heart Fail. 2024 Apr 7. doi: 10.1002/ejhf.3233.
    PubMed    


  77. LENSELINK C, Ricken KWLM, Groot HE, de Bruijne TJ, et al
    Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention.
    Eur J Heart Fail. 2024 Apr 4. doi: 10.1002/ejhf.3225.
    PubMed     Abstract available


  78. TROMP J, Kosiborod MN, Angermann CE, Collins SP, et al
    Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
    Eur J Heart Fail. 2024 Apr 4. doi: 10.1002/ejhf.3218.
    PubMed     Abstract available


  79. MORILLAS H, Nunez J, Moliner P
    Circulating levels of carbohydrate antigen 125 in chronic heart failure: Useful or futile?
    Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3212.
    PubMed    


  80. RODES-CABAU J, Lindenfeld J, Abraham WT, Zile MR, et al
    Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial.
    Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3215.
    PubMed     Abstract available


  81. MOKRI H, Clephas PRD, de Boer RA, van Baal P, et al
    Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands.
    Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3213.
    PubMed     Abstract available


  82. MARTENS P, Greene SJ, Mentz RJ, Li S, et al
    Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.
    Eur J Heart Fail. 2024 Apr 1. doi: 10.1002/ejhf.3207.
    PubMed     Abstract available



  83. HFA Winter Research Meeting on Translational Heart Failure 2024 In collaboration with the ESC Working Group on Myocardial Function, 11 - 14 May 2024, Lisbon & Online.
    Eur J Heart Fail. 2024;26 Suppl 1:3-16.
    PubMed    


  84. PATEL N, Yeboah J
    Multimorbidity in the era of increasing life expectancy and aging population.
    Eur J Heart Fail. 2024;26:869-870.
    PubMed    


  85. ROMMEL KP, Bonnet G, Fortmeier V, Stolz L, et al
    Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry.
    Eur J Heart Fail. 2024;26:1004-1014.
    PubMed     Abstract available


  86. COATS AJS
    Sodium-glucose cotransporter 2 inhibitors and skeletal muscle.
    Eur J Heart Fail. 2024;26:936-937.
    PubMed    


  87. D'AMARIO D, Laborante R, Santangeli P
    Comorbidities and cardiac resynchronization therapy: Do we talk the talk or should we walk the walk?
    Eur J Heart Fail. 2024;26:1047-1050.
    PubMed    


  88. SATTAR N, Butler J, Lee MMY, Harrington J, et al
    Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.
    Eur J Heart Fail. 2024;26:900-909.
    PubMed     Abstract available


  89. KERAMIDA K, Yang EH, Deswal A
    Moving theory and reality closer together in cardio-oncology training.
    Eur J Heart Fail. 2024;26:772-775.
    PubMed    


  90. TANAKA T, Sugiura A, Kavsur R, Ozturk C, et al
    Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge-to-edge repair.
    Eur J Heart Fail. 2024;26:1015-1024.
    PubMed     Abstract available


  91. RASTOGI T, Ferreira JP, Butler J, Kraus BJ, et al
    Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
    Eur J Heart Fail. 2024;26:885-896.
    PubMed     Abstract available


  92. FUDIM M, Dalgaard F, Friedman DJ, Abraham WT, et al
    Comorbidities and clinical response to cardiac resynchronization therapy: Patient-level meta-analysis from eight clinical trials.
    Eur J Heart Fail. 2024;26:1039-1046.
    PubMed     Abstract available


    March 2024
  93. RAO VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, et al
    Serial direct sodium removal in patients with heart failure and diuretic resistance.
    Eur J Heart Fail. 2024 Mar 31. doi: 10.1002/ejhf.3196.
    PubMed     Abstract available


  94. DONAL E, Gegout L, Lee KC
    More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!
    Eur J Heart Fail. 2024 Mar 27. doi: 10.1002/ejhf.3201.
    PubMed    


  95. LIM J, Hashemian M, Blechter B, Roger VL, et al
    Pre-diagnostic free androgen and estradiol levels influence heart failure risk in both women and men: A prospective cohort study in the UK Biobank.
    Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3189.
    PubMed     Abstract available


  96. DEHARO F, Grapsa J
    Global longitudinal strain as a predictor of risk in patients with heart failure with preserved ejection fraction: A deserved role?
    Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3211.
    PubMed    


  97. VAN DER LINDEN L, Karapinar-Carkit F, Forsyth P
    The pharmacist ally in heart failure: Useful when involved. Letter regarding the article 'Effective medications can work only in patients who take them: Implications for post-acute heart failure care'.
    Eur J Heart Fail. 2024 Mar 25. doi: 10.1002/ejhf.3217.
    PubMed    


  98. SAVARESE G, Lindberg F, Christodorescu RM, Ferrini M, et al
    Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.
    Eur J Heart Fail. 2024 Mar 22. doi: 10.1002/ejhf.3214.
    PubMed     Abstract available


  99. DAVIS JA, Booth D, McEwan P, Solomon SD, et al
    Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Eur J Heart Fail. 2024 Mar 20. doi: 10.1002/ejhf.3197.
    PubMed     Abstract available


  100. VANHENTENRIJK S, Tang WHW
    Renal perturbations with sodium-glucose cotransporter 2 inhibitor in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Mar 19. doi: 10.1002/ejhf.3205.
    PubMed    


  101. PANICHELLA G, Tomasoni D, Aimo A
    Dissecting the heart failure phenotype through phenomics.
    Eur J Heart Fail. 2024 Mar 19. doi: 10.1002/ejhf.3204.
    PubMed    


  102. PEIKERT A, Vaduganathan M, Claggett BL, Kulac IJ, et al
    Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
    Eur J Heart Fail. 2024 Mar 15. doi: 10.1002/ejhf.3184.
    PubMed     Abstract available


  103. WOOD N, Straw S, Cheng CW, Hirata Y, et al
    Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3192.
    PubMed     Abstract available


  104. COX ZL, Testani JM
    The salt paradox in heart failure.
    Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3194.
    PubMed    


  105. KRESOJA KP, Rosch S, Schober AR, Fengler K, et al
    Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Mar 11. doi: 10.1002/ejhf.3195.
    PubMed     Abstract available


  106. EZEKOWITZ J, Alemayehu W, Edelmann F, Ponikowski P, et al
    Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3179.
    PubMed     Abstract available


  107. ROUBILLE F, Mercier G, Lancman G, Pasche H, et al
    Weight telemonitoring of heart failure versus standard of care in a real-world setting: Results on mortality and hospitalizations in a 6-month nationwide matched cohort study.
    Eur J Heart Fail. 2024 Mar 7. doi: 10.1002/ejhf.3191.
    PubMed     Abstract available


  108. PAGNESI M, Vilamajo OAG, Meirino A, Dumont CA, et al
    Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial.
    Eur J Heart Fail. 2024 Mar 5. doi: 10.1002/ejhf.3174.
    PubMed     Abstract available


  109. BUTLER J, Mentz RJ, Hernandez AF
    Iron replacement therapy in heart failure: Contextualizing the results of the HEART-FID trial.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3193.
    PubMed    


  110. TUBBEN A, Tingen HSA, Prakken NHJ, van Empel VPM, et al
    Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3186.
    PubMed    


  111. FERREIRA JP, Zannad F, Packer M, Filippatos G, et al
    Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3180.
    PubMed     Abstract available


  112. FERREIRA JP, Packer M, Sattar N, Butler J, et al
    Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3166.
    PubMed     Abstract available


  113. RICHARDS AM, Wang P, Wong LL
    'Micro'-managing heart failure: Restoring that which was lost in translation.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3188.
    PubMed    


  114. CHUNAWALA ZS, Keshvani N, Segar MW, Patel KV, et al
    Association of diabetes-specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study.
    Eur J Heart Fail. 2024 Mar 4. doi: 10.1002/ejhf.3176.
    PubMed    


  115. BAUERSACHS J, Solomon SD, Anker SD, Antorrena-Miranda I, et al
    Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.
    Eur J Heart Fail. 2024;26:674-682.
    PubMed     Abstract available


    February 2024
  116. SEGAR MW, Nair A, Pandey A
    An exercise enigma: Unravelling the complexity of exercise intolerance in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Feb 27. doi: 10.1002/ejhf.3170.
    PubMed    


  117. D'ALTO M, Di Maio M, Argiento P, Romeo E, et al
    Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension.
    Eur J Heart Fail. 2024 Feb 26. doi: 10.1002/ejhf.3172.
    PubMed     Abstract available


  118. PITT B, Iyer SPN, Humes HD
    New opportunity for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation.
    Eur J Heart Fail. 2024 Feb 23. doi: 10.1002/ejhf.3177.
    PubMed    



  119. Correction to 'Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology'.
    Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3171.
    PubMed    


  120. PELLICORI P, Felker GM, Cleland JGF
    Reply to 'Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?'.
    Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3159.
    PubMed    


  121. TALHA KM, Januzzi JL Jr, Meng T, Greene SJ, et al
    Use of natriuretic peptides and echocardiography for diagnosing heart failure.
    Eur J Heart Fail. 2024 Feb 20. doi: 10.1002/ejhf.3165.
    PubMed     Abstract available


  122. MINAMISAWA M, Inciardi RM, Claggett B, Cikes M, et al
    Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study.
    Eur J Heart Fail. 2024 Feb 18. doi: 10.1002/ejhf.3167.
    PubMed     Abstract available


  123. KOK WE
    Unravelling the gut hypothesis of heart failure with gut microbiota-derived metabolites.
    Eur J Heart Fail. 2024 Feb 15. doi: 10.1002/ejhf.3164.
    PubMed    


  124. MIN KH, Jackson SA, Ambrosy AP
    A PACT for the future: Improving medication adherence in heart failure.
    Eur J Heart Fail. 2024 Feb 12. doi: 10.1002/ejhf.3169.
    PubMed    


  125. ZHAO Y, Sun J, Xie C
    The gap between real-world and guidelines in the use of sodium-glucose cotransporter 2 inhibitors for heart failure patients with reduced ejection fraction: Is it underestimated or overestimated? Letter regarding the article 'Real-world use of sodium-
    Eur J Heart Fail. 2024 Feb 8. doi: 10.1002/ejhf.3163.
    PubMed    


  126. BO W, Cheng X
    High blood pressure for heart failure patients: Where do the benefits come from? Letter regarding the article 'Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis'.
    Eur J Heart Fail. 2024 Feb 4. doi: 10.1002/ejhf.3161.
    PubMed    


  127. VAN ESSEN BJ, Tharshana GN, Ouwerkerk W, Yeo PSD, et al
    Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach.
    Eur J Heart Fail. 2024 Feb 4. doi: 10.1002/ejhf.3156.
    PubMed     Abstract available


  128. AVERBUCH T, Lee SF, Zagorski B, Mebazaa A, et al
    Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) randomized controlled trial.
    Eur J Heart Fail. 2024 Feb 1. doi: 10.1002/ejhf.3134.
    PubMed     Abstract available


  129. RICCARDI M, Pagnesi M, Chioncel O, Mebazaa A, et al
    Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors.
    Eur J Heart Fail. 2024;26:411-431.
    PubMed     Abstract available


  130. SUBRAMANIAN V, Keshvani N, Segar MW, Kondamudi NJ, et al
    Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among community-dwelling adults without cardiovascular disease: The Dallas Heart Study.
    Eur J Heart Fail. 2024;26:208-215.
    PubMed     Abstract available


  131. GARCIA-PAVIA P, Grogan M, Kale P, Berk JL, et al
    Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Eur J Heart Fail. 2024;26:397-410.
    PubMed     Abstract available


  132. KRESOJA KP
    Exercise haemodynamics in post-Fontan patients: Diastolic dysfunction, again and again?
    Eur J Heart Fail. 2024;26:324-326.
    PubMed    


  133. MAEDER MT
    Natriuretic peptides - Biomarker companions through thick and thin.
    Eur J Heart Fail. 2024;26:270-273.
    PubMed    


  134. MONDA E, Limongelli G
    Expanding the knowledge on transthyretin p.V142I variant-related cardiomyopathy.
    Eur J Heart Fail. 2024;26:394-396.
    PubMed    


  135. SCISCIOLA L, Paolisso P, Belmonte M, Gallinoro E, et al
    Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study.
    Eur J Heart Fail. 2024;26:471-482.
    PubMed     Abstract available


  136. COUGHLAN JJ, Rossello X
    Anaemia in patients with cardiogenic shock complicating acute myocardial infarction: Surrogate marker of poor outcome or therapeutic target?
    Eur J Heart Fail. 2024;26:458-459.
    PubMed    


  137. MERKELY B, Kosztin A
    De novo versus upgrade cardiac resynchronization therapy: A different patient population and outcome?
    Eur J Heart Fail. 2024;26:521-522.
    PubMed    


  138. MEEKERS E, Petit T, Dauw J, Gruwez H, et al
    Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors - Insights from the ACTION-MEMS study.
    Eur J Heart Fail. 2024;26:523-524.
    PubMed    


  139. MIRANDA WR, Jain CC, Borlaug BA, Connolly HM, et al
    Exercise catheterization in adults post-Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology.
    Eur J Heart Fail. 2024;26:314-323.
    PubMed     Abstract available


  140. OBRADOVIC D, Loncar G, Zeymer U, Poss J, et al
    Impact of anaemia and iron deficiency on outcomes in cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2024;26:448-457.
    PubMed     Abstract available


  141. RAZVI Y, Ioannou A, Patel RK, Chacko L, et al
    Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Eur J Heart Fail. 2024;26:383-393.
    PubMed     Abstract available


  142. TRENSON S, Voros G, Martens P, Ingelaere S, et al
    Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysis.
    Eur J Heart Fail. 2024;26:511-520.
    PubMed     Abstract available


    January 2024
  143. SEGAR MW, Pandey A
    Understanding the language of the heart: The promise of natural language processing to diagnose heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Jan 31. doi: 10.1002/ejhf.3154.
    PubMed    


  144. PARIKH PB, Mack M, Stone GW, Anker SD, et al
    Transcatheter aortic valve replacement in heart failure.
    Eur J Heart Fail. 2024 Jan 31. doi: 10.1002/ejhf.3151.
    PubMed     Abstract available


  145. LIN GM, Lloyd-Jones DM, Colangelo LA, Lima JAC, et al
    Association between secondhand smoke exposure and incident heart failure: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Eur J Heart Fail. 2024 Jan 30. doi: 10.1002/ejhf.3155.
    PubMed     Abstract available


  146. KHAN MS, Fonarow GC, Greene SJ
    Guideline-directed medical therapy for heart failure: The key ingredient for successful in-hospital and post-discharge care.
    Eur J Heart Fail. 2024 Jan 30. doi: 10.1002/ejhf.3152.
    PubMed    


  147. PELLICORI P, Cleland JGF
    Atrial myopathy and heart failure with preserved ejection fraction: When a label does more harm than good?
    Eur J Heart Fail. 2024 Jan 28. doi: 10.1002/ejhf.3148.
    PubMed    


  148. HULLIN R
    Advantage of uptitration of foundational heart failure drugs in heart failure with reduced ejection fraction and low blood pressure.
    Eur J Heart Fail. 2024 Jan 25. doi: 10.1002/ejhf.3144.
    PubMed    


  149. MULLENS W, Dauw J, Gustafsson F, Mebazaa A, et al
    Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2024 Jan 25. doi: 10.1002/ejhf.3150.
    PubMed     Abstract available


  150. ABDIN A, Lauder L, Fudim M, Abraham WT, et al
    Neuromodulation interventions in the management of heart failure.
    Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3147.
    PubMed     Abstract available


  151. GONZALEZ-DEL-HOYO M, Rossello X
    Worsening heart failure comes into focus, chronic heart failure takes a backseat.
    Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3143.
    PubMed    


  152. DAUW J, Meekers E, Martens P, Deferm S, et al
    Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling.
    Eur J Heart Fail. 2024 Jan 21. doi: 10.1002/ejhf.3131.
    PubMed     Abstract available


  153. DE LA ESPRIELLA R, Ortiz A, Nunez J
    The blood urea nitrogen to creatinine ratio in chronic heart failure: 'When the past is prologue'.
    Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3146.
    PubMed    


  154. PITT B, Brown JM, Vaidya A, Diez J, et al
    Reassessing the management of hypertension: Time to prevent aldosterone-mediated heart failure.
    Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3141.
    PubMed    


  155. GREENE SJ, Khan MS, Butler J
    Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3133.
    PubMed    


  156. USMAN MS, Januzzi JL, Anker SD, Salman A, et al
    The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Eur J Heart Fail. 2024 Jan 18. doi: 10.1002/ejhf.3129.
    PubMed     Abstract available


  157. BAYES-GENIS A, Aimo A
    Reply to the letter regarding the article 'Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines'.
    Eur J Heart Fail. 2024 Jan 16. doi: 10.1002/ejhf.3142.
    PubMed    


  158. SEIDU S, Lawson CA, Kunutsor SK, Khunti K, et al
    Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2024 Jan 12. doi: 10.1002/ejhf.3108.
    PubMed     Abstract available



  159. Correction to 'Congestion in heart failure: A circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association' and articles listed below.
    Eur J Heart Fail. 2024 Jan 11. doi: 10.1002/ejhf.3123.
    PubMed    


  160. DE BOER RA, Diez J
    Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium-glucose cotransporter 2 inhibition.
    Eur J Heart Fail. 2024 Jan 9. doi: 10.1002/ejhf.3125.
    PubMed    


  161. SAITO Y, Obokata M
    Diagnostic and therapeutic implications of obesity in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2024 Jan 8. doi: 10.1002/ejhf.3128.
    PubMed    


  162. KALOGEROPOULOS AP, Jang KH, Hall ME
    Predicting heart failure: The promise of proteomics.
    Eur J Heart Fail. 2024 Jan 8. doi: 10.1002/ejhf.3126.
    PubMed    


  163. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ES
    Eur J Heart Fail. 2024 Jan 3. doi: 10.1002/ejhf.3024.
    PubMed     Abstract available


  164. KHAN MS, Sperry BW, Butler J
    Kidney involvement in transthyretin cardiac amyloidosis - Role of urinary albumin to creatinine ratio and need for further evidence generation.
    Eur J Heart Fail. 2024;26:74-76.
    PubMed    


  165. BERTERO E, Chiti C, Schiavo MA, Tini G, et al
    Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
    Eur J Heart Fail. 2024;26:59-64.
    PubMed     Abstract available


  166. SEOUDY H, Voran JC, Frank D
    Growth differentiation factor-15 in sodium-glucose cotransporter 2 inhibition: Mechanistic insights from the EMPEROR program.
    Eur J Heart Fail. 2024;26:165-166.
    PubMed    


  167. RIVAS GARCIA S, Alvarez-Garcia J
    Sacubitril/valsartan: Where mechanism meets evidence-based medicine.
    Eur J Heart Fail. 2024;26:127-129.
    PubMed    


  168. FERREIRA JP, Rossello X, Zannad F
    Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients.
    Eur J Heart Fail. 2024;26:140-141.
    PubMed    


  169. ARDISSINO M, Halliday BP, de Marvao A
    The global landscape of peripartum cardiomyopathy: Morbidity, mortality, recovery and inequity.
    Eur J Heart Fail. 2024;26:43-45.
    PubMed    


  170. IOANNOU A, Rauf MU, Patel RK, Razvi Y, et al
    Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance.
    Eur J Heart Fail. 2024;26:65-73.
    PubMed     Abstract available


  171. MERLO M, Setti M, Sinagra G
    Coronary artery disease and dilated cardiomyopathy: Where parallel universes merge.
    Eur J Heart Fail. 2024;26:56-58.
    PubMed    


  172. SCHOU M, Claggett B, Miao ZM, Fernandez A, et al
    Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
    Eur J Heart Fail. 2024;26:130-139.
    PubMed     Abstract available


  173. MAEDA D, Matsue Y, Dotare T, Sunayama T, et al
    Clinical characteristics and prognosis of patients with isolated cardiac sarcoidosis: Insights from the ILLUMINATE-CS study.
    Eur J Heart Fail. 2024;26:77-86.
    PubMed     Abstract available


  174. JACKSON AM, Bauersachs J, Petrie MC, van der Meer P, et al
    Outcomes at one year in women with peripartum cardiomyopathy: Findings from the ESC EORP PPCM Registry.
    Eur J Heart Fail. 2024;26:34-42.
    PubMed     Abstract available


  175. JONES RE, Hammersley DJ, Zheng S, McGurk KA, et al
    Assessing the association between genetic and phenotypic features of dilated cardiomyopathy and outcome in patients with coronary artery disease.
    Eur J Heart Fail. 2024;26:46-55.
    PubMed     Abstract available


    December 2023
  176. LARSON K, Omar M, Sorimachi H, Omote K, et al
    Impact of Clinical Phenogroup Diversity and Multiplicity: Impact on Mechanisms of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Dec 29. doi: 10.1002/ejhf.3105.
    PubMed     Abstract available


  177. WU J, Biswas D, Ryan M, Bernstein B, et al
    Artificial Intelligence methods for Improved Detection of undiagnosed Heart Failure with Preserved Ejection Fraction (HFpEF).
    Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3115.
    PubMed     Abstract available


  178. KOKKINOS P, Faselis C, Pittaras A, Samuel IBH, et al
    Cardiorespiratory Fitness and Risk of Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3117.
    PubMed     Abstract available


  179. AMINI L, Kazmi S, Patel MJ
    Letter Regarding the Article, "Head-to-Head Comparison Between Recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines"(1).
    Eur J Heart Fail. 2023 Dec 28. doi: 10.1002/ejhf.3121.
    PubMed    


  180. PATEL SM, Morrow DA, Bellavia A, Berg DD, et al
    Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
    Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3118.
    PubMed     Abstract available


  181. TOMASONI D, Vitale C, Guidetti F, Benson L, et al
    The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3112.
    PubMed     Abstract available


  182. ADAMO M, Chioncel O, Pagnesi M, Bayes-Genis A, et al
    Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular
    Eur J Heart Fail. 2023 Dec 22. doi: 10.1002/ejhf.3106.
    PubMed     Abstract available


  183. RANDHAWA VK, Baran DA
    Unraveling Heart Failure Cardiogenic Shock Profiles and Pathways.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3113.
    PubMed    


  184. COTTER G, Davison BA, Adams KF Jr, Ambrosy AP, et al
    Effective medications can work only in patients who take them: implications for post acute heart failure care.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3109.
    PubMed    


  185. TANG WHW, Nemet I, Li XS, Wu Y, et al
    Prognostic Value of Gut Microbe-Generated Metabolite Phenylacetylglutamine in Patients with Heart Failure.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3111.
    PubMed     Abstract available


  186. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
    Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3114.
    PubMed     Abstract available


  187. COLLINS NJ, Ngo DTM, Sverdlov AL
    New cimlanod trial provides insights into mechanistic effects of vasodilators in heart failure.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3110.
    PubMed    


  188. BOCCHINO PP, Gallone G, Frea S, De Ferrari GM, et al
    Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3122.
    PubMed    


  189. DE LA ESPRIELLA R, Wahlberg KJ, Infeld M, Palau P, et al
    Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial.
    Eur J Heart Fail. 2023 Dec 20. doi: 10.1002/ejhf.3107.
    PubMed     Abstract available


  190. BAUDRY G, Pereira O, Duarte K, Ferreira JP, et al
    Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France.
    Eur J Heart Fail. 2023 Dec 7. doi: 10.1002/ejhf.3103.
    PubMed     Abstract available


  191. OMOTE K, Sorimachi H, Obokata M, Verbrugge FH, et al
    Biatrial Myopathy in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Dec 7. doi: 10.1002/ejhf.3104.
    PubMed     Abstract available


  192. FERREIRA JP, Butler J, Anker SD, Januzzi JL, et al
    Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. Findings from the EMPEROR trials.
    Eur J Heart Fail. 2023 Dec 1. doi: 10.1002/ejhf.3101.
    PubMed     Abstract available


  193. TOMASONI D, Adamo M, Metra M
    December 2023 at a glance: Focus on medical therapy in chronic and acute heart failure.
    Eur J Heart Fail. 2023;25:2099-2101.
    PubMed    


  194. D'AMARIO D, Borovac JA, Patti G
    A machine-learning-based prediction model in patients with takotsubo syndrome: 'You can't stop change any more than you can stop the suns from setting!'.
    Eur J Heart Fail. 2023;25:2312-2315.
    PubMed    


  195. CANNATA A, Bromage DI, McDonagh TA
    When observation meets randomization: 'Don't let a crisis go to waste'.
    Eur J Heart Fail. 2023;25:2189-2190.
    PubMed    


  196. DELMAS C, Vandenbriele C, Pappalardo F, Roubille F, et al
    What about current recommendations for extracorporeal life support in acute myocardial infarction-associated cardiogenic shock: Stay or go? or time to revise?
    Eur J Heart Fail. 2023;25:2102-2104.
    PubMed    


  197. RUSSO G, Badano LP, Adamo M, Alessandrini H, et al
    Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry.
    Eur J Heart Fail. 2023;25:2243-2251.
    PubMed     Abstract available


  198. POLOVINA M, Tschope C, Rosano G, Metra M, et al
    Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies.
    Eur J Heart Fail. 2023;25:2144-2163.
    PubMed     Abstract available


  199. MARTYN T, Saef J, Khot UN, Martinez KA, et al
    The utilization and impact of cardiovascular specialists on guideline-directed medical scores: An analysis of a diverse, multi-state, electronic health record-based registry.
    Eur J Heart Fail. 2023;25:2333-2336.
    PubMed    


  200. KOURANOS V, Khattar RS, Okafor J, Ahmed R, et al
    Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation.
    Eur J Heart Fail. 2023;25:2287-2298.
    PubMed     Abstract available


  201. DE FILIPPO O, Cammann VL, Pancotti C, Di Vece D, et al
    Machine learning-based prediction of in-hospital death for patients with takotsubo syndrome: The InterTAK-ML model.
    Eur J Heart Fail. 2023;25:2299-2311.
    PubMed     Abstract available


    November 2023
  202. PELLICORI P, Cleland JGF, Borentain M, Taubel J, et al
    Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231).
    Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3077.
    PubMed     Abstract available


  203. LUND LH, Crespo-Leiro MG, Laroche C, Garcia-Pinilla JM, et al
    Rationale and Design of the ESC Heart Failure III Registry - Implementation and Discovery.
    Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3087.
    PubMed     Abstract available


  204. LITWIN SE, Komtebedde J, Seidler T, Borlaug BA, et al
    Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial.
    Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3092.
    PubMed     Abstract available


  205. FERREIRA JP, Packer M, Butler J, Filippatos G, et al
    GDF-15 and the Effect of Empagliflozin in Heart Failure: Findings from the EMPEROR Program.
    Eur J Heart Fail. 2023 Nov 14. doi: 10.1002/ejhf.3078.
    PubMed     Abstract available


  206. RIDDELL CW, Chan C, McGrinder H, Earle NJ, et al
    College-level reading is required to understand ChatGPT's answers to lay questions relating to heart failure.
    Eur J Heart Fail. 2023 Nov 14. doi: 10.1002/ejhf.3083.
    PubMed    


  207. BOBROWSKI D, Dorovenis A, Abdel-Qadir H, McNaughton CD, et al
    Association of Neighborhood-Level Material Deprivation with Adverse Outcomes and Processes of Care Among Patients with Heart Failure in a Single-Payer Healthcare System: A Population-Based Cohort Study.
    Eur J Heart Fail. 2023 Nov 13. doi: 10.1002/ejhf.3090.
    PubMed     Abstract available


  208. PITT B, Zannad F
    The Use Of Mineralocorticoid Receptor Antagonists For Patients With Heart Failure With A Reduced Ejection Fraction: A Time For Reassessment.
    Eur J Heart Fail. 2023 Nov 13. doi: 10.1002/ejhf.3091.
    PubMed    


  209. SUNDERMEYER J, Kellner C, Beer BN, Besch L, et al
    Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock.
    Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3082.
    PubMed     Abstract available


  210. MCDOWELL K, Adamson C, Jackson C, Campbell R, et al
    Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes.
    Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3085.
    PubMed     Abstract available


  211. EMILSSON V, Jonsson BG, Austin TR, Gudmundsdottir V, et al
    Proteomic prediction of incident heart failure and its main subtypes.
    Eur J Heart Fail. 2023 Nov 8. doi: 10.1002/ejhf.3086.
    PubMed     Abstract available


  212. TOMASONI D, Pagnesi M, Colombo G, Chiarito M, et al
    Guideline directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF Registry.
    Eur J Heart Fail. 2023 Nov 7. doi: 10.1002/ejhf.3081.
    PubMed     Abstract available


  213. MILLER RJ, Howlett JG
    Un(b)locking Therapeutic Options: Potential for Calcium Channel Blockers in Heart Failure with non-Reduced LVEF.
    Eur J Heart Fail. 2023 Nov 6. doi: 10.1002/ejhf.3080.
    PubMed    


  214. TOMASONI D, Adamo M, Metra M
    November 2023 at a glance: Focus on cardiogenic shock, post-discharge outcomes and cardiomyopathies.
    Eur J Heart Fail. 2023;25:1887-1890.
    PubMed    


  215. LOBEEK M, Rienstra M, Gorter TM
    Epicardial adipose tissue and cardiac dysfunction: Progress in knowledge but questions remain.
    Eur J Heart Fail. 2023;25:1944-1946.
    PubMed    


  216. DELMAS C, Vandenbriele C, Pappalardo F
    Persistent high mortality in acute myocardial infarction-associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care.
    Eur J Heart Fail. 2023;25:2034-2036.
    PubMed    


  217. MOLLER JE, Kjaergaard J, Hassager C
    Contemporary use of temporary mechanical circulatory support in infarct-related cardiogenic shock: Time to stop and reflect?
    Eur J Heart Fail. 2023;25:2032-2033.
    PubMed    


  218. VISHRAM-NIELSEN JKK, Gustafsson F
    Watchful waiting for venting in venoarterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2023;25:2047-2049.
    PubMed    


  219. HAMMERSLEY DJ, Jones RE, Owen R, Mach L, et al
    Phenotype, outcomes and natural history of early-stage non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2023;25:2050-2059.
    PubMed     Abstract available


  220. BOGERD M, Ten Berg S, Peters EJ, Vlaar APJ, et al
    Impella and venoarterial extracorporeal membrane oxygenation in cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2023;25:2021-2031.
    PubMed     Abstract available


  221. CHIN JF, Aga YS, Abou Kamar S, Kroon D, et al
    Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity.
    Eur J Heart Fail. 2023;25:1936-1943.
    PubMed     Abstract available


  222. PARK H, Yang JH, Ahn JM, Kang DY, et al
    Early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support: The EVOLVE-ECMO randomized clinical trial.
    Eur J Heart Fail. 2023;25:2037-2046.
    PubMed     Abstract available


  223. SEFEROVIC PM, Polovina M, Rosano G, Bozkurt B, et al
    State-of-the-art document on optimal contemporary management of cardiomyopathies.
    Eur J Heart Fail. 2023;25:1899-1922.
    PubMed     Abstract available


    October 2023
  224. DOEHNER W, Bohm M, Boriani G, Christersson C, et al
    Interaction of Heart Failure and Stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis.
    Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3071.
    PubMed     Abstract available


  225. TER MAATEN JM, Mebazaa A, Davison B, Edwards C, et al
    Early changes in renal function during rapid uptitration of guideline directed medical therapy following an admission for acute heart failure.
    Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3074.
    PubMed     Abstract available


  226. NESTEROV SV, Raty J, Nammas W, Maaniitty T, et al
    The short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction. A randomized controlled study.
    Eur J Heart Fail. 2023 Oct 31. doi: 10.1002/ejhf.3072.
    PubMed     Abstract available


  227. GIRERD N, Coiro S, Benson L, Savarese G, et al
    Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: Insights from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Oct 26. doi: 10.1002/ejhf.3066.
    PubMed     Abstract available


  228. PACKER M
    Qiliqiangxin: a Multifaceted Holistic Treatment for Heart Failure or a Pharmacological Probe for the Identification of Cardioprotective Mechanisms?
    Eur J Heart Fail. 2023 Oct 25. doi: 10.1002/ejhf.3068.
    PubMed     Abstract available


  229. WUSSLER D, Belkin M, Maeder MT, Walter J, et al
    Comprehensive Vasodilation in Women with Acute Heart Failure: Novel Insights from the GALACTIC randomized controlled trial.
    Eur J Heart Fail. 2023 Oct 23. doi: 10.1002/ejhf.3065.
    PubMed     Abstract available


  230. MOLLOY CD, Long L, Mordi IR, Bridges C, et al
    Exercise-based cardiac rehabilitation for adults with heart failure - 2023 Cochrane systematic review and meta-analysis.
    Eur J Heart Fail. 2023 Oct 18. doi: 10.1002/ejhf.3046.
    PubMed     Abstract available


  231. SAVARESE G, Butler J, Ponikowki P, Anker SD, et al
    SGLT2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: any incremental effect?
    Eur J Heart Fail. 2023 Oct 17. doi: 10.1002/ejhf.3064.
    PubMed    


  232. SHAHIM A, Shahim B, Lund LH
    Reply by Shahim et al. to Letter "Aortic regurgitation for adverse cardiovascular events: really harmless or just hidden?" Regarding Article "Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3062.
    PubMed    


  233. PARK JJ, Jang SY, Adler E, Ahmad F, et al
    A Machine Learning Derived Risk Score Predicts Mortality in East Asian Patients with Acute Heart Failure.
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3059.
    PubMed    


  234. MORICI N, Pappalardo F
    Heart Failure-Cardiogenic Shock: A Need for Time-Dependent Quality Indicators.
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3058.
    PubMed    


  235. CASTAGNA F, Simitsis P, Mehra MR
    Overcoming Vulnerability in Heart Failure: Transitional Tactical Toughness.
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3054.
    PubMed    


  236. SHAKOOR A, Abou Kamar S, Malgie J, Kardys I, et al
    The Different Risk of New-onset, Chronic, Worsening, and Advanced Heart Failure A Systematic Review and Meta-Regression Analysis.
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3048.
    PubMed     Abstract available


  237. SCOTTI A, Slipczuk L, Latib A
    Aortic stenosis and heart failure with preserved ejection fraction: A shared phenotypic puzzle.
    Eur J Heart Fail. 2023 Oct 12. doi: 10.1002/ejhf.3050.
    PubMed    


  238. GUIDETTI F, Lund LH, Benson L, Hage C, et al
    Safety of Continuing Mineralocorticoid Receptor Antagonists Treatment in Patients with Heart Failure with Reduced Ejection Fraction and Severe Kidney Disease: Data from Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Oct 5. doi: 10.1002/ejhf.3049.
    PubMed     Abstract available


  239. TUBBEN A, Nienhuis HLA, van der Meer P
    Tafamidis in Patients with Severe Heart Failure Due to Transthyretin Amyloidosis Cardiomyopathy: Improved Long-term Survival.
    Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3053.
    PubMed    


  240. PASCUAL-FIGAL D, Fuster JJ, Bayes-Genis A
    Personalizing Anti-Inflammatory Therapy in Heart Failure: A New Way.
    Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3052.
    PubMed    


  241. BIEGUS J, Ponikowski P
    Striving for the "Perfect" Definition of Iron Deficiency in Heart Failure.
    Eur J Heart Fail. 2023 Oct 4. doi: 10.1002/ejhf.3051.
    PubMed    


  242. TOMASONI D, Adamo M, Metra M
    October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities.
    Eur J Heart Fail. 2023;25:1719-1721.
    PubMed    


  243. MARTENS P, Mullens W
    Using combinational diuretics across the spectrum of renal function.
    Eur J Heart Fail. 2023;25:1794-1796.
    PubMed    


  244. BEER BN, Schrage B
    REMIniscence of aldosterone's role in myocardial remodelling.
    Eur J Heart Fail. 2023;25:1753-1754.
    PubMed    


  245. REDDY YNV, Borlaug BA
    Provocative testing in the evaluation of heart failure with preserved ejection fraction: Not all stresses are created equal.
    Eur J Heart Fail. 2023;25:1781-1783.
    PubMed    


  246. LEVI N, Hasin T
    Myocardial injury related to SARS-CoV-2 mRNA vaccination: The plot thickens.
    Eur J Heart Fail. 2023;25:1882-1883.
    PubMed    


  247. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
    Prevalence and predictive value of fluid overload in patients with severe symptomatic aortic valve stenosis.
    Eur J Heart Fail. 2023;25:1819-1821.
    PubMed    


  248. ABBASI K, Ali P, Barbour V, Bibbins-Domingo K, et al
    Reducing the risks of nuclear war-the role of health professionals.
    Eur J Heart Fail. 2023;25:1722-1723.
    PubMed    


  249. MONZO L, Huttin O, Ferreira JP, Lamiral Z, et al
    Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
    Eur J Heart Fail. 2023;25:1742-1752.
    PubMed     Abstract available


  250. BUERGIN N, Lopez-Ayala P, Hirsiger JR, Mueller P, et al
    Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination.
    Eur J Heart Fail. 2023;25:1871-1881.
    PubMed     Abstract available


  251. HALAVINA K, Koschutnik M, Dona C, Autherith M, et al
    Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes.
    Eur J Heart Fail. 2023;25:1808-1818.
    PubMed     Abstract available


    September 2023
  252. BHATT AS, Kosiborod MN, Claggett BL, Miao ZM, et al
    Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial.
    Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3043.
    PubMed     Abstract available


  253. SAITO Y, Obokata M
    Reply to 'Phenotypic characterization of heart failure with preserved ejection fraction'.
    Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3040.
    PubMed    


  254. HAGE C, Lund LH
    Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease - No heterogeneity.
    Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3041.
    PubMed    


  255. MATSUMOTO S, Kondo T, Yang M, Campbell RT, et al
    Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
    Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3044.
    PubMed     Abstract available


  256. ELLIOTT P, Gundapaneni B, Garcia-Pavia P
    Reply to 'Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark.
    Eur J Heart Fail. 2023 Sep 28. doi: 10.1002/ejhf.3042.
    PubMed    


  257. CHIONCEL O, Davison B, Adamo M, Antohi LE, et al
    Noncardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial.
    Eur J Heart Fail. 2023 Sep 20. doi: 10.1002/ejhf.3039.
    PubMed     Abstract available


  258. BAYES-GENIS A, Doherty KF, Petrie MC, Januzzi JL, et al
    Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 Sep 15. doi: 10.1002/ejhf.3036.
    PubMed     Abstract available


  259. FEUERSTEIN A, Schoenrath F, Belyavskiy E, Knierim J, et al
    Supervised exercise training in patients with advanced heart failure and left ventricular assist device: a multicenter randomized controlled trial (Ex-VAD trial).
    Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3032.
    PubMed     Abstract available


  260. AGOSTONI P, Pluchinotta FR, Salvioni E, Mapelli M, et al
    Heart failure patients with improved ejection fraction: insights from the MECKI Score database.
    Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3031.
    PubMed     Abstract available


  261. SEGAR MW, Keshvani N, Pandey A
    From Prediction to Prevention: The Role of Heart Failure Risk Models.
    Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3034.
    PubMed    


  262. AMERI P, Vaduganathan M
    When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure.
    Eur J Heart Fail. 2023 Sep 13. doi: 10.1002/ejhf.3035.
    PubMed    


  263. BURGER PM, Savarese G, Tromp J, Adamson C, et al
    Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model.
    Eur J Heart Fail. 2023 Sep 10. doi: 10.1002/ejhf.3028.
    PubMed     Abstract available


  264. SHERROD CF, Ikemura N, Spertus JA
    Knowledge is Power, Can It Be Leveraged to Improve Heart Failure Care?
    Eur J Heart Fail. 2023 Sep 6. doi: 10.1002/ejhf.3027.
    PubMed    


  265. KALRA R
    SGLT2 Inhibitors in Hospitalized Heart Failure Patients: No Time Like Now.
    Eur J Heart Fail. 2023 Sep 4. doi: 10.1002/ejhf.3022.
    PubMed    


  266. ABDIN A, Anker SD, Cowie MR, Filippatos GS, et al
    Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry.
    Eur J Heart Fail. 2023 Sep 4. doi: 10.1002/ejhf.3023.
    PubMed     Abstract available


  267. YOGASUNDARAM H, Zheng Y, Ly E, Ezekowitz J, et al
    Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
    Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3021.
    PubMed     Abstract available


  268. HAGE C, Stahlberg M, Thorvaldsen T, Faxen UL, et al
    Acyl ghrelin infusion increases circulating growth hormone in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3019.
    PubMed    


  269. DE BIASE N, Mazzola M, Del Punta L, Di Fiore V, et al
    Haemodynamic and metabolic phenotyping of patients with aortic stenosis and preserved ejection fraction: a specific phenotype of heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3018.
    PubMed     Abstract available


  270. TOMASONI D, Adamo M, Metra M
    September 2023 at a glance: focus on acute heart failure and health status.
    Eur J Heart Fail. 2023;25:1473-1476.
    PubMed    


  271. HARRINGTON J, Udell JA, Jones WS, Anker SD, et al
    Baseline characteristics of patients enrolled in the EMPACT-MI trial.
    Eur J Heart Fail. 2023;25:1708-1715.
    PubMed     Abstract available


  272. YANG M, Kondo T, Adamson C, Butt JH, et al
    Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
    Eur J Heart Fail. 2023;25:1606-1618.
    PubMed     Abstract available


  273. ANKER MS, Potthoff SK, Lena A, Porthun J, et al
    Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
    Eur J Heart Fail. 2023;25:1635-1647.
    PubMed     Abstract available


    August 2023
  274. PAPADOPOULOU C, Reinhold J, Gruner-Hegge N, Kydd A, et al
    Prognostic value of three iron deficiency definitions in patients with advanced heart failure.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.2949.
    PubMed     Abstract available


  275. ZHU Q, Wang S
    Aortic regurgitation for adverse cardiovascular events: Really harmless or just hidden? Letter regarding the article 'Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced,
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3016.
    PubMed    


  276. SANDEEP B, Huang X, Xiao Z
    Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article 'Artificial intelligence and heart failure: A state-of-the-art review'.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3017.
    PubMed    


  277. DONAL E, Neveu A, Fontes-Carvalho R
    Global longitudinal strain: Ready for 'prime time' in heart failure characterization.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3012.
    PubMed    


  278. AIMO A, Vergaro G, Emdin M
    Effects of tafamidis on heart failure hospitalization: the tale of the dog that did not bark.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3015.
    PubMed    


  279. FAUVEL C, Giraldo CIS, Barassa A, Shchendrygina A, et al
    Differences between heart failure specialists and non-specialists regarding heart failure drug implementation and up-titration.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3010.
    PubMed    


  280. POLZL G, Altenberger J, Comin-Colet J, Delgado JF, et al
    Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial.
    Eur J Heart Fail. 2023 Aug 27. doi: 10.1002/ejhf.3006.
    PubMed     Abstract available


  281. BUTT JH, Lu H, Kondo T, Bachus E, et al
    Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
    Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3000.
    PubMed     Abstract available


  282. PABON M, Claggett BL, Wang X, Miao ZM, et al
    Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
    Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3001.
    PubMed     Abstract available


  283. KESHVANI N, Shah S, Ayodele I, Chiswell K, et al
    Sex differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines-Heart Failure registry.
    Eur J Heart Fail. 2023 Aug 26. doi: 10.1002/ejhf.3003.
    PubMed     Abstract available


  284. NANAYAKKARA S, Kaye DM
    No Longer From Pillar to Post: The First Effective Step in Treating Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3007.
    PubMed    


  285. BUCKLEY LF, Dorbala P, Claggett BL, Libby P, et al
    Circulating Neutrophil-Related Proteins Associate with Incident Heart Failure and Cardiac Dysfunction: The ARIC Study.
    Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3008.
    PubMed     Abstract available


  286. FATIMA K, Butler J, Fonarow GC
    Residual Risk in Heart Failure and the Need for Simultaneous Implementation and Innovation.
    Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3005.
    PubMed    


  287. RIPAMONTI CI, Chelazzi C
    Is Palliative care in Heart Failure Patients Coming Up?
    Eur J Heart Fail. 2023 Aug 22. doi: 10.1002/ejhf.3002.
    PubMed    


  288. MOURA B, Aimo A, Al-Mohammad A, Keramida K, et al
    Diagnosis and Management of Patients with Left Ventricular Hypertrophy: Role of Multimodality Cardiac Imaging. A Scientific Statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2997.
    PubMed     Abstract available


  289. CHIONCEL O, Tomasoni D, Metra M
    Addressing Comorbidities in Heart Failure: When Feeling Better and Living Longer Go in the Same Direction.
    Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2998.
    PubMed    


  290. PIERCE JB, Butler J, Greene SJ
    Implementation of SGLT2 Inhibitors for Heart Failure with Reduced Ejection Fraction: Where We Are Versus Where We Need To Be.
    Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2999.
    PubMed    


  291. BRENNAN AC, Campbell RT, Lee MMY
    Influenza vaccination: a simple, safe, and effective treatment for patients with ischaemic heart disease and heart failure.
    Eur J Heart Fail. 2023 Aug 15. doi: 10.1002/ejhf.2993.
    PubMed    


  292. KHAN MS, Arshad MS, Greene SJ, Van Spall HGC, et al
    Artificial Intelligence and Heart Failure: A State-of-the-Art Review.
    Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2994.
    PubMed     Abstract available


  293. JHA AK
    Phenotypic characterization of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2996.
    PubMed    


  294. VAZIR A, Kapelios CJ, Agaoglu E, Metra M, et al
    Decongestion Strategies in patients presenting with acutely decompensated heart failure: a worldwide survey among physicians.
    Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2985.
    PubMed     Abstract available


  295. WERNHART S, Goertz A, Hedderich J, Papathanasiou M, et al
    Diastolic Exercise Stress Testing in Heart Failure with Preserved Ejection Fraction - The DEST HF study.
    Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2995.
    PubMed     Abstract available


  296. MARQUES P, Matias P, Packer M, Vieira JT, et al
    Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
    Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2992.
    PubMed     Abstract available


  297. FERREIRA JP, Blatchford JP, Teerlink JR, Kosiborod MN, et al
    Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE.
    Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2982.
    PubMed     Abstract available


  298. TRULLAS JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, et al
    Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: a post-hoc analysis of the CLOROTIC trial.
    Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2988.
    PubMed     Abstract available


  299. NOUHRAVESH N, Strange JE, Holt A, Tonnesen J, et al
    Patient mortality following new-onset heart failure stratified by cancer type and status.
    Eur J Heart Fail. 2023 Aug 3. doi: 10.1002/ejhf.2984.
    PubMed     Abstract available


  300. PAGNESI M, Serafini L, Adamo M
    Moving towards a comprehensive heart failure management beyond ejection fraction.
    Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2987.
    PubMed    


  301. COHEN-SOLAL A, Logeart D
    Exercise hypoxaemia in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2989.
    PubMed    


  302. PACKER M
    Foetal recapitulation of nutrient surplus signalling by O-GlcNAcylation and the failing heart.
    Eur J Heart Fail. 2023;25:1199-1212.
    PubMed     Abstract available


  303. CHATUR S, Ezekowitz JA
    Give a nudge a shot: NUDGE-FLU bridging the cardiovascular quality chasm.
    Eur J Heart Fail. 2023;25:1459-1463.
    PubMed    


  304. MYHRE PL, Liu Y, Kulac IJ, Claggett BL, et al
    Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
    Eur J Heart Fail. 2023;25:1396-1405.
    PubMed     Abstract available


  305. MONDA E, Limongelli G
    Thromboembolic events in peripartum cardiomyopathy: Current dilemmas and future perspectives.
    Eur J Heart Fail. 2023;25:1467-1469.
    PubMed    


  306. ROSSELLO X
    Globalization does not lead to homogenization in randomized controlled trials: Impact on sample size estimation.
    Eur J Heart Fail. 2023;25:1243-1245.
    PubMed    


  307. MCDOWELL K, Campbell R, Simpson J, Cunningham JW, et al
    Incremental prognostic value of biomarkers in PARADIGM-HF.
    Eur J Heart Fail. 2023;25:1406-1414.
    PubMed     Abstract available


  308. TROMP J, Jackson AM, Abdelhamid M, Fouad D, et al
    Thromboembolic events in peripartum cardiomyopathy: Results from the ESC EORP PPCM registry.
    Eur J Heart Fail. 2023;25:1464-1466.
    PubMed    


  309. DHONT S, Martens P, Meekers E, Dauw J, et al
    Sodium and potassium changes during decongestion with acetazolamide - A pre-specified analysis from the ADVOR trial.
    Eur J Heart Fail. 2023;25:1310-1319.
    PubMed     Abstract available


  310. BUTT JH, Claggett BL, Miao ZM, Jering KS, et al
    Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.
    Eur J Heart Fail. 2023;25:1228-1242.
    PubMed     Abstract available


    July 2023
  311. BLUM M, Goldstein NE, Jaarsma T, Allen LA, et al
    Palliative Care in Heart Failure Guidelines - A Comparison of the 2021 ESC and the 2022 AHA/ACC/HFSA Guidelines on Heart Failure.
    Eur J Heart Fail. 2023 Jul 26. doi: 10.1002/ejhf.2981.
    PubMed     Abstract available


  312. BIEGUS J, Fudim M, Salah HM, Heerspink HJL, et al
    SGLT-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies.
    Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2967.
    PubMed    


  313. HILL L, Baruah R, Beattie JM, Bistola V, et al
    Culture, ethnicity, and socio-economic status as determinants of the management of patients with advanced heart failure who need palliative care: A Clinical Consensus Statement from the Heart Failure Association (HFA) of the ESC, the ESC Patient Forum
    Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2973.
    PubMed     Abstract available


  314. WARNER B, Bruhn EJ, Olson TP, Bissen TG, et al
    Inspiratory Muscle Strength is Related to Exertional Dyspnea in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Jul 21. doi: 10.1002/ejhf.2980.
    PubMed    


  315. LUND LH, Lam CSP, Pizzato PE, Gabrielsen A, et al
    Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
    Eur J Heart Fail. 2023 Jul 20. doi: 10.1002/ejhf.2977.
    PubMed     Abstract available


  316. HARRINGTON J, Butler J
    Heart Failure after Myocardial Infarction: Glass Emptier Than Full.
    Eur J Heart Fail. 2023 Jul 18. doi: 10.1002/ejhf.2961.
    PubMed    


  317. BELDHUIS IE, Damman K, Pang PS, Greenberg B, et al
    Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.
    Eur J Heart Fail. 2023 Jul 18. doi: 10.1002/ejhf.2975.
    PubMed     Abstract available


  318. ELLIOTT P, Gundapaneni B, Sultan MB, Ines M, et al
    Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
    Eur J Heart Fail. 2023 Jul 11. doi: 10.1002/ejhf.2974.
    PubMed     Abstract available


  319. STOLFO D, Lund LH, Benson L, Lindberg F, et al
    Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Jul 7. doi: 10.1002/ejhf.2971.
    PubMed     Abstract available


  320. NADARAJAH R, Younsi T, Romer E, Raveendra K, et al
    Prediction models for heart failure in the community: a systematic review and meta-analysis.
    Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2970.
    PubMed     Abstract available


  321. PACKER M, Butler J
    Similarities and Distinctions Between Acetazolamide and SGLT2 Inhibitors in Patients With Acute Heart Failure: Key Insights Into ADVOR and EMPULSE.
    Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2968.
    PubMed     Abstract available


  322. PIESKE B, Armstrong PW
    Reply to 'Vericiguat in heart failure with reduced ejection fraction: the right choice above all else?'.
    Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2964.
    PubMed    


  323. VOORDES G, Damman K
    Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney.
    Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2963.
    PubMed    


  324. WU CK, Yang LT, Hung CL
    Exercise left atrial compliance: One more tool in the heart failure with preserved ejection fraction assistance toolbox?
    Eur J Heart Fail. 2023 Jul 5. doi: 10.1002/ejhf.2966.
    PubMed    


  325. CHANG AJ, Bhatt AS, Ambrosy AP
    Understanding Cardiohepatic Interactions in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2960.
    PubMed    


  326. DOCHERTY KF, Jackson AM, Macartney M, Campbell RT, et al
    Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991-2016.
    Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2965.
    PubMed     Abstract available


  327. GUSTAFSON SE, Ambrosy AP, Bhatt AS
    Special DELIVERy: Reducing High-Complexity Hospitalizations in Heart Failure.
    Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2958.
    PubMed    


  328. OSKOUIE S, Michael F, Whitelaw S, Bozkurt B, et al
    A Scoping Review of Heart Failure Transitional Care Quality Indicators and Outcomes for Use in Clinical Care and Research.
    Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2955.
    PubMed     Abstract available


  329. BAYES-GENIS A, Lupon J, Codina P
    Quality Over Quantity: Assessing the Need for Multiple Biomarkers in Predicting Heart Failure Outcomes.
    Eur J Heart Fail. 2023 Jul 4. doi: 10.1002/ejhf.2956.
    PubMed    



  330. Abstracts of the Heart Failure 2023 and the World Congress on Acute Heart Failure, 20 - 23 May 2023, Prague, Czechia.
    Eur J Heart Fail. 2023;25 Suppl 2:3-457.
    PubMed    


  331. TOMASONI D, Adamo M, Metra M
    July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities.
    Eur J Heart Fail. 2023;25:925-928.
    PubMed    


  332. GREUTMANN M, Tobler D, Engel R, Heg D, et al
    Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.
    Eur J Heart Fail. 2023;25:1105-1114.
    PubMed     Abstract available


  333. GOLDSMITH AJ, Jin M, Lucassen R, Duggan NM, et al
    Comparison of pulmonary congestion severity using artificial intelligence-assisted scoring versus clinical experts: A secondary analysis of BLUSHED-AHF.
    Eur J Heart Fail. 2023;25:1166-1169.
    PubMed     Abstract available


  334. BHATT AS, Kosiborod MN, Vaduganathan M, Claggett BL, et al
    Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Eur J Heart Fail. 2023;25:981-988.
    PubMed     Abstract available


  335. KHAN MS, Grayburn PA, Butler J
    Cardiac reverse remodelling with vericiguat: Victory or no victory?
    Eur J Heart Fail. 2023;25:1022-1024.
    PubMed    


    June 2023
  336. MONZO L, Girerd N, Duarte K, Ferreira JP, et al
    Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2952.
    PubMed     Abstract available


  337. MODIN D, Lassen MCH, Claggett B, Johansen ND, et al
    Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2945.
    PubMed     Abstract available


  338. JOURY A
    Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-hoc Analysis of SHIFT Trial.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2953.
    PubMed    


  339. BAYES-GENIS A, Rosano G
    Unlocking the Potential of Natriuretic Peptide Testing in Primary Care: A Roadmap for Early Heart Failure Diagnosis.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2950.
    PubMed    


  340. YANG M, Kondo T, Adamson C, Butt JH, et al
    Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2944.
    PubMed     Abstract available


  341. BRANN A, Miller J, Eshraghian E, Park JJ, et al
    Global Longitudinal Strain Predicts Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2947.
    PubMed     Abstract available


  342. DOCHERTY KF, Lam CSP, Rakisheva A, Coats AJS, et al
    Heart Failure Diagnosis in the General Community - Who, How and When? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2946.
    PubMed     Abstract available


  343. KERWAGEN F, Koehler K, Vettorazzi E, Stangl V, et al
    Remote patient management of heart failure across the ejection fraction spectrum: A prespecified analysis of the TIM-HF2 trial.
    Eur J Heart Fail. 2023 Jun 27. doi: 10.1002/ejhf.2948.
    PubMed     Abstract available


  344. ADAMO M, Chioncel O, Benson L, Shahim B, et al
    Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: insight from the ESC-HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2023 Jun 26. doi: 10.1002/ejhf.2929.
    PubMed     Abstract available


  345. STRACHINARU M, Roussoulieres A, Manintveld OC
    SGLT2i for Chronic Heart Failure: The Ultimate Solution?
    Eur J Heart Fail. 2023 Jun 22. doi: 10.1002/ejhf.2942.
    PubMed    


  346. SINAGRA G, Gigli M, Dal Ferro M
    Heart failure with reduced ejection fraction and monogenic dilated cardiomyopathy: distinct diseases? Insights from randomized controlled trials.
    Eur J Heart Fail. 2023 Jun 22. doi: 10.1002/ejhf.2943.
    PubMed    


  347. NAITO R, Kasai T
    One step towards tailor-made medicine for patients with heart failure.
    Eur J Heart Fail. 2023 Jun 21. doi: 10.1002/ejhf.2941.
    PubMed    


  348. BOOTH D, Davis JA, McEwan P, Solomon SD, et al
    The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
    Eur J Heart Fail. 2023 Jun 21. doi: 10.1002/ejhf.2940.
    PubMed     Abstract available


  349. DONAL E, Cosyns B
    Moving forwards from clinical trials to a more individualized management of treatments in heart failure? Great value of echocardiography-Doppler data.
    Eur J Heart Fail. 2023 Jun 20. doi: 10.1002/ejhf.2938.
    PubMed    


  350. GIRERD N
    Combating Therapeutic Inertia: Optimizing Iron Deficiency Treatment in Heart Failure.
    Eur J Heart Fail. 2023 Jun 20. doi: 10.1002/ejhf.2933.
    PubMed    


  351. GIRERD N
    Beyond Loop Diuretics: Unlocking the Potential of Codiuretics in Heart Failure Management.
    Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2936.
    PubMed    


  352. BUTTE Z, Ambrosy AP
    Acetazolamide as a Decongestion Strategy in Acute Decompensated Heart Failure: Balancing Fluid Removal and Electrolyte Disturbances.
    Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2935.
    PubMed    


  353. NGUYEN NV, Lindberg F, Benson L, Ferrannini G, et al
    Eligibility for vericiguat in a real-world heart failure population according to trial, guidelines, and label criteria: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Jun 16. doi: 10.1002/ejhf.2939.
    PubMed     Abstract available


  354. WANG S, Sun Q, Wang L
    Vericiguat in HFrEF: the right choice above all else? The answer may lie in time. Letter regarding the article 'Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA
    Eur J Heart Fail. 2023 Jun 15. doi: 10.1002/ejhf.2931.
    PubMed    


  355. BAYES-GENIS A, Lupon J, Revuelta-Lopez E, Llibre C, et al
    Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO-HF trial.
    Eur J Heart Fail. 2023 Jun 15. doi: 10.1002/ejhf.2932.
    PubMed     Abstract available


  356. OMAR M, Omote K, Sorimachi H, Popovic D, et al
    Hypoxemia in Patients with Heart Failure and Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Jun 14. doi: 10.1002/ejhf.2930.
    PubMed     Abstract available


  357. SCHRAGE B, Lund LH, Benson L, Braunschweig F, et al
    Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments - An analysis from the Swedish heart failure registry.
    Eur J Heart Fail. 2023 Jun 14. doi: 10.1002/ejhf.2928.
    PubMed     Abstract available


  358. SAKANIWA R, Tromp J, Streng KW, Suthahar N, et al
    Trajectories of renal biomarkers and new onset heart failure in the general population: Findings from the PREVEND study.
    Eur J Heart Fail. 2023 Jun 7. doi: 10.1002/ejhf.2925.
    PubMed     Abstract available


  359. BOHM M, Butler J, Krawczyk M, Mahfoud F, et al
    Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2023 Jun 6. doi: 10.1002/ejhf.2922.
    PubMed     Abstract available



  360. Corrigendum to 'Weight change and clinical outcomes in heart failure with reduced ejection fraction: Insights from EMPEROR-Reduced' [Eur J Heart Fail 2023;25:117-127].
    Eur J Heart Fail. 2023 Jun 5. doi: 10.1002/ejhf.2910.
    PubMed    


  361. ZIMERMAN A, da Silveira AD, Solomon SD, Rohde LE, et al
    NYHA Classification for Decision-Making in Heart Failure: Time to Reassess?
    Eur J Heart Fail. 2023 Jun 1. doi: 10.1002/ejhf.2923.
    PubMed    


  362. TOMASONI D, Adamo M, Metra M
    June 2023 at a glance: focus on worsening heart failure, heart failure with preserved ejection fraction and valvular heart disease.
    Eur J Heart Fail. 2023;25:773-775.
    PubMed    


  363. MULLER SA, Oerlemans MIFJ
    Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2023;25:854-856.
    PubMed    


  364. KARAM N, Hausleiter J
    Hypoalbuminaemia and secondary mitral regurgitation mortality: an inevitable fate?
    Eur J Heart Fail. 2023;25:888-889.
    PubMed    


  365. SCOTTI A, Jorde UP, Latib A
    Transcatheter edge-to-edge repair: fix the heart, heal the liver.
    Eur J Heart Fail. 2023;25:885-887.
    PubMed    


  366. STOLZ L, Orban M, Karam N, Lubos E, et al
    Cardio-hepatic syndrome in patients undergoing mitral valve transcatheter edge-to-edge repair.
    Eur J Heart Fail. 2023;25:872-884.
    PubMed     Abstract available


  367. TINI G, Milani P, Zampieri M, Caponetti AG, et al
    Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Eur J Heart Fail. 2023;25:845-853.
    PubMed     Abstract available


    May 2023
  368. ARRIGO M, Biegus J, Asakage A, Mebazaa A, et al
    Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial.
    Eur J Heart Fail. 2023 May 29. doi: 10.1002/ejhf.2920.
    PubMed     Abstract available


  369. HAVAKUK O, Topilsky Y
    Secondary Tricuspid Regurgitation in Heart Failure - Not Merely an Innocent Bystander?
    Eur J Heart Fail. 2023 May 25. doi: 10.1002/ejhf.2919.
    PubMed    


  370. ALVAREZ-GARCIA J
    SGLT2 inhibitors for Heart Failure: time's up for indulging in wishful thinking.
    Eur J Heart Fail. 2023 May 23. doi: 10.1002/ejhf.2917.
    PubMed    


  371. CHIONCEL O, Adamo M, Nikolaou M, Parissis J, et al
    Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of
    Eur J Heart Fail. 2023 May 23. doi: 10.1002/ejhf.2918.
    PubMed     Abstract available


  372. COTTER G, Davison B
    Acute heart failure is a remitting-relapsing disorder and not a step towards advanced heart failure: Implications for decongestion therapy.
    Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2916.
    PubMed    


  373. CHATUR S, Cunningham JW, Vaduganathan M, Mc Causland FR, et al
    Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial.
    Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2915.
    PubMed     Abstract available


  374. IACONELLI A, Pellicori P, Dolce P, Busti M, et al
    Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials.
    Eur J Heart Fail. 2023 May 22. doi: 10.1002/ejhf.2911.
    PubMed     Abstract available


  375. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Electronic nudges to increase influenza vaccination uptake among patients with heart failure: a prespecified analysis of the NUDGE-FLU trial.
    Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2913.
    PubMed     Abstract available


  376. PASCUAL-FIGAL DA, Zamorano JL, Domingo M, Morillas H, et al
    Impact of Dapagliflozin on cardiac remodeling in patients with chronic heart failure: DAPA-MODA study.
    Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2884.
    PubMed     Abstract available


  377. SHAHIM B, Shahim A, Adamo M, Chioncel O, et al
    Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and Reduced, Mildly Reduced, and Preserved Ejection Fraction: An Analysis of the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2908.
    PubMed     Abstract available


  378. CHATUR S, Kondo T, Claggett BL, Docherty K, et al
    Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA-HF.
    Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2912.
    PubMed     Abstract available


  379. MUSELLA F, Rosano GMC, Hage C, Benson L, et al
    Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population.
    Eur J Heart Fail. 2023 May 21. doi: 10.1002/ejhf.2892.
    PubMed     Abstract available


  380. ANKER SD, Usman MS, Anker MS, Butler J, et al
    Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology
    Eur J Heart Fail. 2023 May 19. doi: 10.1002/ejhf.2894.
    PubMed     Abstract available


  381. GUAZZI M
    The Biventricular Paths to Exercise Dyspnea in Heart Failure Preserved Ejection Fraction: The Future is Now.
    Eur J Heart Fail. 2023 May 18. doi: 10.1002/ejhf.2914.
    PubMed    


  382. METRA M, Adamo M, Tomasoni D, Mebazaa A, et al
    Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 May 18. doi: 10.1002/ejhf.2888.
    PubMed     Abstract available


  383. HORIUCHI Y, Asami M, Ide T, Yahagi K, et al
    Prevalence, Characteristics and Cardiovascular and Non-cardiovascular Outcomes in Patients with Heart Failure with Supra-normal Ejection Fraction; Insight from the JROADHF Study.
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2895.
    PubMed     Abstract available


  384. CERLINSKAITE-BAJORE K, Lam CSP, Sliwa K, Adamo M, et al
    Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalisation for acute heart failure: insights from the STRONG-HF trial.
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2882.
    PubMed     Abstract available


  385. HARRINGTON J, Mentz RJ
    Ironing out the Wrinkles: Unanswered Questions in Intravenous Iron Repletion in Heart Failure.
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2893.
    PubMed    


  386. RICHARDS AM
    Plasma Markers to Risk Stratify for Heart Failure in Atrial Fibrillation.
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2885.
    PubMed    


  387. BAUDRY G, Lescroart M, Kimmoun A
    Are LVEF phenotypes meaningful in acute heart failure?
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2889.
    PubMed    


  388. BORIANI G, Mei DA, Imberti JF
    Therapeutic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: from outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progress
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2891.
    PubMed    


  389. BARAT A, Chen CW, Patel-Murray N, McMurray JJV, et al
    Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial.
    Eur J Heart Fail. 2023 May 16. doi: 10.1002/ejhf.2886.
    PubMed     Abstract available


  390. TOMASONI D, Adamo M, Metra M
    May 2023 at a glance: focus on pathophysiology, comorbidities and devices.
    Eur J Heart Fail. 2023;25:599-601.
    PubMed    


  391. POETSCH MS, Palus S, Van Linthout S, von Haehling S, et al
    The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia.
    Eur J Heart Fail. 2023;25:673-686.
    PubMed     Abstract available


  392. JAVED S, Halliday BP
    Implantable cardioverter-defibrillator implantation in non-ischaemic cardiomyopathy: towards individualized risk stratification.
    Eur J Heart Fail. 2023;25:751-753.
    PubMed    


  393. ARRIGO M, Blet A, Morley-Smith A, Aissaoui N, et al
    Current and future trial design in refractory cardiogenic shock.
    Eur J Heart Fail. 2023;25:609-615.
    PubMed    


  394. FONTANA M, Ioannou A, Bandera F
    Non-invasive left ventricle pressure-volume loops: a new tool to track treatment response in cardiac transthyretin amyloidosis?
    Eur J Heart Fail. 2023;25:737-739.
    PubMed    


  395. GIANNONI A, Borrelli C, Gentile F, Sciarrone P, et al
    Autonomic and respiratory consequences of altered chemoreflex function: clinical and therapeutic implications in cardiovascular diseases.
    Eur J Heart Fail. 2023;25:642-656.
    PubMed     Abstract available


  396. SHERIDAN WS, Wetterling F, Testani JM, Borlaug BA, et al
    Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation.
    Eur J Heart Fail. 2023;25:754-763.
    PubMed     Abstract available


  397. DI MARCO A, Brown P, Mateus G, Faga V, et al
    Late gadolinium enhancement and the risk of ventricular arrhythmias and sudden death in NYHA class I patients with non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2023;25:740-750.
    PubMed     Abstract available


  398. ROSENBLUM HR, Griffin JM, Minamisawa M, Prasad N, et al
    Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study.
    Eur J Heart Fail. 2023;25:727-736.
    PubMed     Abstract available


    April 2023
  399. CAPPELLETTO C, Stolfo D, Savarese G
    Reply to Letter to the Editor "Why do obese patients with heart failure reduced ejection fraction have better outcomes from pharmacological treatments?".
    Eur J Heart Fail. 2023 Apr 28. doi: 10.1002/ejhf.2880.
    PubMed    


  400. LINDBERG F, Lund LH, Benson L, Linde C, et al
    Iron deficiency in heart failure: screening, prevalence, incidence and outcome Data from the Swedish Heart Failure registry and the Stockholm CREAtinine Measurements collaborative project.
    Eur J Heart Fail. 2023 Apr 28. doi: 10.1002/ejhf.2879.
    PubMed     Abstract available


  401. REDDY YNV, Borlaug BA
    Exercise Echocardiography to Diagnose Heart Failure with preserved Ejection Fraction - Are Two Measures Better than One?
    Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2876.
    PubMed    


  402. MYON F, Curtis E, L'official G, Donal E, et al
    Heart Failure with Preserved ejection Fraction: a haemodynamic explanation of exertional dyspnoea.
    Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2877.
    PubMed    


  403. KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
    Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2023 Apr 27. doi: 10.1002/ejhf.2873.
    PubMed     Abstract available


  404. SCHROEDER M, Lim YMF, Savarese G, Suzart-Woischnik K, et al
    Sex Differences in the Generalizability of Randomized Clinical Trials in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2868.
    PubMed     Abstract available


  405. TSUTSUI H, Albert NM, Coats AJS, Anker SD, et al
    Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
    Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2848.
    PubMed     Abstract available


  406. METRA M, Tomasoni D, Adamo M, Bayes-Genis A, et al
    Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2023 Apr 26. doi: 10.1002/ejhf.2874.
    PubMed     Abstract available


  407. BOHM M, Abdin A, Slawik J, Mahfoud F, et al
    Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2870.
    PubMed     Abstract available


  408. PEIGH G, Patel RB
    The Left Atrium: A Window into Cardiopulmonary Hemodynamics in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2872.
    PubMed    


  409. D'AMARIO D, Meerkin D, Restivo A, Ince H, et al
    Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR-HF trial.
    Eur J Heart Fail. 2023 Apr 24. doi: 10.1002/ejhf.2869.
    PubMed     Abstract available


  410. ALOGNA A, Omar M, Popovic D, Sorimachi H, et al
    Biventricular Cardiac Power Reserve in Heart Failure and Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Apr 17. doi: 10.1002/ejhf.2867.
    PubMed     Abstract available


  411. KOBAYASHI M, Huttin O, Ferreira JP, Duarte K, et al
    A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2859.
    PubMed     Abstract available


  412. HARADA T, Kagami K, Shina T, Sorimachi H, et al
    Diagnostic Value of Reduced Left Atrial Compliance during Ergometry Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2862.
    PubMed     Abstract available


  413. ANKER SD, Shahzeb Khan M, Butler J, von Haehling S, et al
    Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-Analysis.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2860.
    PubMed     Abstract available


  414. FILIPPATOS G, Farmakis D, Butler J, Zannad F, et al
    Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2861.
    PubMed     Abstract available


  415. TALHA KM, Butler J, Greene SJ, Aggarwal R, et al
    Potential Global Impact of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2864.
    PubMed     Abstract available


  416. HEITZINGER G, Pavo N, Koschatko S, Jantsch C, et al
    Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2858.
    PubMed     Abstract available


  417. BO W, Yanchun C, Cheng X
    Why do obese patients with heart failure reduced ejection fraction have better outcomes from pharmacological treatments?
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2865.
    PubMed    


  418. SHARMA A, Ferreira JP, Zannad F, Pocock SJ, et al
    Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2857.
    PubMed     Abstract available


  419. DEWAN P, Ferreira JP, Butt JH, Petrie MC, et al
    Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2023 Apr 16. doi: 10.1002/ejhf.2856.
    PubMed     Abstract available


  420. BIEGUS J, Zymlinski R, Testani J, Fudim M, et al
    The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery.
    Eur J Heart Fail. 2023 Apr 11. doi: 10.1002/ejhf.2852.
    PubMed     Abstract available


  421. POCOCK SJ, Ferreira JP, Collier TJ, Angermann CE, et al
    The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse.
    Eur J Heart Fail. 2023 Apr 10. doi: 10.1002/ejhf.2853.
    PubMed     Abstract available


  422. BUTLER J, Siddiqi TJ, Zannad F, Ferreira JP, et al
    Interaction of Natriuretic Peptide Levels and Ejection Fraction on Outcomes with Dapagliflozin and Empagliflozin in Heart Failure.
    Eur J Heart Fail. 2023 Apr 10. doi: 10.1002/ejhf.2854.
    PubMed    


  423. HOGAN J
    9th March 2023, 25in25 Summit - reducing heart failure mortality by 25% in the next 25 years.
    Eur J Heart Fail. 2023 Apr 4. doi: 10.1002/ejhf.2835.
    PubMed    


  424. GUALANDRO DM, Puelacher C, Mueller C
    Reply to the Letter regarding the article "Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes".
    Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2850.
    PubMed    


  425. ROSANO G, Bayes-Genis A, Metra M
    The Heart Failure Association endorses the 25in25 initiative.
    Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2847.
    PubMed    


  426. PACKER M
    A Reclassification of Heart Failure Based on Recognition of Heart Failure With Normal to Supranormal Ejection Fraction, a Clinically Common Form of Cardiac Contracture, With Distinctive Pathophysiological and Therapeutic Features.
    Eur J Heart Fail. 2023 Apr 3. doi: 10.1002/ejhf.2849.
    PubMed    



  427. HFA Winter Research Meeting on Translational Heart Failure 2023 In collaboration with the ESC Working Group on Myocardial Function, 20-23 May 2023.
    Eur J Heart Fail. 2023;25 Suppl 1:3-34.
    PubMed    


  428. TOMASONI D, Adamo M, Metra M
    April 2023 at a glance: focus on diagnosis and comorbidities.
    Eur J Heart Fail. 2023;25:445-447.
    PubMed    


  429. DELMAS C, Bonello L, Roubille F
    For the best management, please ask for assistance!
    Eur J Heart Fail. 2023;25:573-575.
    PubMed    


  430. AIMO A, Tomasoni D, Porcari A, Vergaro G, et al
    Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis.
    Eur J Heart Fail. 2023;25:510-514.
    PubMed     Abstract available


  431. DIEZ J, Rosano GMC, Butler J
    Time to reconsider the perception and management of hypertensive heart disease.
    Eur J Heart Fail. 2023;25:450-453.
    PubMed    


  432. ITZHAKI BEN ZADOK O, Falk RH
    Variant and wild type transthyretin amyloidosis: two sides of the same coin or different currencies in different pockets?
    Eur J Heart Fail. 2023;25:525-527.
    PubMed    


  433. SCHRAGE B, Sundermeyer J, Beer BN, Bertoldi L, et al
    Use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock.
    Eur J Heart Fail. 2023;25:562-572.
    PubMed     Abstract available


  434. PORCARI A, Razvi Y, Masi A, Patel R, et al
    Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2023;25:515-524.
    PubMed     Abstract available


    March 2023
  435. POPOVIC D, Alogna A, Omar M, Sorimachi H, et al
    Ventricular Stiffening and Chamber Contracture in Heart Failure with Higher Ejection Fraction.
    Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2843.
    PubMed     Abstract available


  436. PIESKE B, Pieske-Kraigher E, Lam CSP, Melenovsky V, et al
    Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy.
    Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2836.
    PubMed     Abstract available


  437. PUGLIESE NR, De Biase N, Del Punta L, Balletti A, et al
    Deep phenotype characterization of hypertensive response to exercise: implications on functional capacity and prognosis across the heart failure spectrum.
    Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2827.
    PubMed     Abstract available


  438. ROZENTRYT P, Niedziela JT, Gasior M
    Bones in heart failure - missing piece of the body wasting puzzle.
    Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2846.
    PubMed    


  439. OYAMA K, Giugliano RP, Ruff CT, Berg DD, et al
    Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.
    Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2844.
    PubMed     Abstract available


  440. D'AMARIO D, Rodolico D, Savarese G
    Reply to: Xie et al. What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?
    Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2837.
    PubMed    


  441. PAGNESI M, Baldetti L, Adamo M
    Inferior vena cava monitoring in heart failure: don't wait until the last drop makes the cup run over.
    Eur J Heart Fail. 2023 Mar 29. doi: 10.1002/ejhf.2839.
    PubMed    


  442. FARMAKIS D, Tromp J, Marinaki S, Ouwerkerk W, et al
    Impact of left ventricular ejection fraction phenotypes on healthcare-resource utilization in hospitalized heart failure: A secondary analysis of REPORT-HF.
    Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2833.
    PubMed     Abstract available


  443. CARBONE S, Elagizi A, Lavie CJ
    Better Pharmacotherapy in Heart Failure with Reduced Ejection Fraction May Partly Explain the Obesity Paradox.
    Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2832.
    PubMed    


  444. SIDDIQI TJ, Anker SD, Filippatos G, Ferreira JP, et al
    Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction.
    Eur J Heart Fail. 2023 Mar 28. doi: 10.1002/ejhf.2831.
    PubMed     Abstract available


  445. FUDIM M, Parikh K, Ganesh A, Molinger J, et al
    Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure - Mechanism of Action (SPONGE-HF).
    Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2829.
    PubMed    


  446. ZANNAD F, Alikhaani J, Alikhaani S, Butler J, et al
    PATIENT REPORTED OUTCOME MEASURES AND PATIENT ENGAGEMENT IN HEART FAILURE CLINICAL TRIALS: MULTI-STAKEHOLDER PERSPECTIVES.
    Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2828.
    PubMed     Abstract available


  447. AKTAA S, Gale CP, Brida M, Giannakoulas G, et al
    European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2830.
    PubMed     Abstract available


  448. DOBBIN SJH, Shen L, Petrie MC, Packer M, et al
    Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.
    Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2818.
    PubMed     Abstract available


  449. PANDEY AK, Dhingra NK, Pandey A, Puar P, et al
    Efficacy of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors for heart failure in black patients: a systematic review and meta-analysis of randomized controlled trials.
    Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2825.
    PubMed    


  450. SAITO Y, Obokata M, Harada T, Kagami K, et al
    Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non-invasive echocardiographic study.
    Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2821.
    PubMed     Abstract available


  451. PAGNESI M, Adamo M, Ter Maaten JM, Beldhuis IE, et al
    Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
    Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2820.
    PubMed     Abstract available


  452. LUDWIG S, Kalbacher D, Ali WB, Weimann J, et al
    Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis.
    Eur J Heart Fail. 2023;25:399-410.
    PubMed     Abstract available


  453. SCOTTI A, Latib A
    MitraClip evolution: EXPANDed options for a bespoke treatment.
    Eur J Heart Fail. 2023;25:422-424.
    PubMed    


  454. ROSSIGNOL P, Pitt B
    Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from 'real-world' evidence?
    Eur J Heart Fail. 2023;25:361-363.
    PubMed    


  455. CODINA P, Zamora E, Bayes-Genis A
    Reply to 'The frail patient and the frailing heart'.
    Eur J Heart Fail. 2023;25:441-442.
    PubMed    


  456. SCHRAGE B, Westermann D
    Cardiogenic shock is not a sprint, but a marathon.
    Eur J Heart Fail. 2023;25:436-437.
    PubMed    


  457. PATOULIAS D, Fragakis N
    The frail patient and the frailing heart. Letter regarding the article 'Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment'.
    Eur J Heart Fail. 2023;25:441.
    PubMed    


  458. SCHUSTER A, Schulz A, Lange T, Evertz R, et al
    Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023;25:322-331.
    PubMed     Abstract available


  459. VERGARO G, Castiglione V, Aimo A, Prontera C, et al
    N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
    Eur J Heart Fail. 2023;25:335-346.
    PubMed     Abstract available


    February 2023
  460. BLUMER V, Truby LK, Zieroth S
    Sex Differences in Heart Failure: The Evolving Use of Biomarkers.
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2817.
    PubMed    


  461. PACKER M
    Dosing of Iron Supplementation for Iron-Deficient Patients With Heart Failure: Should We Prefer More Intensive or Less Intensive Repletion Targets?
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2816.
    PubMed    


  462. GUSTAFSSON F, Damman K, Nalbantgil S, Van Laake LW, et al
    Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2814.
    PubMed     Abstract available


  463. GARD EK, Beale AL, Telles F, Silvestry FE, et al
    Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2805.
    PubMed     Abstract available


  464. CHIONCEL O, Antohi L, Mebazaa A
    Heart Failure and Non-cardiac Surgery: "A Call To Action" for Multidisciplinary Care Supporting Surgeons and Anesthesiologists.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2813.
    PubMed    


  465. FENG KY, Ambrosy AP, Zhou Z, Li D, et al
    Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2809.
    PubMed     Abstract available


  466. GRAHAM FJ, Pellicori P, Kalra PR, Ford I, et al
    Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2810.
    PubMed     Abstract available


  467. SANZ-RUIZ R, Perin EC, Fernandez-Aviles F
    Cell Therapy for Heart Failure: Lessons Learned from SCIENCE.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2807.
    PubMed    


  468. MARCHANDOT B, Trimaille A, Morel O
    Letter regarding the article "Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes".
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2812.
    PubMed    


  469. JANKOWSKA EA, Liu PP, Cowie MR, Groenhart M, et al
    Personalised care of patients with heart failure - are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals' needs and patients' perceptions.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2798.
    PubMed     Abstract available



  470. Correction to: "A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry" and articles listed below.
    Eur J Heart Fail. 2023 Feb 17. doi: 10.1002/ejhf.2789.
    PubMed    


  471. MICHOU E, Wussler D, Mueller C
    Reply to the Letter to the Editor regarding the article "Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure".
    Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2802.
    PubMed    


  472. ABBASI MA, Borlaug BA
    Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows.
    Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2800.
    PubMed    


  473. LONCAR G, Garfias-Veitl T, Valentova M, Vatic M, et al
    Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
    Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2794.
    PubMed     Abstract available


  474. CAPPELLETTO C, Stolfo D, Orsini N, Benson L, et al
    Use of and Association between Heart Failure Pharmacological Treatments and Outcomes in Obese vs. non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2795.
    PubMed     Abstract available


  475. KALOGEROPOULOS AP, Lewis GD
    Benefits of Intravenous Iron Supplementation in Patients with Heart Failure: Mounting Evidence and Open Questions.
    Eur J Heart Fail. 2023 Feb 1. doi: 10.1002/ejhf.2787.
    PubMed    


  476. PATEL L, Keshvani N, Pandey A
    Are post-influenza vaccine reactions truly 'adverse'?
    Eur J Heart Fail. 2023;25:311-312.
    PubMed    


  477. DOMINGUEZ F, Cabrera E
    Mavacamten in obstructive hypertrophic cardiomyopathy - Are beta-blockers blocking part of its shine?
    Eur J Heart Fail. 2023;25:271-273.
    PubMed    


  478. LIM HS, Yim IHW
    De novo aortic regurgitation related to left ventricular assist device therapy: the difficult questions in need of new perspectives.
    Eur J Heart Fail. 2023;25:295-298.
    PubMed    


  479. OMOTE K, Verbrugge FH, Sorimachi H, Omar M, et al
    Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2023;25:185-196.
    PubMed     Abstract available


  480. URIEL N, Milano C, Agarwal R, Lee S, et al
    Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
    Eur J Heart Fail. 2023;25:286-294.
    PubMed     Abstract available


  481. WHEELER MT, Jacoby D, Elliott PM, Saberi S, et al
    Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Eur J Heart Fail. 2023;25:260-270.
    PubMed     Abstract available


  482. PEIKERT A, Claggett BL, Kim K, Udell JA, et al
    Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.
    Eur J Heart Fail. 2023;25:299-310.
    PubMed     Abstract available


  483. LEVI N, Moravsky G, Weitsman T, Amsalem I, et al
    A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
    Eur J Heart Fail. 2023;25:313-318.
    PubMed     Abstract available


    January 2023
  484. MCEWAN P, Harrison C, Binnie R, Lewis RD, et al
    Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalisation: A European multinational economic evaluation.
    Eur J Heart Fail. 2023 Jan 31. doi: 10.1002/ejhf.2788.
    PubMed     Abstract available


  485. WANG S, Sun J, Wang L
    Interleukin-6 in acute heart failure: it does work, but how much? Letter regarding the article 'Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure'.
    Eur J Heart Fail. 2023 Jan 25. doi: 10.1002/ejhf.2785.
    PubMed    


  486. FUCHS ANDERSEN C, Glenthoj A, Jensen J
    Letter regarding the editorial "Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure".
    Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2782.
    PubMed    


  487. WEENING EH, Al-Mubarak AA, Damman K, Voors AA, et al
    Trace element equilibrium in acute heart failure and the effect of empagliflozin.
    Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2779.
    PubMed    


  488. MAEDER MT
    The beta3-adrenoreceptor agonist mirabegron for the treatment of combined pre- and post-capillary pulmonary hypertension: new pathway or dead end?
    Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2780.
    PubMed    


  489. LECLERCQ C, Burri H
    His bundle pacing for correcting atrioventricular dyssynchrony in heart failure: HYPE or HOPE?
    Eur J Heart Fail. 2023 Jan 17. doi: 10.1002/ejhf.2775.
    PubMed    


  490. GUALANDRO DM, Puelacher C, Chew MS, Andersson H, et al
    Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2773.
    PubMed     Abstract available


  491. SAVARESE G, Lindenfeld J, Stolfo D, Adams K, et al
    Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2778.
    PubMed     Abstract available


  492. MILLER RJ, Chew DS, Qin L, Fine NM, et al
    Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2777.
    PubMed     Abstract available


  493. MASTORIS I, Campain J, Lewis GD
    Invasive Exercise Hemodynamics: An Oracle in Heart Failure with Preserved Ejection Fraction Diagnosis and Prognostication.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2774.
    PubMed    


  494. QAYYUM AA, van Klarenbosch B, Frljak S, Cerar A, et al
    Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction - The SCIENCE Trial.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2772.
    PubMed     Abstract available


  495. ORBAN M, Rottbauer W, Williams M, Mahoney P, et al
    Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with 3(rd) Generation Devices in Heart Failure Patients-Results from the Global EXPAND Post-Market Study.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2770.
    PubMed     Abstract available


  496. AIMO A, Bayes-Genis A
    Biomarkers of inflammation in heart failure: from risk prediction to possible treatment targets.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2771.
    PubMed    


  497. GRASSI G
    HEART FAILURE RELATED CENTRAL SYMPATHETIC ACTIVATION: DEBUNKING THE "HOLY GRAIL" ?
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2764.
    PubMed    


  498. MICHOU E, Wussler D, Belkin M, Simmen C, et al
    Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2767.
    PubMed     Abstract available


  499. VON HAEHLING S, Sato R, Butler J, Anker SD, et al
    Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2766.
    PubMed    


  500. VARSHNEY AS, Berg DD, Zhou G, Sinnenberg L, et al
    Bridging Strategies and Cardiac Replacement Outcomes in Patients with Acute Decompensated Heart Failure-Related Cardiogenic Shock.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2762.
    PubMed     Abstract available


  501. DOCHERTY KF, McMurray JJV, Claggett BL, Miao ZM, et al
    Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2763.
    PubMed     Abstract available


  502. VAN DER HOEF CCS, Boorsma EM, Emmens JE, van Essen BJ, et al
    Biomarker signature and pathophysiological pathways in chronic heart failure patients with metabolic syndrome.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2760.
    PubMed     Abstract available


  503. TOMASONI D, Adamo M, Metra M
    January 2023 at a glance: focus on acute heart failure and medical therapy.
    Eur J Heart Fail. 2023;25:1-3.
    PubMed    


  504. CARAVITA S, Baratto C
    Understanding mechanisms of Fontan failure: exercise haemodynamics to unmask diastolic dysfunction, again!
    Eur J Heart Fail. 2023;25:26-29.
    PubMed    


  505. CODINA P, Lupon J, Subirana I, Zamora E, et al
    Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment.
    Eur J Heart Fail. 2023;25:131-132.
    PubMed    


  506. BERTERO E, Maack C
    The attack of the clones to the cardiovascular system.
    Eur J Heart Fail. 2023;25:14-16.
    PubMed    


  507. YU Y, Niu H, Hua W
    Letter regarding the article 'Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure'.
    Eur J Heart Fail. 2023;25:133.
    PubMed    


    December 2022
  508. BORIANI G, Imberti JF, Vitolo M
    The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: a call to action for detecting atrial fibrillation and improving outcome.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2755.
    PubMed    


  509. KALOGEROPOULOS AP, Jacobs M
    Improve Heart Function to Improve Heart Failure Outcomes: The Disease-Modifying Effects of Spironolactone.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2757.
    PubMed    


  510. CARBONE S, daSilva-deAbreu A, Lavie CJ
    Weighing in on Weight Loss in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2753.
    PubMed    


  511. COTTER G, Davison B, Cohen-Solal A, Freund Y, et al
    Targeting the "vulnerable" period - first 3 - 6 months after an acute heart failure admission - the light gets brighter.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2754.
    PubMed    


  512. HUNGERFORD SL, Dahle G, Duncan A, Hayward CS, et al
    Peri-procedural management of transcatheter mitral valve replacement in patients with heart failure.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2758.
    PubMed     Abstract available


  513. INCIARDI R, Pellicori P, Chandra A
    Identification and Quantification of Congestion in Heart Failure: a Work in Progress.
    Eur J Heart Fail. 2022 Dec 4. doi: 10.1002/ejhf.2751.
    PubMed    


  514. BADROV MB, Keir DA, Tomlinson G, Notarius CF, et al
    Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation.
    Eur J Heart Fail. 2022 Dec 2. doi: 10.1002/ejhf.2749.
    PubMed     Abstract available


  515. TOMASONI D, Adamo M, Metra M
    December 2022 at a glance: heart failure with preserved ejection fraction, sodium-glucose cotransporter 2 inhibitors and cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:2209-2211.
    PubMed    


  516. PATEL RK, Ioannou A, Razvi Y, Chacko L, et al
    Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Eur J Heart Fail. 2022;24:2355-2363.
    PubMed     Abstract available


  517. CERLINSKAITE-BAJORE K, Mebazaa A, Celutkiene J
    Guideline-directed medical therapy improves not only left but also right heart function.
    Eur J Heart Fail. 2022;24:2235-2237.
    PubMed    


  518. CHANDRA A, Polanczyk CA, Claggett BL, Vaduganathan M, et al
    Health-related quality of life outcomes in PARAGON-HF.
    Eur J Heart Fail. 2022;24:2264-2274.
    PubMed     Abstract available


  519. DOMINGUEZ-RODRIGUEZ A, Hernandez-Vaquero D, Miro O
    Reply to 'Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?'.
    Eur J Heart Fail. 2022;24:2393-2394.
    PubMed    


  520. NETO GONCALVES T, Margarida Andrade M
    Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice? Letter regarding the article 'Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled tri
    Eur J Heart Fail. 2022;24:2392-2393.
    PubMed    


  521. NICKLAS JM, Perry D
    Non-intuitive findings from the MEMS-HF haemodynamic substudy.
    Eur J Heart Fail. 2022;24:2331-2332.
    PubMed    


  522. NITSCHE C
    How prevalent is cardiac amyloidosis and which patients should be screened?
    Eur J Heart Fail. 2022;24:2352-2354.
    PubMed    


  523. RAPEZZI C, Emdin M, Aimo A
    Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:2364-2366.
    PubMed     Abstract available


  524. MAESTRO-BENEDICTO A, Vela P, de Frutos F, Mora N, et al
    Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Eur J Heart Fail. 2022;24:2367-2373.
    PubMed     Abstract available


  525. AIMO A, Merlo M, Porcari A, Georgiopoulos G, et al
    Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
    Eur J Heart Fail. 2022;24:2342-2351.
    PubMed     Abstract available


    November 2022
  526. SINHA A, Patel RB
    Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    Eur J Heart Fail. 2022 Nov 29. doi: 10.1002/ejhf.2750.
    PubMed    


  527. LIN DS, Lin FI, Lin YS, Lee JK, et al
    The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End-Stage Renal Disease and Heart Failure.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2740.
    PubMed     Abstract available


  528. GARCIA-ALVAREZ A, Blanco I, Garcia-Lunar I, Jorda P, et al
    beta3-adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2745.
    PubMed     Abstract available


  529. FAUVEL C, Bonnet G, Mullens W, Giraldo CIS, et al
    Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2743.
    PubMed     Abstract available


  530. WHINNETT ZI, Shun-Shin MJ, Tanner M, Foley P, et al
    Effects of haemodynamically atrio-ventricular optimized His-pacing on heart failure symptoms and exercise capacity: The His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) randomised, double-blind, cross-over trial.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2736.
    PubMed     Abstract available


  531. MOHEBI R, Liu Y, van Kimmenade R, Gaggin HK, et al
    Inflammation across Universal Definition of Heart Failure Stages: The CASABLANCA Study.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2742.
    PubMed     Abstract available


  532. PATEL HC, Kaye DM
    SGLT2i: Efficacious and Safe in Elderly Patients with Heart Failure.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2744.
    PubMed    


  533. VAN WOERDEN G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, et al
    Connecting Epicardial Adipose Tissue and Heart Failure with Preserved Ejection Fraction: Mechanisms, Management and Modern Perspectives.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2741.
    PubMed     Abstract available


  534. PACKER M
    How Can SGLT2 Inhibitors Stimulate Erythrocytosis in Patients Who Are Iron Deficient? Implications for Understanding Iron Hemostasis in Heart Failure.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2731.
    PubMed     Abstract available


  535. DE BIASE N, Del Punta L, Pugliese NR
    The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2733.
    PubMed    


  536. FUCHS ANDERSEN C, Omar M, Glenthoj A, El Fassi D, et al
    Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2735.
    PubMed     Abstract available


  537. LERMAN JB, Felker GM
    Time to Diuretics in Acute Heart Failure: the tortoise or the hare?
    Eur J Heart Fail. 2022 Nov 9. doi: 10.1002/ejhf.2732.
    PubMed    


  538. PATEL RB, Greene SJ, Xu H, Alhanti B, et al
    Intersection of Atrial Fibrillation and Heart Failure with Mildly Reduced and Preserved Ejection Fraction in >400,000 Participants in the Get With The Guidelines Heart Failure Registry.
    Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2729.
    PubMed     Abstract available


  539. YANG M, Butt JH, Kondo T, Jering KS, et al
    Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2722.
    PubMed     Abstract available


  540. GREENE SJ, Goto D, Wang D, Hilkert R, et al
    Outpatient versus Inpatient Intravenous Diuretic Therapy for Heart Failure in the United States.
    Eur J Heart Fail. 2022 Nov 5. doi: 10.1002/ejhf.2727.
    PubMed    


  541. ANKER SD, Khan MS, Butler J, Ofstad AP, et al
    Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced.
    Eur J Heart Fail. 2022 Nov 2. doi: 10.1002/ejhf.2728.
    PubMed     Abstract available


  542. ADAMO M, Pagnesi M, Ghizzoni G, Estevez-Loureiro R, et al
    Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality.
    Eur J Heart Fail. 2022;24:2175-2184.
    PubMed     Abstract available


  543. TOMASONI D, Adamo M, Metra M
    November 2022 at a glance: focus on epidemiology, prognosis and comorbidities.
    Eur J Heart Fail. 2022;24:1997-1999.
    PubMed    


  544. MARTINO M, Sannino A
    From forgotten to rediscovered: shifting focus to the right ventricle in primary mitral regurgitation.
    Eur J Heart Fail. 2022;24:2172-2174.
    PubMed    


  545. JHUND PS
    Implementing the evidence - the true summit of evidence-based care and the false peak of guidelines.
    Eur J Heart Fail. 2022;24:2090-2092.
    PubMed    


  546. CEDARS A, Joseph S
    Don't tell your patients where they are, let them tell you.
    Eur J Heart Fail. 2022;24:2105-2107.
    PubMed    


  547. HEIDECKER B, Dagan N, Balicer R, Eriksson U, et al
    Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ES
    Eur J Heart Fail. 2022;24:2000-2018.
    PubMed     Abstract available


  548. DOLDI PM, Stolz L, Kalbacher D, Koll B, et al
    Right ventricular dysfunction predicts outcome after transcatheter mitral valve repair for primary mitral valve regurgitation.
    Eur J Heart Fail. 2022;24:2162-2171.
    PubMed     Abstract available


  549. VERGARO G, Aimo A, Rapezzi C, Castiglione V, et al
    Atrial amyloidosis: mechanisms and clinical manifestations.
    Eur J Heart Fail. 2022;24:2019-2028.
    PubMed     Abstract available


  550. STANTON LJ, Dershowitz LB, Lang KJ, Brandwein R, et al
    Insights from a clinical heart valve centre: characteristics and management of functional mitral regurgitation.
    Eur J Heart Fail. 2022;24:2202-2205.
    PubMed    


  551. HIGUCHI S, Orban M, Adamo M, Giannini C, et al
    Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:2152-2161.
    PubMed     Abstract available


    October 2022
  552. FERREIRA JP, Cleland JG, Girerd N, Bozec E, et al
    Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
    Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2726.
    PubMed     Abstract available


  553. BATRA G, Aktaa S, Benson L, Dahlstrom U, et al
    Association between heart failure quality of care and mortality: population-based cohort study using nationwide registries.
    Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2725.
    PubMed     Abstract available


  554. PATEL KV, Khan MS, Segar MW, Bahnson JL, et al
    Optimal Cardiometabolic Health and Risk of Heart Failure in Type 2 Diabetes: An Analysis from the Look AHEAD Trial.
    Eur J Heart Fail. 2022 Oct 24. doi: 10.1002/ejhf.2723.
    PubMed     Abstract available


  555. ANSARI RAMANDI MM, van Melle JP, Gorter TM, Hoendermis ES, et al
    Right ventricular dysfunction in patients with new-onset heart failure: Longitudinal follow-up during guideline-directed medical therapy.
    Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2721.
    PubMed     Abstract available


  556. BUTLER J, Usman MS, Anstrom KJ, Blaustein RO, et al
    Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum.
    Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2720.
    PubMed     Abstract available


  557. DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
    Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
    Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2717.
    PubMed    


  558. BRANCH KRH, Gerstein HC, Probstfield JL
    Letter regarding the article Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-Hoc Analysis from the REWIND Randomized Trial: Reply.
    Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2719.
    PubMed    


  559. ZHANG Y, Feng J, Zhang J
    Heart failure with preserved ejection fraction in China: An urgent need for improving the management.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2718.
    PubMed    


  560. SHI C, Aboumsallem JP, Suthahar N, de Graaf AO, et al
    Clonal hematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2715.
    PubMed     Abstract available


  561. ZAKERI R, Ahluwalia N, Tindale A, Omar F, et al
    Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2714.
    PubMed     Abstract available


  562. INCIARDI RM, Pagnesi M, Lombardi CM, Solomon SD, et al
    Reply to "Clinical implications of left atrial changes after optimization of medical therapy in heart failure patients".
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2713.
    PubMed    


  563. VENKATESHVARAN A, Faxen UL, Hage C, Michaelsson E, et al
    Association of Epicardial Adipose Tissue with Proteomics, Coronary Flow Reserve, Cardiac Structure and Function, and Quality of Life in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF study.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2709.
    PubMed     Abstract available


  564. OUWERKERK W, Tromp J, Cleland JGF, Angermann CE, et al
    Association of time-to-IV-furosemide with mortality in acute heart failure: data from REPORT-HF.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2708.
    PubMed     Abstract available


  565. FILIPPATOS G, Anker SD, Butler J, Farmakis D, et al
    Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2707.
    PubMed     Abstract available


  566. MIRANDA WR, Borlaug BA, Jain CC, Anderson JH, et al
    Exercise-induced changes in pulmonary artery wedge pressure in adults post-Fontan versus heart failure with preserved ejection fraction and noncardiac dyspnea.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2706.
    PubMed     Abstract available


  567. MARTENS P
    Inhibiting the proximal nephron in acute heart failure - emerging data on kidney safety and efficacy.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2711.
    PubMed    


  568. CHATUR S, Claggett BL, Vardeny O, Jering K, et al
    Sacubitril/Valsartan and Loop Diuretic Requirement in Heart Failure with Preserved Ejection Fraction in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Oct 1. doi: 10.1002/ejhf.2703.
    PubMed     Abstract available


  569. ARONSON D
    Can subgroup analyses in randomized trials guide individualized patient care?
    Eur J Heart Fail. 2022;24:1802-1804.
    PubMed    


  570. CHATUR S, Lakdawala NK, Cunningham JW
    Random admission urinary sodium for diuretic response: promise in pragmatism?
    Eur J Heart Fail. 2022;24:1988-1989.
    PubMed    


  571. CHIONCEL O, Metra M
    Morphine in acute pulmonary oedema: a signal of harm but more questions than answers.
    Eur J Heart Fail. 2022;24:1963-1966.
    PubMed    


  572. BERWANGER O, Pfeffer M, Claggett B, Jering KS, et al
    Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
    Eur J Heart Fail. 2022;24:1918-1927.
    PubMed     Abstract available


  573. BELDHUIS IE, Martens P, Ter Maaten JM
    Early changes in renal function after sodium-glucose cotransporter 2 inhibitor initiation in EMPEROR-Reduced: the end of the dilemma?
    Eur J Heart Fail. 2022;24:1840-1843.
    PubMed    


  574. PAPPALARDO F, Tavazzi G, Savonitto S, Morici N, et al
    Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock-2 registry.
    Eur J Heart Fail. 2022;24:1748-1750.
    PubMed    


  575. MOHR E, Thum T, Bar C
    Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models.
    Eur J Heart Fail. 2022;24:1778-1791.
    PubMed     Abstract available


  576. DOMINGUEZ-RODRIGUEZ A, Suero-Mendez C, Burillo-Putze G, Gil V, et al
    Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.
    Eur J Heart Fail. 2022;24:1953-1962.
    PubMed     Abstract available


  577. ZANNAD F, Ferreira JP, Gregson J, Kraus BJ, et al
    Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
    Eur J Heart Fail. 2022;24:1829-1839.
    PubMed     Abstract available


    September 2022
  578. KEIR DA, Floras JS
    Iron repletion in heart failure: a central chemoreceptor reflex tonic?
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2697.
    PubMed    


  579. BAEZA-TRINIDAD R, Mosquera-Lozano JD
    "Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2701.
    PubMed    


  580. PARVAN R, Hosseinpour M, Moradi Y, Devaux Y, et al
    Diagnostic Performance of MicroRNAs in the Detection of Heart Failure with Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2700.
    PubMed     Abstract available


  581. LEE MMY, Campbell RT, Claggett BL, Lewis EF, et al
    Health-related quality of life in acute heart failure: Association between patient-reported symptoms and markers of congestion.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2699.
    PubMed     Abstract available


  582. PELLICORI P, Kalra PR, Clark AL, Friday JM, et al
    CKD and CKD-ism in heart failure - what a mess!
    Eur J Heart Fail. 2022 Sep 21. doi: 10.1002/ejhf.2696.
    PubMed    



  583. Corrigendum to 'Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata' [Eur J Heart Fail 2022;24:1047-1062].
    Eur J Heart Fail. 2022 Sep 20. doi: 10.1002/ejhf.2691.
    PubMed    


  584. FERREIRA JP, Neves JS
    Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
    Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2694.
    PubMed    


  585. COOPER TJ, Pellicori P, Ushakova A, Dickstein K, et al
    Reply to the letter "Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases".
    Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2690.
    PubMed    


  586. VAN ESSEN BJ, Tromp J, Ter Maaten JM, Greenberg BH, et al
    Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.
    Eur J Heart Fail. 2022 Sep 16. doi: 10.1002/ejhf.2695.
    PubMed     Abstract available


  587. DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
    Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
    Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2692.
    PubMed    


  588. FERREIRA JP, Neves JS
    Glucagon-Like Peptide 1 Receptor Agonists in Heart Failure: the need for a rewind.
    Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2693.
    PubMed    


  589. JOURY A, Razaghizad A, Sharma A
    Multi-Biomarkers Approach to Predict Survival and Adverse Cardiovascular Events Among Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2689.
    PubMed    



  590. Corrigendum to 'Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction' [Eur J Heart Fail 2022;24:782-790].
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2676.
    PubMed    


  591. GREENE SJ, Fonarow GC, Butler J
    SGLT2 Inhibitors for Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Time to Deliver Implementation.
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2688.
    PubMed    


  592. ADAMSON C, Jhund PS, McMurray JJ
    Reply: Liver function tests and outcomes in heart failure with reduced ejection fraction: Findings from DAPA-HF.
    Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2683.
    PubMed    


  593. MCDOWELL K, Jhund PS, McMurray JJ
    Reply to 'Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. Letter regarding the article 'Dapagliflozin reduces uric acid concentrat
    Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2686.
    PubMed    


  594. GIRERD N
    Worsening renal function precedes and follows worsening heart failure.
    Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2673.
    PubMed    


  595. BUTLER J, Siddiqi TJ, Anker SD
    Patiromer Use in Patients with Heart Failure Lessons and Clinical Considerations from the DIAMOND Trial.
    Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2684.
    PubMed    


  596. BOHM M, Butler J, Mahfoud F, Filippatos G, et al
    Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2022 Sep 10. doi: 10.1002/ejhf.2677.
    PubMed     Abstract available


  597. BRANCH KRH, Dagenais GR, Avezum A, Basile J, et al
    Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial.
    Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2670.
    PubMed     Abstract available


  598. BAYES-GENIS A, Aimo A, Jhund P, Richards AM, et al
    A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2675.
    PubMed     Abstract available


  599. VOORS AA, Damman K, Teerlink JR, Angermann CE, et al
    Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2681.
    PubMed     Abstract available


  600. NAHAR TAK, Shah A, Ahmad M
    "Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2679.
    PubMed    


  601. KRAWCZYK M, Bohm M
    The 50 shades of bilirubin.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2671.
    PubMed    


  602. LUND LH, Eldhagen P
    Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2678.
    PubMed    


  603. XIE C, Zhang Y, Lin J
    What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?
    Eur J Heart Fail. 2022 Sep 4. doi: 10.1002/ejhf.2668.
    PubMed    


  604. JHUND PS
    Cardiopulmonary functional capacity: Another piece of the puzzle of SGLT2 inhibition in heart failure?
    Eur J Heart Fail. 2022 Sep 2. doi: 10.1002/ejhf.2672.
    PubMed    


  605. TOMASONI D, Adamo M, Metra M
    September 2022 at a glance.
    Eur J Heart Fail. 2022;24:1455-1457.
    PubMed    


  606. ROSANO GMC, Metra M, Volterrani M
    The strategic vision of the 2022-2024 mandate - greater involvement of members, young specialists for an HFA community without borders.
    Eur J Heart Fail. 2022;24:1458-1459.
    PubMed    


  607. MEEKERS E, Mullens W
    When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy.
    Eur J Heart Fail. 2022;24:1662-1664.
    PubMed    


  608. BUTT JH, McMurray JJV
    Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    Eur J Heart Fail. 2022;24:1623-1624.
    PubMed    


  609. PORCARI A, Merlo M, Sinagra G
    Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?
    Eur J Heart Fail. 2022;24:1716-1718.
    PubMed    


  610. MUSIGK N, Heidecker B
    Transthyretin amyloidosis: the picture is getting clearer.
    Eur J Heart Fail. 2022;24:1697-1699.
    PubMed    


  611. NITSCHE C
    Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most?
    Eur J Heart Fail. 2022;24:1713-1715.
    PubMed    


  612. BAUERSACHS J, Koenig T
    Peripartum cardiomyopathy - a global challenge.
    Eur J Heart Fail. 2022;24:1737-1738.
    PubMed    


  613. ALVAREZ-GARCIA J
    Sacubitril/valsartan adherence... because the best is sometimes difficult to replace the good.
    Eur J Heart Fail. 2022;24:1516-1518.
    PubMed    


  614. DENIAU B, Asakage A, Mebazaa A
    Clonal haematopoiesis mutations in cardiogenic shock: a beginning of a new era?
    Eur J Heart Fail. 2022;24:1583-1585.
    PubMed    


  615. BURTON JO, Coats AJS, Kovesdy CP, Palmer BF, et al
    An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.
    Eur J Heart Fail. 2022;24:1467-1477.
    PubMed     Abstract available


  616. CHACKO L, Karia N, Venneri L, Bandera F, et al
    Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1700-1712.
    PubMed     Abstract available


  617. HOEVELMANN J, Engel ME, Muller E, Hohlfeld A, et al
    A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022;24:1719-1736.
    PubMed     Abstract available


  618. ANTONOPOULOS AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, et al
    Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022;24:1677-1696.
    PubMed     Abstract available


  619. SCOLARI FL, Abelson S, Brahmbhatt DH, Medeiros JJF, et al
    Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock.
    Eur J Heart Fail. 2022;24:1573-1582.
    PubMed     Abstract available


    August 2022
  620. NUNEZ J, de la Espriella R, Rossignol P, Voors AA, et al
    Congestion in Heart Failure: a circulating biomarker-based perspective.
    Eur J Heart Fail. 2022 Aug 30. doi: 10.1002/ejhf.2664.
    PubMed     Abstract available


  621. PATEL HC, Kaye DM
    The rise of devices in heart failure with preserved ejection fraction: the future is not set.
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2667.
    PubMed    


  622. NAITO R, Kasai T
    Obstructive coronary artery disease, a common and curable but critical comorbidity in acute decompensated heart failure.
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2665.
    PubMed    


  623. DOEHNER W, Packer M
    Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an ind
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2666.
    PubMed    


  624. SINAGRA G, Paldino A, Dal Ferro M
    HEART FAILURE WITH SUPRA-NORMAL LEFT VENTRICLE EJECTION FRACTION: DISTINCT POLYGENIC BASES OF AN UNRECOGNIZED PHENOTYPE.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2657.
    PubMed    


  625. ZITO A, Princi G, Romiti GF, Galli M, et al
    Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2655.
    PubMed     Abstract available


  626. ASSMUS B, Angermann CE, Alkhlout B, Asselbergs FW, et al
    Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2656.
    PubMed     Abstract available


  627. MARTENS P, Chen HH, Verbrugge FH, Testani JT, et al
    Assessing Intrinsic Renal Sodium Avidity in Acute Heart Failure: Implications in Predicting and Guiding Decongestion.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2662.
    PubMed     Abstract available


  628. CAI A, Qiu W, Zhou Y, Feng Y, et al
    Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: Results from the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2654.
    PubMed     Abstract available


  629. FERREIRA JP, Sharma A, Vasques-Novoa F, Angelico-Goncalves A, et al
    Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2660.
    PubMed     Abstract available


  630. OSTROMINSKI JW, Vaduganathan M, Claggett BL, de Boer RA, et al
    Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Eur J Heart Fail. 2022 Aug 11. doi: 10.1002/ejhf.2652.
    PubMed     Abstract available


  631. RICHARDS AM
    Optimizing the diagnostic utility of NT-proBNP for acute heart failure in obesity and beyond.
    Eur J Heart Fail. 2022 Aug 9. doi: 10.1002/ejhf.2653.
    PubMed    


  632. ADAMSON C, Cowan LM, de Boer RA, Diez M, et al
    Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
    Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2649.
    PubMed     Abstract available


  633. DE LA ESPRIELLA R, Amiguet M, Minana G, Rodriguez JC, et al
    Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure.
    Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2651.
    PubMed     Abstract available


  634. ANTOHI LE, Adamo M, Chioncel O
    Long-term Survival after Acute Heart Failure Hospitalization; From Observation to Collaborative Interventions.
    Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2645.
    PubMed    


  635. LINDBERG F, Lund LH, Benson L, Dahlstrom U, et al
    Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2644.
    PubMed     Abstract available


  636. TOMASONI D, Adamo M, Metra M
    August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1325-1326.
    PubMed    


  637. CHANDRAMOULI C, Lam CSP
    Sex, fat and the heart: it's all in the waist.
    Eur J Heart Fail. 2022;24:1371-1376.
    PubMed    


  638. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply.
    Eur J Heart Fail. 2022;24:1450-1451.
    PubMed    


  639. CLEMMENSEN TS, Poulsen SH
    Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future.
    Eur J Heart Fail. 2022;24:1397-1399.
    PubMed    


  640. VILCHES S, Fontana M, Gonzalez-Lopez E, Mitrani L, et al
    Systemic embolism in amyloid transthyretin cardiomyopathy.
    Eur J Heart Fail. 2022;24:1387-1396.
    PubMed     Abstract available


  641. JERING KS, Campagnari C, Claggett B, Adler E, et al
    Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations.
    Eur J Heart Fail. 2022;24:1418-1426.
    PubMed     Abstract available


  642. MERLO M, Pagura L, Porcari A, Cameli M, et al
    Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.
    Eur J Heart Fail. 2022;24:1377-1386.
    PubMed     Abstract available


    July 2022
  643. BORIANI G, Vitolo M, Imberti JF
    Effectiveness of atrial fibrillation ablation in heart failure across the entire spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2022 Jul 29. doi: 10.1002/ejhf.2642.
    PubMed    


  644. CHATUR S, Vaduganathan M, Peikert A, Claggett BL, et al
    Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Jul 27. doi: 10.1002/ejhf.2638.
    PubMed     Abstract available


  645. METRA M, Jankowska EA, Pagnesi M, Anker SD, et al
    Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
    Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2630.
    PubMed    


  646. VADUGANATHAN M, Ferreira JP, Rossignol P, Neuen B, et al
    Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2635.
    PubMed     Abstract available


  647. SALAH HM, Fudim M
    Tolerability and Safety Barriers of SGLT2 Inhibitors Initiation in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2633.
    PubMed    


  648. BROMAGE DI, Cannata A, McDonagh TA
    Combination diuretic therapy for acute heart failure: "Alone we can do so little; together we can do so much".
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2634.
    PubMed    


  649. METRA M, Chioncel O, Cotter G, Davison B, et al
    Safety and Efficacy of Istaroxime for Patients with Acute-Heart-Failure-Related Pre-cardiogenic Shock - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study (SEISMiC).
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2629.
    PubMed     Abstract available


  650. CARAVITA S, Faini A, Vignati C, Pelucchi S, et al
    Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2628.
    PubMed     Abstract available


  651. LINDE C, Grabowski M, Ponikowski P, Rao I, et al
    Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF).
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2619.
    PubMed     Abstract available


  652. TOMASONI D, Aimo A, Merlo M, Nardi M, et al
    Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2616.
    PubMed     Abstract available


  653. PAPALIA F, Charles-Edwards G, Okonko DO
    Reply to the letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2625.
    PubMed    


  654. DANDEL M, Hetzer R
    Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2622.
    PubMed    


  655. GENTILE F, Passino C, Emdin M, Giannoni A, et al
    Baroreflex activation therapy in heart failure: targeting the right patient.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2627.
    PubMed    


  656. REDDY YNV, Sundaram V
    Spironolactone, fibrosis and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2626.
    PubMed    


  657. KRISTENSEN SL, Gustafsson F
    Advanced Heart Failure: time to screen?
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2624.
    PubMed    


  658. JANSE RJ, Fu EL, Dahlstrom U, Benson L, et al
    Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2620.
    PubMed     Abstract available


  659. CHUNAWALA ZS, Qamar A, Arora S, Pandey A, et al
    Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: The ARIC study community surveillance.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2617.
    PubMed     Abstract available


  660. KOZHUHAROV N, Martin J, Wussler D, Lopez-Ayala P, et al
    Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2618.
    PubMed     Abstract available


  661. POCOCK SJ, Ferreira JP, Packer M, Zannad F, et al
    Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2022 Jul 7. doi: 10.1002/ejhf.2607.
    PubMed     Abstract available


  662. MERKELY B, Geller L, Zima E, Osztheimer I, et al
    Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2609.
    PubMed     Abstract available


  663. SENNI M, Alemayehu WG, Sim D, Edelmann F, et al
    Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.
    PubMed     Abstract available


  664. WANG X, Cunningham JW
    Restoring Balance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2599.
    PubMed    


  665. KRISTENSEN SL, Barasa A, Thune JJ
    The Challenge of Addressing Heart Failure in Low and Middle Income Countries.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2598.
    PubMed    


  666. BAYES-GENIS A, Aimo A, Lupon J
    Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2597.
    PubMed    


  667. GULIZIA MM, Orso F, Mortara A, Lucci D, et al
    BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.
    Eur J Heart Fail. 2022 Jul 3. doi: 10.1002/ejhf.2605.
    PubMed     Abstract available


  668. VON OLSHAUSEN G, Benson L, Dahlstrom U, Lund LH, et al
    Catheter Ablation for Patients with Atrial Fibrillation and Heart Failure: Insights from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Jul 2. doi: 10.1002/ejhf.2604.
    PubMed     Abstract available


  669. VRTOVEC B, Frljak S, Poglajen G, Zemljic G, et al
    A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2596.
    PubMed     Abstract available


  670. MARCO GUAZZI M, Wilhelm M, Halle M, Van Craenenbroeck E, et al
    Exercise Testing in HFpEF: an Appraisal Through Diagnosis, Pathophysiology and Therapy A Clinical Consensus Statement of the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2601.
    PubMed     Abstract available



  671. Abstracts of the Heart Failure 2022 and the World Congress on Acute Heart Failure, 21 - 24 May 2022, Madrid, Spain.
    Eur J Heart Fail. 2022;24 Suppl 2:3-282.
    PubMed    


  672. TOMASONI D, Adamo M, Metra M
    July 2022 at a glance: focus on prognosis, devices and valvular heart disease.
    Eur J Heart Fail. 2022;24:1145-1147.
    PubMed    


  673. SCHRAGE B, Westermann D
    Enough iron in transcatheter aortic valve implantation already.
    Eur J Heart Fail. 2022;24:1280-1281.
    PubMed    


  674. DOMINGUEZ F
    Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG.
    Eur J Heart Fail. 2022;24:1237-1238.
    PubMed    


  675. MCGURK KA, Halliday BP
    Dilated cardiomyopathy - details make the difference.
    Eur J Heart Fail. 2022;24:1197-1199.
    PubMed    


  676. PETUTSCHNIGG J, Edelmann F
    Closing the gap, or the beauty of alleviating our patients' symptoms.
    Eur J Heart Fail. 2022;24:1302-1304.
    PubMed    


  677. BORIANI G, Vitolo M, Leyva F
    Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'?
    Eur J Heart Fail. 2022;24:1223-1226.
    PubMed    


  678. NAYAK A, Mehra MR
    Global challenges in left ventricular assist device therapy: a tale across two continents.
    Eur J Heart Fail. 2022;24:1316-1318.
    PubMed    


  679. ILIADIS C, Kalbacher D, Lurz P, Petrescu AM, et al
    Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:1282-1292.
    PubMed     Abstract available


  680. KVASLERUD AB, Bardan S, Andresen K, Klove SF, et al
    Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.
    Eur J Heart Fail. 2022;24:1269-1279.
    PubMed     Abstract available


  681. PORCARI A, Rossi M, Cappelli F, Canepa M, et al
    Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1227-1236.
    PubMed     Abstract available


  682. JAKUS N, Brugts JJ, Claggett B, Timmermans P, et al
    Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry.
    Eur J Heart Fail. 2022;24:1305-1315.
    PubMed     Abstract available


  683. MIRELIS JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, et al
    Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1183-1196.
    PubMed     Abstract available


  684. MANCA P, Stolfo D, Merlo M, Gregorio C, et al
    Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1171-1179.
    PubMed     Abstract available


  685. STOCKER TJ, Cohen DJ, Arnold SV, Sommer S, et al
    Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy.
    Eur J Heart Fail. 2022;24:1293-1301.
    PubMed     Abstract available


    June 2022
  686. ABDELHAMID M, Rosano G, Metra M, Adamopoulos S, et al
    Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need ICD for primary prevention?
    Eur J Heart Fail. 2022 Jun 26. doi: 10.1002/ejhf.2594.
    PubMed     Abstract available


  687. HARIHARAPUTHIRAN S, Peng Y, Ngo L, Ali A, et al
    Long-term Survival and Life Expectancy Following an Acute Heart Failure Hospitalisation in Australia and New Zealand.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2595.
    PubMed     Abstract available


  688. INCIARDI RM, Pagnesi M, Lombardi CM, Anker SD, et al
    Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2593.
    PubMed     Abstract available


  689. MULLENS W, Dauw J, Martens P, Meekers E, et al
    Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline Characteristics.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2587.
    PubMed     Abstract available


  690. VUKADINOVIC D, Abdin A, Anker SD, Rosano GM, et al
    Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2584.
    PubMed     Abstract available


  691. RYAN M, Perera D, Petrie MC
    Revascularization and heart failure with preserved ejection fraction - time for randomized trials.
    Eur J Heart Fail. 2022 Jun 21. doi: 10.1002/ejhf.2583.
    PubMed    


  692. REDDY YNV
    Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil.
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2582.
    PubMed    


  693. AIMO A, Castiglione V, Bayes-Genis A
    Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2580.
    PubMed    


  694. COATS A, Abraham WT, Zile MR, Lindenfeld JA, et al
    Baroreflex activation therapy with the barostim device in patients with heart failure with reduced ejection fraction: A patient level meta-analysis of randomized controlled trials.
    Eur J Heart Fail. 2022 Jun 17. doi: 10.1002/ejhf.2573.
    PubMed     Abstract available


  695. KOBAYASHI M, Girerd N, Ferreira JP, Kevin D, et al
    The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2579.
    PubMed     Abstract available


  696. BURRAGE MK, Valkovic L, Rider OJ
    Letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2574.
    PubMed    


  697. SEFEROVIC P, Farmakis D, Bayes-Genis A, Ben Gal T, et al
    Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2575.
    PubMed     Abstract available


  698. LUND LH, Pitt B, Metra M
    Left ventricular ejection fraction as the primary heart failure phenotyping parameter.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2576.
    PubMed    


  699. INCIARDI RM, Chandra A
    Epicardial Adipose Tissue in Heart Failure: Risk Factor or Mediator?
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2577.
    PubMed    


  700. BHATT AS, Vaduganathan M, Solomon SD, Schneeweiss S, et al
    Sacubitril/Valsartan Use Patterns among Older Adults with Heart Failure in Clinical Practice: A Population-Based Cohort Study of >25,000 Medicare Beneficiaries.
    Eur J Heart Fail. 2022 Jun 11. doi: 10.1002/ejhf.2572.
    PubMed     Abstract available


  701. RAGAVAN A, Hogan J, Halliday BP
    The spectrum of heart failure with improved ejection fraction - persistent congestion, to heart failure remission and perhaps recovery?
    Eur J Heart Fail. 2022 Jun 6. doi: 10.1002/ejhf.2571.
    PubMed    


  702. HAVAKUK O, Topilsky Y
    The Impact of Early Surgery on Mortality in Infective Endocarditis Complicated by Heart Failure - How Much More Data Do We Need?
    Eur J Heart Fail. 2022 Jun 1. doi: 10.1002/ejhf.2567.
    PubMed    


  703. TOMASONI D, Adamo M, Metra M
    June 2022 at a glance: prevention, outcomes and treatment.
    Eur J Heart Fail. 2022;24:913-915.
    PubMed    


  704. LEYVA F, Boriani G
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1091-1093.
    PubMed    


  705. COOPER LT JR
    Sex and autoimmunity in acute myocarditis: time for a refresh.
    Eur J Heart Fail. 2022;24:1045-1046.
    PubMed    


  706. CLELAND JGF, Bristow MR, Freemantle N, Olshansky B, et al
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1080-1090.
    PubMed     Abstract available


  707. YAMAMOTO M, Tajiri K, Ayuzawa S, Ieda M, et al
    Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination.
    Eur J Heart Fail. 2022;24:1132-1138.
    PubMed     Abstract available


  708. BARITUSSIO A, Schiavo A, Basso C, Giordani AS, et al
    Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.
    Eur J Heart Fail. 2022;24:1033-1044.
    PubMed     Abstract available


  709. GONZALEZ A, Richards AM, de Boer RA, Thum T, et al
    Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022;24:927-943.
    PubMed     Abstract available


  710. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Eur J Heart Fail. 2022;24:1106-1113.
    PubMed     Abstract available


  711. CHIANG CH, Chiang CH, Chiang CH
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'.
    Eur J Heart Fail. 2022;24:1142-1143.
    PubMed    


  712. MCDOWELL K, Welsh P, Docherty KF, Morrow DA, et al
    Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
    Eur J Heart Fail. 2022;24:1066-1076.
    PubMed     Abstract available


    May 2022

  713. Corrigendum to 'A population-based study of 92 clinicallyrecognized risk factors for heart failure: co-occurrence, prognosis and preventive potential' [Eur J Heart Fail 2022;24:466-480].
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2544.
    PubMed    


  714. ANKER SD, Siddiqi TJ, Filippatos G, Zannad F, et al
    Outcomes with Empagliflozin in Heart Failure with Preserved Ejection Fraction Using DELIVER-like Endpoint Definitions.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2558.
    PubMed     Abstract available


  715. PALAU P, Amiguet M, Dominguez E, Sastre C, et al
    Short-term Effects of Dapagliflozin on Maximal Functional Capacity in Heart Failure with Reduced Ejection Fraction (DAPA-VO2 ): A Randomized Clinical Trial.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2560.
    PubMed     Abstract available


  716. PAGNESI M, Lombardi CM, Chiarito M, Stolfo D, et al
    Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: Results from the HELP-HF Registry.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2561.
    PubMed     Abstract available


  717. SORIMACHI H, Omote K, Omar M, Popovic D, et al
    Sex and Central Obesity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2563.
    PubMed     Abstract available


  718. INCIARDI RM, Bonelli A, Biering-Sorensen T, Cameli M, et al
    Left atrial disease and left atrial reverse remodeling across different stages of heart failure development and progression: a new target for prevention and treatment.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2562.
    PubMed     Abstract available


  719. FUDIM M, Fail PS, Litwin SE, Shaburishvili T, et al
    Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Early Results of the REBALANCE-HF Trial Roll-in Cohort.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2559.
    PubMed     Abstract available


  720. COOPER TJ, Cleland JG, Guazzi M, Pellicori P, et al
    Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2527.
    PubMed     Abstract available


  721. RAVERA A, Santema BT, de Boer RA, Anker SD, et al
    Distinct pathophysiological pathways in women and men with heart failure.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2534.
    PubMed     Abstract available


  722. JANUS SE, Hajjari J, Chami T, Mously H, et al
    Multi-Variable Biomarker Approach in Identifying Incident Heart Failure in Chronic Kidney Disease Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Eur J Heart Fail. 2022 May 19. doi: 10.1002/ejhf.2543.
    PubMed     Abstract available


  723. BAYES-GENIS A, Aimo A, Metra M, Anker S, et al
    Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines.
    Eur J Heart Fail. 2022 May 17. doi: 10.1002/ejhf.2542.
    PubMed     Abstract available


  724. JOHANSSON I, Balasubramanian K, Bangdiwala S, Mielniczuk L, et al
    Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the G-CHF Research Program.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2535.
    PubMed     Abstract available


  725. NATH M, Romaine SP, Koekemoer A, Hamby S, et al
    Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2540.
    PubMed     Abstract available


  726. VAN ESSEN B, Voors AA, Tromp J
    Risk factors for the development of heart failure in patients with or without prior myocardial infarction.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2538.
    PubMed    


  727. ASLEH R, Briasoulis A, Borlaug BA
    Nonsteroidal Aldosterone Receptor Antagonism: A "Fine" Treatment for Heart Failure Patients?
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2537.
    PubMed    


  728. DAMMAN K
    When two worlds collide - Making sense of changes in renal function with life saving heart failure therapies.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2539.
    PubMed    


  729. MYHRE PL, Claggett BL, Shah AM, Prescott MF, et al
    Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2541.
    PubMed     Abstract available


  730. BOHBOT Y, Habib G, Laroche C, Stohr E, et al
    Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: A substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry.
    Eur J Heart Fail. 2022 May 4. doi: 10.1002/ejhf.2525.
    PubMed     Abstract available


  731. SCHRAGE B, Lund LH, Benson L, Dahlstrom U, et al
    Predictors of primary prevention implantable cardioverter defibrillator use in heart failure with reduced ejection fraction: Impact of the predicted risk of sudden cardiac death and all-cause mortality.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2530.
    PubMed     Abstract available


  732. ERQOU S, Adler AI, Challa AA, Fonarow GC, et al
    Insulin Resistance and Incident Heart Failure: A Meta-Analysis.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2531.
    PubMed    


  733. TOMASONI D, Adamo M, Metra M
    May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices.
    Eur J Heart Fail. 2022;24:735-737.
    PubMed    


  734. COATS AJS
    What's all the fuss about a new guideline?
    Eur J Heart Fail. 2022;24:743-745.
    PubMed    


  735. SORAJJA P, Cavalcante J, Bapat V
    Setting expectations for transcatheter mitral valve replacement in the real world.
    Eur J Heart Fail. 2022;24:908-909.
    PubMed    


  736. FRERKER C, Karam N, Hahn RT, Thiele H, et al
    New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence.
    Eur J Heart Fail. 2022;24:746-749.
    PubMed    


  737. REDDY YNV
    Using the ejection fraction to guide medical therapy: a necessary but imperfect first step.
    Eur J Heart Fail. 2022;24:779-781.
    PubMed    


  738. BEN ALI W, Ludwig S, Duncan A, Weimann J, et al
    Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry.
    Eur J Heart Fail. 2022;24:887-898.
    PubMed     Abstract available


  739. ROSANO GMC, Celant S, Olimpieri PP, Colatrella A, et al
    Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
    Eur J Heart Fail. 2022;24:855-860.
    PubMed     Abstract available


  740. BUTLER J, Spertus JA, Bamber L, Khan MS, et al
    Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
    Eur J Heart Fail. 2022;24:843-850.
    PubMed     Abstract available


  741. WILD MG, Kreidel F, Hell MM, Praz F, et al
    Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.
    Eur J Heart Fail. 2022;24:899-907.
    PubMed     Abstract available


    April 2022
  742. AIMO A, Vergaro G, Gonzalez A, Barison A, et al
    Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2022 Apr 30. doi: 10.1002/ejhf.2522.
    PubMed     Abstract available


  743. CARTER S, Hendren NS, Grodin JL
    Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
    Eur J Heart Fail. 2022 Apr 29. doi: 10.1002/ejhf.2516.
    PubMed    


  744. REZA N, Butler J
    Assessing Health Status After Discharge for Decompensated Heart Failure: A Patient-Centered Priority.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2521.
    PubMed    


  745. BORIANI G, Imberti JF, Vitolo M
    Dronedarone in the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long Odyssey?
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2519.
    PubMed    


  746. PELLICORI P, Cleland JG
    Heart failure: age is no excuse for complacency.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2517.
    PubMed    


  747. CANNATA A, Bromage DI, McDonagh TA
    COVID and heart failure: the dark side of the moon.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2518.
    PubMed    


  748. KALOGEROPOULOS AP, Tam E
    Intravenous iron in heart failure with reduced ejection fraction: just about right.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2520.
    PubMed    


  749. JIN X, Hung CL, Tay WT, Soon D, et al
    Epicardial Adipose Tissue related to Left Atrial and Ventricular Function in Heart Failure with Preserved (HFpEF) versus Reduced and Mildly Reduced Ejection Fraction (HFrEF/HFmrEF).
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2513.
    PubMed     Abstract available


  750. XIE C
    Could angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor be used in heart failure patients with atrial fibrillation and low blood pressure?
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2515.
    PubMed    


  751. EMDIN M, Aimo A, Castiglione V
    Is Targeting Cyclic Guanosine Monophosphate by Vericiguat Effective to Treat Ischaemic Heart Failure with Reduced Ejection Fraction? Yes, It Is.
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2511.
    PubMed    


  752. STRAW S, Gierula J, Witte KK
    Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2510.
    PubMed    


  753. MCNAUGHTON CD, McConnachie A, Cleland JG, Spertus JA, et al
    Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from REPORT-HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).
    Eur J Heart Fail. 2022 Apr 16. doi: 10.1002/ejhf.2508.
    PubMed     Abstract available


  754. GIRERD N, Mewton N, Tartiere JM, Guijarro D, et al
    Practical outpatient management of worsening chronic heart failure.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2503.
    PubMed     Abstract available


  755. STEWART COATS AJ
    HeartFailureNews Figures of the Heart Failure Association: Professor Finn Gustafsson, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2502.
    PubMed    


  756. KALOGEROPOULOS AP, Butler J
    Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2507.
    PubMed    


  757. STEWART COATS AJ
    Figures of the Heart Failure Association: Doctor Amina Rakisheva, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2499.
    PubMed    


  758. ALNUWAYSIR RIS, Grote Beverborg N, van der Meer P
    Fluctuating iron levels in heart failure: when and where to look at?
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2500.
    PubMed    


  759. VOORDES GHD, Heerspink HJL, Ter Maaten JM
    The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2501.
    PubMed    


  760. SINHA A, Yancy CW, Patel RB
    Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2505.
    PubMed    


  761. RASTOGI T, Ho FK, Rossignol P, Merkling T, et al
    Comparing and contrasting risk factors for Heart failure in patients with and without history of myocardial infarction: Data from HOMAGE and the UK Biobank.
    Eur J Heart Fail. 2022 Apr 1. doi: 10.1002/ejhf.2495.
    PubMed     Abstract available


  762. TOMASONI D, Adamo M, Metra M
    April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022;24:593-595.
    PubMed    


  763. CLELAND JGF, Butler J, Januzzi JL Jr, Pellicori P, et al
    Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice.
    Eur J Heart Fail. 2022;24:678-680.
    PubMed    


  764. GROTE BEVERBORG N
    The heart during iron deficiency: a non-rechargeable battery?
    Eur J Heart Fail. 2022;24:724-726.
    PubMed    


  765. TAVAZZI L, Maggioni AP, Rapezzi C, Ferrari R, et al
    Clinical trials: conventional or pragmatic?
    Eur J Heart Fail. 2022;24:596-599.
    PubMed    


  766. SIDHU K, Castrini AI, Parikh V, Reza N, et al
    The response to cardiac resynchronization therapy in LMNA cardiomyopathy.
    Eur J Heart Fail. 2022;24:685-693.
    PubMed     Abstract available


  767. CHIONCEL O, Adamo M, Bauersachs J
    Risk stratification in cardiogenic shock: from clinical utility to improving outcomes.
    Eur J Heart Fail. 2022;24:668-671.
    PubMed    


  768. MARINO PN, Zanaboni J
    Does left atrial deformation impact on symptoms and prognosis in functional mitral regurgitation patients with poor left ventricular function?
    Eur J Heart Fail. 2022;24:705-707.
    PubMed    


  769. HOLM H, Magnusson M, Jujic A, Bozec E, et al
    How to calculate ventricular-arterial coupling?
    Eur J Heart Fail. 2022;24:600-602.
    PubMed    


  770. HAVAKUK O, Topilsky Y
    The interplay between functional mitral regurgitation and left atrial function.
    Eur J Heart Fail. 2022;24:703-704.
    PubMed    


  771. IKONOMIDIS I, Lambadiari V, Mitrakou A, Kountouri A, et al
    Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection.
    Eur J Heart Fail. 2022;24:727-729.
    PubMed    


  772. BEER BN, Jentzer JC, Weimann J, Dabboura S, et al
    Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score.
    Eur J Heart Fail. 2022;24:657-667.
    PubMed     Abstract available


    March 2022
  773. NIJHOLT KT, Westenbrink BD
    Reply to letter to the editor regarding the article 'Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?'
    Eur J Heart Fail. 2022 Mar 26. doi: 10.1002/ejhf.2494.
    PubMed    


  774. ANKER SD, Ponikowski P, Khan MS, Friede T, et al
    Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Eur J Heart Fail. 2022 Mar 25. doi: 10.1002/ejhf.2491.
    PubMed     Abstract available



  775. Corrigendum to 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy' [Eur J Heart Fail 2021;23:854-871].
    Eur J Heart Fail. 2022 Mar 17. doi: 10.1002/ejhf.2474.
    PubMed    


  776. DEVORE AD, Hellkamp AS, Thomas L, Albert NM, et al
    The Association of Improvement in Left Ventricular Ejection Fraction with Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Data from CHAMP-HF.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2486.
    PubMed     Abstract available


  777. VADUGANATHAN M, Piccini JP, Camm AJ, Crijns HJGM, et al
    Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2487.
    PubMed     Abstract available


  778. KESHVANI N, Mehta A, Alger HM, Rutan C, et al
    Heart Failure Quality of Care and In-Hospital Outcomes During the COVID-19 Pandemic Findings from the Get With The Guidelines-Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 14. doi: 10.1002/ejhf.2484.
    PubMed     Abstract available


  779. BUTLER J, Khan MS, Friede T, Jankowska EA, et al
    Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
    Eur J Heart Fail. 2022 Mar 13. doi: 10.1002/ejhf.2478.
    PubMed     Abstract available


  780. FORREST IS, Rocheleau G, Bafna S, Argulian E, et al
    Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2482.
    PubMed     Abstract available


  781. STOLFO D, Lund LH, Becher PM, Orsini N, et al
    Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2483.
    PubMed     Abstract available



  782. Corrigendum to 'Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2473.
    PubMed    



  783. Corrigendum to 'Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry [Eur J Heart Fail 2021;23:1844-1854].
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2472.
    PubMed    


  784. D'AMARIO D, Rodolico D, Rosano GM, Dahlstrom U, et al
    Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 8. doi: 10.1002/ejhf.2477.
    PubMed     Abstract available


  785. KONSTAM MA
    Autonomic Dysregulation in Diabetes: CAN We Prevent Heart Failure?
    Eur J Heart Fail. 2022 Mar 4. doi: 10.1002/ejhf.2476.
    PubMed    


  786. SALDARRIAGA C, Atar D, Stebbins A, Lewis BS, et al
    Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2468.
    PubMed     Abstract available


  787. KHAN MS, Shahid I, Fonarow GC, Greene SJ, et al
    Classifying Heart Failure Based on Ejection Fraction: Imperfect but Enduring.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2470.
    PubMed    


  788. FILIPPATOS G, Pitt B, Agarwal R, Farmakis D, et al
    Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2469.
    PubMed     Abstract available


  789. MULLENS W, Martens P, Testani JM, Tang WHW, et al
    Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2471.
    PubMed    


  790. KOKHAN E, Kiyakbaev G, Medovchshikov V
    Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article "Early benefit with empagliflozin in heart failure with preserved ejecti
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2466.
    PubMed    


  791. ANDRIOPOULOU M, Dimaki N, Kallistratos MS, Chamodraka E, et al
    Skeletal muscle alterations and exercise intolerance in heart failure with preserved ejection fraction patients: ultrasonography assessment of diaphragm and quadriceps.
    Eur J Heart Fail. 2022 Mar 1. doi: 10.1002/ejhf.2462.
    PubMed    


  792. TOMASONI D, Adamo M, Metra M
    March 2022 at a glance: focus on medical therapy, prevention and comorbidities.
    Eur J Heart Fail. 2022;24:403-405.
    PubMed    


  793. DAUW J, Mullens W, Girerd N
    The fastest way to the heart is through the veins: towards a better understanding of congestion.
    Eur J Heart Fail. 2022;24:463-465.
    PubMed    


  794. KOEHLER F, Schulz M
    The AMULET menage a trois: nurse, telemedicine support, and remote cardiologist.
    Eur J Heart Fail. 2022;24:578-580.
    PubMed    


  795. DE SOUSA C, Pinto FJ
    Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
    Eur J Heart Fail. 2022;24:589-590.
    PubMed    


  796. DONAL E, Sade LE, Thomas L
    Left atrial function: the HbA1c for the cardiologist and even more.
    Eur J Heart Fail. 2022;24:494-496.
    PubMed    


  797. CURTAIN JP, Jackson AM, Shen L, Jhund PS, et al
    Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
    Eur J Heart Fail. 2022;24:551-561.
    PubMed     Abstract available


  798. RUSSO G, Taramasso M, Pedicino D, Gennari M, et al
    Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?
    Eur J Heart Fail. 2022;24:442-454.
    PubMed     Abstract available


  799. IVEY-MIRANDA JB, Wetterling F, Gaul R, Sheridan S, et al
    Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone.
    Eur J Heart Fail. 2022;24:455-462.
    PubMed     Abstract available


  800. AMAT-SANTOS IJ, Sanchez-Luna JP, Abu-Assi E, Melendo-Viu M, et al
    Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
    Eur J Heart Fail. 2022;24:581-588.
    PubMed     Abstract available


    February 2022
  801. BHATT AS, Fonarow GC, Greene SJ
    Prioritizing Prevention of De Novo and Worsening Chronic Heart Failure.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2464.
    PubMed    


  802. KAMBIC T, Piepoli MF, Lainscak M
    Exercise intolerance in heart failure: beyond mitochondrial dysfunction.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2461.
    PubMed    


  803. FERREIRA JP, Verdonschot JAJ, Girerd N, Bozec E, et al
    Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2455.
    PubMed     Abstract available


  804. BUTT JH, Adamson C, Docherty KF, Vaduganathan M, et al
    Eligibility for Pharmacological Therapies in Heart Failure with Reduced Ejection Fraction: Implications of the New CKD-EPI Creatinine Equation for Estimating Glomerular Filtration Rate.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2460.
    PubMed     Abstract available


  805. PAPALIA F, Jouhra F, Amin-Youssef G, Shah AM, et al
    Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2454.
    PubMed     Abstract available


  806. FERREIRA JP, Packer M, Butler J, Zannad F, et al
    Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.
    Eur J Heart Fail. 2022 Feb 22. doi: 10.1002/ejhf.2457.
    PubMed     Abstract available


  807. ROSSIGNOL P, Pitt B
    Time to Shift our Focus from the Treatment to the Prevention of Heart Failure with a Mineralocorticoid Receptor Antagonist (MRA)?
    Eur J Heart Fail. 2022 Feb 21. doi: 10.1002/ejhf.2459.
    PubMed    


  808. IKONOMIDIS I, Vlastos D
    Corrigendum to 'The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Periph
    Eur J Heart Fail. 2022 Feb 9. doi: 10.1002/ejhf.2452.
    PubMed    


  809. PEIKERT A, Vaduganathan M, McCausland F, Claggett BL, et al
    Effects of Sacubitril/Valsartan Versus Valsartan on Renal Function in Patients with and without Diabetes and Heart Failure with Preserved Ejection Fraction: Insights From PARAGON-HF.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2450.
    PubMed     Abstract available


  810. DEO SV, Reddy YN, Zakeri R, Karnib M, et al
    Revascularization in Ischemic Heart Failure with Preserved Ejection Fraction: A Nationwide Cohort Study.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2446.
    PubMed    


  811. MOHAMED MO
    Prevention is better than cure: modifiable risk factors for heart failure better understood.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2448.
    PubMed    


  812. KONDO T, Jhund PS, McMurray JJV
    Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2447.
    PubMed     Abstract available


  813. VARSHNEY AS, Singh JP, Vaduganathan M
    A Heart Team Approach to Contemporary Device Decision-Making in Heart Failure.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2445.
    PubMed    


  814. PITT B, Epstein M
    A Promise Unfulfilled : The use of Mineralocorticoid Receptor Antagonists ( MRAs ) in patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2441.
    PubMed    


  815. ARITA VA, Van Veldhuisen DJ, Rienstra M
    Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2443.
    PubMed    


  816. EL-BATTRAWY I, Akin I
    Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baselin
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2444.
    PubMed    


  817. OMAR M, Jensen MD, Borlaug BA
    Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2440.
    PubMed    



  818. HFA Winter Meeting on Translational Heart Failure Research 27-28 January 2022.
    Eur J Heart Fail. 2022;24 Suppl 1:3-12.
    PubMed    


  819. TOMASONI D, Adamo M, Metra M
    February 2022 at a glance: focus on pathophysiology and acute heart failure.
    Eur J Heart Fail. 2022;24:243-244.
    PubMed    


  820. TREVISAN M, Fu EL, Carrero JJ
    Reply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399-400.
    PubMed    


  821. WARRAICH HJ, Nohria A
    Is worsening renal function relevant without clinical context?
    Eur J Heart Fail. 2022;24:375-377.
    PubMed    


  822. FACILE A, Mewton N, Nguon M, Durand de Gevigney G, et al
    Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA(R) coding in the MITRA-FR study.
    Eur J Heart Fail. 2022;24:396-398.
    PubMed    


  823. ALEXANDROU ME, Sarafidis PA
    Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399.
    PubMed    


  824. OBOKATA M, Reddy YNV, Melenovsky V, Sorimachi H, et al
    Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
    Eur J Heart Fail. 2022;24:353-361.
    PubMed     Abstract available


    January 2022
  825. PABON MA, Cunningham JW, Claggett BL, Packer M, et al
    Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.
    Eur J Heart Fail. 2022 Jan 26. doi: 10.1002/ejhf.2439.
    PubMed     Abstract available


  826. KAZE AD, Yuyun MF, Erqou S, Fonarow GC, et al
    Cardiac Autonomic Neuropathy and Risk of Incident Heart Failure Among Adults with Type 2 Diabetes.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2432.
    PubMed     Abstract available


  827. TROMP J, Beusekamp JC, Ouwerkerk W, van der Meer P, et al
    Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2431.
    PubMed     Abstract available


  828. CHANDRAMOULI C, Ting TW, Tromp J, Agarwal A, et al
    Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2022 Jan 21. doi: 10.1002/ejhf.2435.
    PubMed     Abstract available


  829. MULLENS W, Coats A, Seferovic P, Metra M, et al
    Education and Certification on Heart Failure of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2430.
    PubMed     Abstract available


  830. POTTER E, Stephenson G, Harris J, Wright L, et al
    Screening-Guided Spironolactone Treatment of Subclinical Left Ventricular Dysfunction for Heart Failure Prevention in At-risk Patients.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2428.
    PubMed     Abstract available


  831. MALAGOLI A, Rossi L, Zanni A, Sticozzi C, et al
    Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2429.
    PubMed     Abstract available


  832. MC CAUSLAND FR, Lefkowitz MP, Claggett B, Packer M, et al
    Angiotensin-Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2421.
    PubMed     Abstract available


  833. PATEL RB, Shah SJ, Inciardi RM
    Collagen Homeostasis of the Left Atrium: An Emerging Treatment Target to Prevent Heart Failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2422.
    PubMed    


  834. MADIAS JE
    Pathophysiology and therapy of Takotsubo syndrome. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Gro
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2413.
    PubMed    


  835. DOUMAS M, Patoulias D, Papadopoulos C
    Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, m
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2412.
    PubMed    


  836. CEELEN D, Voors AA, Tromp J, van Veldhuisen DJ, et al
    Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2424.
    PubMed     Abstract available


  837. BUTLER J, Siddiqi TJ, Filippatos G, Ferreira JP, et al
    Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2420.
    PubMed     Abstract available


  838. DE BIASE N, Del Punta L, Pugliese NR
    Reply: Epicardial adipose tissue: does it mediate the cardio-protective effects of SGLT-2 inhibitors in subjects with heart failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2423.
    PubMed    


  839. PIEPOLI MF, Adamo M, Barison A, Bestetti RB, et al
    Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.
    Eur J Heart Fail. 2022;24:143-168.
    PubMed     Abstract available


  840. TOMASONI D, Adamo M, Metra M
    January 2022 at a glance: time for the new ESC guidelines on heart failure.
    Eur J Heart Fail. 2022;24:1-3.
    PubMed    


  841. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contri
    Eur J Heart Fail. 2022;24:4-131.
    PubMed     Abstract available


  842. AKTAA S, Polovina M, Rosano G, Abdin A, et al
    European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society o
    Eur J Heart Fail. 2022;24:132-142.
    PubMed     Abstract available


  843. ROSENKRANZ S, Channick R, Chin KM, Jenner B, et al
    The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Eur J Heart Fail. 2022;24:205-214.
    PubMed     Abstract available


    December 2021
  844. ZAHIR D, Bonde A, Madelaire C, Malmborg M, et al
    Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2418.
    PubMed     Abstract available


  845. BANERJEE A, Pasea L, Chung SC, Direk K, et al
    A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2417.
    PubMed     Abstract available


  846. DE BOER RA, Heymans S, Backs J, Carrier L, et al
    Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society o
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2414.
    PubMed     Abstract available


  847. MEEMS LMG, van Veldhuisen DJ, de Boer RA
    Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out...?!
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2415.
    PubMed    


  848. KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
    A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ejhf.2408.
    PubMed     Abstract available


  849. BAYES-GENIS A, Nunez J, Lupon J
    Dysglycemia and High Natriuretic Peptides: The Prelude to Heart Failure.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2410.
    PubMed    


  850. NIJHOLT KT, Sanchez-Aguilera PI, Voorrips SN, de Boer RA, et al
    Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2407.
    PubMed     Abstract available


  851. FERREIRA JP, Anker SD, Butler J, Filippatos G, et al
    Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2409.
    PubMed     Abstract available


  852. AL-MUBARAK AA, Beverborg NG, Suthahar N, Gansevoort RT, et al
    High selenium levels associate with reduced risk of mortality and new onset heart failure: data from PREVEND.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2405.
    PubMed     Abstract available



  853. Corrigendum to 'Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials' [Eur J Heart Fail 2020;11:2160-2171].
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2404.
    PubMed    


  854. ANDERSEN DM, Sengelov M, Olsen FJ, Marott JL, et al
    Measures of Left Atrial Function Predicts Incident Heart Failure in a Low Risk General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2406.
    PubMed     Abstract available


  855. JACKSON AM, Rorth R, Liu J, Kristensen SL, et al
    Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Dec 17. doi: 10.1002/ejhf.2403.
    PubMed     Abstract available


  856. WEIR RA, Clements S, Steedman T, Dargie HJ, et al
    Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow-up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial.
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2402.
    PubMed     Abstract available


  857. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2400.
    PubMed     Abstract available


  858. TOMASONI D, Fonarow GC, Adamo M, Anker SD, et al
    Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2397.
    PubMed     Abstract available


  859. PAGNESI M, Butler J, Metra M
    Ejection fraction in heart failure: just become Emperor's new clothes?
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2399.
    PubMed    


  860. TOMASONI D, Adamo M, Metra M
    December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.
    Eur J Heart Fail. 2021;23:1993-1994.
    PubMed    


  861. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
    Prime time for machine learning to predict clinical outcomes in valvular heart disease?
    Eur J Heart Fail. 2021;23:2033-2034.
    PubMed    


  862. SINAGRA G, Porcari A, Fabris E, Merlo M, et al
    Standardizing the role of endomyocardial biopsy in current clinical practice worldwide.
    Eur J Heart Fail. 2021;23:1995-1998.
    PubMed    


  863. VIDULA MK, Orlenko A, Zhao L, Salvador L, et al
    Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
    Eur J Heart Fail. 2021;23:2021-2032.
    PubMed     Abstract available


  864. STRACHINARU M, Nijveldt R, Vernooy K
    Arrhythmic risk management after acute myocarditis: never too early, only too late.
    Eur J Heart Fail. 2021;23:2055-2057.
    PubMed    


  865. HALLIDAY BP, de Marvao A, Thilaganathan B
    Peripartum cardiomyopathy and pre-eclampsia: two tips of the same iceberg.
    Eur J Heart Fail. 2021;23:2070-2072.
    PubMed    


  866. GENTILE P, Merlo M, Peretto G, Ammirati E, et al
    Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias.
    Eur J Heart Fail. 2021;23:2045-2054.
    PubMed     Abstract available


  867. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
    Eur J Heart Fail. 2021;23:2085-2090.
    PubMed     Abstract available


  868. JACKSON AM, Petrie MC, Frogoudaki A, Laroche C, et al
    Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.
    Eur J Heart Fail. 2021;23:2058-2069.
    PubMed     Abstract available


    November 2021
  869. RAVASSA S, Lopez B, Ferreira JP, Girerd N, et al
    Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling.
    Eur J Heart Fail. 2021 Nov 28. doi: 10.1002/ejhf.2394.
    PubMed     Abstract available



  870. Corrigendum to 'High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality' [Eur J Heart Fail 2021;23:919-932].
    Eur J Heart Fail. 2021 Nov 24. doi: 10.1002/ejhf.2383.
    PubMed    


  871. FAUCHIER L, Bisson A, Lip GYH
    Age, sex and clinical outcomes with digoxin vs beta-blocker in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2389.
    PubMed    


  872. ALNUWAYSIR RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, et al
    Additional Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia Syndrome: Findings from the BIOSTAT-CHF Study.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2393.
    PubMed     Abstract available


  873. CULIC V
    Digoxin and beta-blockers in patients with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2392.
    PubMed    


  874. NAITO R, Kasai T
    Bereavement of a child as a risk of heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2388.
    PubMed    


  875. MADIAS JE
    Pathophysiology of Takotsubo syndrome: still a puzzle. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2390.
    PubMed    


  876. MAEDER MT
    Selexipag and the Pulmonary Hypertension Continuum.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2387.
    PubMed    


  877. BUTLER J, Anker SD, Siddiqi TJ, Coats AJS, et al
    Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Eur J Heart Fail. 2021 Nov 20. doi: 10.1002/ejhf.2386.
    PubMed     Abstract available


  878. TER MAATEN JM, Beldhuis IE, van der Meer P, Krikken JA, et al
    Natriuresis guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2385.
    PubMed     Abstract available


  879. EMMENS JE, Ter Maaten JM, Matsue Y, Figarska SM, et al
    Worsening renal function in acute heart failure in the context of diuretic response.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2384.
    PubMed     Abstract available


  880. GREENE SJ, Butler J, Fonarow GC
    In-hospital Initiation of Quadruple Medical Therapy for Heart Failure: Making the Post-Discharge Vulnerable Phase Far Less Vulnerable.
    Eur J Heart Fail. 2021 Nov 14. doi: 10.1002/ejhf.2382.
    PubMed    


  881. BUTT JH, Docherty KF, Jhund PS, De Boer RA, et al
    Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF.
    Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.
    PubMed     Abstract available


  882. SEFEROVIC PM, Polovina M, Adlbrecht C, BElohlavek J, et al
    Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2378.
    PubMed     Abstract available


  883. FERREIRA JP, Liu J, Claggett BL, Vardeny O, et al
    Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2376.
    PubMed     Abstract available


  884. SEGAR MW, Khan MS, Patel KV, Vaduganathan M, et al
    Incorporation of Natriuretic Peptides with Clinical Risk-scores to Predict Heart Failure Among Individuals with Dysglycemia.
    Eur J Heart Fail. 2021 Nov 3. doi: 10.1002/ejhf.2375.
    PubMed     Abstract available


  885. COHEN-SOLAL A, Beauvais F
    New treatments for heart failure and exercise capacity.
    Eur J Heart Fail. 2021 Nov 1. doi: 10.1002/ejhf.2374.
    PubMed    


  886. GHANTOUS E, Topilsky Y
    Recovery of cardiac function following COVID-19.
    Eur J Heart Fail. 2021;23:1913-1915.
    PubMed    


  887. LASSEN MCH, Skaarup KG, Lind JN, Alhakak AS, et al
    Recovery of cardiac function following COVID-19 - ECHOVID-19: a prospective longitudinal cohort study.
    Eur J Heart Fail. 2021;23:1903-1912.
    PubMed     Abstract available


  888. LAMBADIARI V, Mitrakou A, Kountouri A, Thymis J, et al
    Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection.
    Eur J Heart Fail. 2021;23:1916-1926.
    PubMed     Abstract available


  889. DERDA AA, Garg A, Bar C, Thum T, et al
    Reply to 'COVID-19 severity, miR-21 targets, and common human genetic variation'.
    Eur J Heart Fail. 2021;23:1987-1988.
    PubMed    


  890. DINGSDAG SA, Clay OK, Quintero GA
    COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article 'Circulating cardiovascular microRNAs in critically ill COVID-19 patients'.
    Eur J Heart Fail. 2021;23:1986-1987.
    PubMed    


  891. TOMASONI D, Adamo M, Metra M
    November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices.
    Eur J Heart Fail. 2021;23:1803-1805.
    PubMed    


  892. WITTE KK, Goldberg SL, Kaye D, Starling R, et al
    Reply to 'Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'.
    Eur J Heart Fail. 2021;23:1985-1986.
    PubMed    


  893. SEFEROVIC PM
    Reply to "Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy".
    Eur J Heart Fail. 2021;23:1984.
    PubMed    


  894. COTTER G, Davison B, Metra M, Sliwa K, et al
    Amended STRONG-HF study design.
    Eur J Heart Fail. 2021;23:1981-1982.
    PubMed    


  895. CHIONCEL O, Metra M
    Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock.
    Eur J Heart Fail. 2021;23:1938-1941.
    PubMed    


  896. BARAN DA
    A deceptively simple problem: the case of cardiogenic shock.
    Eur J Heart Fail. 2021;23:1952-1954.
    PubMed    


  897. WITTE KK, Kaye DM, Lipiecki J, Siminiak T, et al
    Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1971-1978.
    PubMed     Abstract available


  898. SCHRAGE B, Beer BN, Savarese G, Dabboura S, et al
    Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
    Eur J Heart Fail. 2021;23:1942-1951.
    PubMed     Abstract available


  899. LU DY, Adelsheimer A, Chan K, Yeo I, et al
    Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
    Eur J Heart Fail. 2021;23:1927-1937.
    PubMed     Abstract available


    October 2021
  900. FRASER AG, Szymanski P
    Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2373.
    PubMed    


  901. WEI D, Li J, Janszky I, Chen H, et al
    Death of a child and the risk of heart failure: a population-based cohort study from Denmark and Sweden.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2372.
    PubMed     Abstract available


  902. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gend
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2368.
    PubMed     Abstract available


  903. MINANA G, Bayes-Genis A, Nunez J
    Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2365.
    PubMed    


  904. MARTENS P
    Detecting Subclinical Congestion in Stage A/B pre-Heart Failure - A glimpse into the future?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2366.
    PubMed    


  905. TROMP J, Packer M, Lam C
    The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2363.
    PubMed    


  906. ADAMO M, Metra M
    Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2362.
    PubMed    


  907. CUTHBERT JJ, Pellicori P, Flockton R, Kallvikbacka-Bennett A, et al
    The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2353.
    PubMed     Abstract available


  908. LAUDER L, Pereira TV, Degenhardt MC, Ewen S, et al
    Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2360.
    PubMed     Abstract available


  909. LOGEART D, Berthelot E, Bihry N, Eschalier R, et al
    Early and short-term intensive management after discharge for patients hospitalized with acute heart failure, a randomized study (ECAD-HF).
    Eur J Heart Fail. 2021 Oct 9. doi: 10.1002/ejhf.2357.
    PubMed     Abstract available


  910. KRZESINSKI P, Jankowska EA, Siebert J, Galas A, et al
    Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET Study): a randomised controlled trial.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2358.
    PubMed     Abstract available


  911. ROSANO G, Jankowska EA, Ray R, Metra M, et al
    COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2356.
    PubMed     Abstract available



  912. Corrigendum to 'Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials' [Eur J Heart Fail 2016;18:684-692].
    Eur J Heart Fail. 2021 Oct 4. doi: 10.1002/ejhf.2354.
    PubMed    


  913. TOMASONI D, Adamo M, Metra M
    October 2021 at a glance: focus on imaging, biomarkers and comorbidities.
    Eur J Heart Fail. 2021;23:1569-1571.
    PubMed    


  914. PACKER M, Zannad F, Butler J, Filippatos G, et al
    Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2021;23:1798-1799.
    PubMed    


  915. BEN GAL T, Ben Avraham B, Milicic D, Crespo-Leiro MG, et al
    Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
    Eur J Heart Fail. 2021;23:1597-1609.
    PubMed     Abstract available


  916. GUAZZI M, Adamo M
    Cardiac output in severe tricuspid regurgitation: when more is less.
    Eur J Heart Fail. 2021;23:1795-1797.
    PubMed    


  917. CAMPOCHIARO C, De Luca G, Dagna L
    Cardiac immune-related adverse events: an immune-cardio-oncology puzzle.
    Eur J Heart Fail. 2021;23:1748-1749.
    PubMed    


  918. USMAN MS, Pitt B, Butler J
    Target trial emulations: bridging the gap between clinical trial and real-world data.
    Eur J Heart Fail. 2021;23:1708-1711.
    PubMed    


  919. ENRIQUEZ-SARANO M, Benfari G, Messika-Zeitoun D, Grigioni F, et al
    Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
    Eur J Heart Fail. 2021;23:1759-1762.
    PubMed    


  920. PATTERSON T, Gregson J, Erglis A, Joseph J, et al
    Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
    Eur J Heart Fail. 2021;23:1775-1783.
    PubMed     Abstract available


  921. CAIFFA T, De Luca A, Biagini E, Lupi L, et al
    Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1765-1774.
    PubMed     Abstract available


  922. UNTERHUBER M, Kresoja KP, Besler C, Rommel KP, et al
    Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.
    Eur J Heart Fail. 2021;23:1784-1794.
    PubMed     Abstract available


  923. RIZZO S, De Gaspari M, Basso C
    Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria.
    Eur J Heart Fail. 2021;23:1736-1738.
    PubMed    


  924. ZENG DX, Jiang JH
    Letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'.
    Eur J Heart Fail. 2021;23:1800.
    PubMed    


  925. TREVISAN M, Fu EL, Xu Y, Savarese G, et al
    Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Eur J Heart Fail. 2021;23:1698-1707.
    PubMed     Abstract available


  926. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Eur J Heart Fail. 2021;23:1739-1747.
    PubMed     Abstract available


  927. PALASKAS NL, Segura A, Lelenwa L, Siddiqui BA, et al
    Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Eur J Heart Fail. 2021;23:1725-1735.
    PubMed     Abstract available


    September 2021
  928. HALLE M, Schobel C, Winzer EB, Bernhardt P, et al
    A randomized clinical trial on the short-term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY-HF study.
    Eur J Heart Fail. 2021 Sep 30. doi: 10.1002/ejhf.2355.
    PubMed     Abstract available


  929. CODINA P, Lupon J, Borrellas A, Spitaleri G, et al
    Head-to-head comparison of contemporary heart failure risk scores.
    Eur J Heart Fail. 2021 Sep 24. doi: 10.1002/ejhf.2352.
    PubMed     Abstract available


  930. YEOH SE, Dewan P, Serenelli M, Ferreira JP, et al
    Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
    Eur J Heart Fail. 2021 Sep 18. doi: 10.1002/ejhf.2350.
    PubMed     Abstract available



  931. Corrigendum to 'Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction' [Eur J Heart Fail 2021; 23, 983-991.].
    Eur J Heart Fail. 2021 Sep 12. doi: 10.1002/ejhf.2341.
    PubMed    


  932. KAMMERLANDER AA, Nitsche C, Dona C, Koschutnik M, et al
    Heart Failure with Preserved Ejection Fraction after Left-sided Valve Surgery: Prevalent and Relevant.
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2345.
    PubMed     Abstract available


  933. COMPAGNUCCI P, Dello Russo A, Casella M
    Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy. Letter regarding the article 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Fai
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2340.
    PubMed    


  934. MEIJERS WC, Bayes-Genis A, Mebazaa A, Bauersachs J, et al
    Circulating Heart Failure Biomarkers beyond Natriuretic Peptides: updated review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2346.
    PubMed     Abstract available


  935. INCIARDI RM, Solomon SD
    Cardiac Mechanics Assessment and the Risk of Heart Failure in the General Population.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2342.
    PubMed    


  936. HEUSSER K, Wittkoepper J, Bara C, Haverich A, et al
    Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end-stage heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2344.
    PubMed     Abstract available


  937. BARTKO PE, Kreidel F, von Bardeleben RS, Goliasch G, et al
    Mitral regurgitation tips the scales in acute or worsening heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2343.
    PubMed    


  938. MOURA B, Aimo A, Al-Mohammad A, Flammer A, et al
    Integration of imaging and circulating biomarkers in heart failure: a Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2021 Sep 5. doi: 10.1002/ejhf.2339.
    PubMed     Abstract available


  939. BECHER PM, Schrage B, Benson L, Fudim M, et al
    Phenotyping Heart Failure Patients for Iron Deficiency and Use of Intravenous Iron Therapy: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
    PubMed     Abstract available



  940. Abstracts of the Heart Failure 2021 and the World Congress on Acute Heart Failure, 29 June - 1 July 2021, Online Congress.
    Eur J Heart Fail. 2021;23 Suppl 2:2-322.
    PubMed    


  941. CRESPO-LEIRO MG, Barge-Caballero E, Gustafsson F
    Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore.
    Eur J Heart Fail. 2021;23:1560-1562.
    PubMed    


  942. ITZHAKI BEN ZADOK O, Shaul AA, Ben-Avraham B, Yaari V, et al
    Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Eur J Heart Fail. 2021;23:1555-1559.
    PubMed     Abstract available


  943. TOMASONI D, Adamo M, Metra M
    September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment.
    Eur J Heart Fail. 2021;23:1419-1421.
    PubMed    


  944. BLUMER V, Gayowsky A, Xie F, Greene SJ, et al
    Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial.
    Eur J Heart Fail. 2021;23:1488-1498.
    PubMed     Abstract available


  945. TOPS LF, Coats AJS, Ben Gal T
    The ever-changing field of mechanical circulatory support: new challenges at the advent of the 'single device era'.
    Eur J Heart Fail. 2021;23:1428-1431.
    PubMed    


  946. AIMO A, Saccaro LF, Borrelli C, Fabiani I, et al
    The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease.
    Eur J Heart Fail. 2021;23:1458-1467.
    PubMed     Abstract available


  947. YUZEFPOLSKAYA M, Colombo PC
    Reply to 'Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus'.
    Eur J Heart Fail. 2021;23:1566-1567.
    PubMed    


  948. NURJADI D, Ruhparwar A, Zanger P
    Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus. Letter regarding the article 'Association of preoperative infections, nasal Staphylococcus aur
    Eur J Heart Fail. 2021;23:1566.
    PubMed    


  949. FERREIRA JP, Konstam MA, McMurray JJV, Butler J, et al
    Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
    Eur J Heart Fail. 2021;23:1477-1484.
    PubMed     Abstract available


    August 2021
  950. CARBONE S, DaSilva-deAbreu A, Lavie CJ
    The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2336.
    PubMed    


  951. DANDEL M, Hetzer R
    Benefits of Transvenous Mitral Annuloplasty in Heart Failure with Lower Degrees of Functional Mitral Regurgitation. Letter regarding the article ' Treating symptoms and reversing remodeling: clinical and echocardiographic 1-year outcomes with percutan
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2335.
    PubMed    


  952. PUGLIESE NR, Paneni F, Mazzola M, De Biase N, et al
    Impact of epicardial adipose tissue on cardiovascular hemodynamics, metabolic profile, and prognosis in heart failure.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2337.
    PubMed     Abstract available


  953. RICHARDS AM, Pemberton CJ
    Progress in proteomic probing for pathogenic pathways in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Aug 18. doi: 10.1002/ejhf.2332.
    PubMed    


  954. STEWART COATS A
    Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018-2022, Coordinator of Study Group of Cardiorenal Dysfunction and Co-coordinator of Committee on Cardiac Devices.
    Eur J Heart Fail. 2021 Aug 9. doi: 10.1002/ejhf.2325.
    PubMed    


  955. STEWART COATS AJ
    Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse representative 2016-2020, and HFA Secretary 2020-2022).
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2323.
    PubMed    


  956. STEWART COATS AJ
    The HFA further develops it educational engagement working together on an MSc in Heart Failure with St George's Hospital in London.
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2324.
    PubMed    


  957. TOMASONI D, Adamo M, Metra M
    August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices.
    Eur J Heart Fail. 2021;23:1247-1249.
    PubMed    


  958. HERRINGTON WG, Savarese G, Haynes R, Marx N, et al
    Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2021;23:1260-1275.
    PubMed     Abstract available


  959. SINAGRA G, Dal Ferro M, Gigli M
    The heart of dystrophinopathies.
    Eur J Heart Fail. 2021;23:1287-1289.
    PubMed    


  960. GUSTAFSSON F, Netuka I
    Progressive elimination of adverse events: the key to success for left ventricular assist devices.
    Eur J Heart Fail. 2021;23:1401-1403.
    PubMed    


  961. ROSARIO KF, DeVore AD
    Can we prevent infections in patients with left ventricular assist devices?
    Eur J Heart Fail. 2021;23:1416-1418.
    PubMed    


  962. RESTREPO-CORDOBA MA, Wahbi K, Florian AR, Jimenez-Jaimez J, et al
    Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.
    Eur J Heart Fail. 2021;23:1276-1286.
    PubMed     Abstract available


  963. RAPEZZI C, Pavasini R, Serenelli M
    The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process.
    Eur J Heart Fail. 2021;23:1296-1299.
    PubMed    


  964. YUZEFPOLSKAYA M, Lumish HS, Javaid A, Cagliostro B, et al
    Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes.
    Eur J Heart Fail. 2021;23:1404-1415.
    PubMed     Abstract available


  965. MEHRA MR, Cleveland JC Jr, Uriel N, Cowger JA, et al
    Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
    Eur J Heart Fail. 2021;23:1392-1400.
    PubMed     Abstract available


  966. IUNG B, Urena M
    Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry.
    Eur J Heart Fail. 2021;23:1377-1379.
    PubMed    


  967. MINAMISAWA M, Inciardi RM, Claggett B, Cuddy SAM, et al
    Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.
    Eur J Heart Fail. 2021;23:1290-1295.
    PubMed     Abstract available


  968. COLOMBO A, Mangieri A
    Can we set a threshold for the learning curve of MitraClip procedures?
    Eur J Heart Fail. 2021;23:1390-1391.
    PubMed    


  969. CHATTERJEE NA, Levy WC
    Looking forward and backward for sudden death risk: competing risk is everywhere.
    Eur J Heart Fail. 2021;23:1357-1360.
    PubMed    


  970. KELLER K, Hobohm L, Schmidtmann I, Munzel T, et al
    Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in Germany.
    Eur J Heart Fail. 2021;23:1380-1389.
    PubMed     Abstract available


  971. BEDOGNI F, Popolo Rubbio A, Grasso C, Adamo M, et al
    Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation.
    Eur J Heart Fail. 2021;23:1364-1376.
    PubMed     Abstract available


  972. GILL H, Chehab O, Allen C, Patterson T, et al
    The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease.
    Eur J Heart Fail. 2021;23:1325-1333.
    PubMed     Abstract available


    July 2021
  973. SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
    Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
    PubMed     Abstract available


  974. PANDEY A, Butler J
    Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
    Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
    PubMed    


  975. KHAN MS, Butler J, Greene SJ
    Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
    Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
    PubMed    


  976. SWEDBERG K
    The clinical practise of treating patients with chronic heart failure needs to be improved.
    Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
    PubMed    


  977. ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
    Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
    PubMed     Abstract available


  978. MILLER RJ, Howlett JG
    Untying the Gordian Knot of Sex and Heart Failure Therapy.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
    PubMed    


  979. SAVARESE G, Merlo M, Coats AJ, Metra M, et al
    Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
    PubMed    


  980. ANKER MS, Tschope C
    Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
    PubMed    


  981. GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
    REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
    PubMed    


  982. GREENE SJ, Butler J, Metra M
    Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
    PubMed    


  983. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    PubMed     Abstract available


  984. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    PubMed     Abstract available


  985. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    PubMed    


  986. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    PubMed    


  987. CARAVITA S, Iacovoni A, Senni M
    The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
    PubMed    


  988. TOMASONI D, Adamo M, Metra M
    July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy.
    Eur J Heart Fail. 2021;23:1059-1061.
    PubMed    


  989. MEHRA MR, Crandall DL, Gustafsson F, Jorde UP, et al
    Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Eur J Heart Fail. 2021;23:1226-1237.
    PubMed     Abstract available


  990. TURNER JM, Cox ZL, Testani JM
    Improving renal function during diuresis: useful information or just noise?
    Eur J Heart Fail. 2021;23:1131-1133.
    PubMed    


  991. AMMIRATI E, Varrenti M, Veronese G, Fanti D, et al
    Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab.
    Eur J Heart Fail. 2021;23:1242-1245.
    PubMed    


  992. PELLICORI P, Fitchett D, Kosiborod MN, Ofstad AP, et al
    Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2021;23:1085-1093.
    PubMed     Abstract available


  993. KUSCHYK J, Falk P, Demming T, Marx O, et al
    Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
    Eur J Heart Fail. 2021;23:1160-1169.
    PubMed     Abstract available


  994. DENIAU B, Picod A, Azibani F, Gayat E, et al
    The CLIP-based mortality score in cardiogenic shock: suitable only for cardiogenic shock?
    Eur J Heart Fail. 2021;23:1240-1242.
    PubMed    


  995. ZYMLINSKI R, Biegus J, Ponikowski P
    Not all fluid overloads are the same: some practical considerations for better decongestion.
    Eur J Heart Fail. 2021;23:1106-1109.
    PubMed    


  996. KARAMICHALAKIS N, Ikonomidis I, Parissis J, Simitsis P, et al
    Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy.
    Eur J Heart Fail. 2021;23:1238-1240.
    PubMed    


  997. FINOCCHIARO G, Sinagra G, Papadakis M, Carr-White G, et al
    The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era.
    Eur J Heart Fail. 2021;23:1062-1067.
    PubMed    


    June 2021
  998. PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
    Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
    PubMed     Abstract available


  999. MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
    Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
    PubMed     Abstract available


  1000. YAFASOVA A, Butt JH, Rorth R
    Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
    PubMed    


  1001. GREENE SJ, Fonarow GC
    Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
    PubMed    


  1002. ABDIN A, Bohm M
    Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
    PubMed    


  1003. KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
    Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
    PubMed     Abstract available


  1004. ANKER SD, Khan MS, Shahid I, Filippatos G, et al
    SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
    PubMed    


  1005. SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
    Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
    PubMed     Abstract available


  1006. PAGNESI M, Adamo M, Sama IE, Anker SD, et al
    Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
    PubMed     Abstract available


  1007. BARATTO C, Caravita S, Parati G
    HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
    Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
    PubMed    


  1008. SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
    Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
    PubMed     Abstract available


  1009. RICHARDS AM, Pemberton CJ
    Urinary Peptides in Heart Failure - the need for care with pees and cues.
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
    PubMed    


  1010. PATEL RB, Shah SJ
    The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
    PubMed    


  1011. STOLFO D, Savarese G
    Association Between Heart Failure and Cancer: Is Gender the Answer?
    Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
    PubMed    


  1012. BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
    Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
    Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
    PubMed     Abstract available


  1013. TOMASONI D, Adamo M, Metra M
    June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment.
    Eur J Heart Fail. 2021;23:847-849.
    PubMed    


  1014. SEGAR MW, Pandey A
    Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope?
    Eur J Heart Fail. 2021;23:992-994.
    PubMed    


  1015. FERREIRA JP
    Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis.
    Eur J Heart Fail. 2021;23:945-946.
    PubMed    


  1016. RAAFS AG, Verdonschot JAJ, Henkens MTHM, Adriaans BP, et al
    The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment o
    Eur J Heart Fail. 2021;23:933-944.
    PubMed     Abstract available


  1017. GARCIA-PAVIA P, Bengel F, Brito D, Damy T, et al
    Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2021;23:895-905.
    PubMed     Abstract available


  1018. HAVERKAMP W, Butler J, Anker SD
    Can we trust a smartwatch ECG? Potential and limitations.
    Eur J Heart Fail. 2021;23:850-853.
    PubMed    


  1019. SATTAR N, Januzzi JL
    Can biomarkers help find the 'sweet spot' for treating patients with diabetes?
    Eur J Heart Fail. 2021;23:1037-1039.
    PubMed    


  1020. PARCHA V, Arora P
    Sodium-glucose co-transporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy.
    Eur J Heart Fail. 2021;23:1009-1011.
    PubMed    


  1021. GREENBERG B, Adler E, Campagnari C, Yagil A, et al
    A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:995-999.
    PubMed     Abstract available


  1022. DAMY T, Sultan MB, Witteles R
    Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:1057-1058.
    PubMed    


    May 2021
  1023. PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
    Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
    PubMed     Abstract available


  1024. BUTLER J, Yang M, Sawhney B, Chakladar S, et al
    Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
    PubMed     Abstract available


  1025. SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
    Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
    PubMed     Abstract available


  1026. SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
    PubMed     Abstract available


  1027. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
    PubMed     Abstract available


  1028. GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
    Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
    PubMed     Abstract available


  1029. FADINI GP, Avogaro A
    A simple way to spotlight hidden heart failure in type 2 diabetes?
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
    PubMed    


  1030. VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
    Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
    Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
    PubMed    


  1031. SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
    Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
    Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
    PubMed     Abstract available


  1032. VOORS AA, Mulder H, Reyes E, Cowie MR, et al
    Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
    Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
    PubMed     Abstract available


  1033. BRAUNWALD E
    The War on Heart Failure.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
    PubMed    


  1034. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
    PubMed    


  1035. BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
    Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
    PubMed     Abstract available


  1036. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 8. doi: 10.1002/ejhf.2214.
    PubMed    


  1037. TOCCHETTI CG, Mercurio V, Maack C
    The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
    Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
    PubMed    


  1038. HILL L, Lambrinou E, Antoniou S
    Optimizing evidence-based heart failure medication: Every contact counts.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
    PubMed    


  1039. ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
    Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
    PubMed    


  1040. LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
    The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
    PubMed     Abstract available


  1041. MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
    Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
    PubMed     Abstract available


  1042. MULDER BA, van Veldhuisen DJ, Rienstra M
    Sudden cardiac death in heart failure: more than meets the eye.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
    PubMed    


  1043. HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
    Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
    PubMed     Abstract available


  1044. TOMASONI D, Adamo M, Metra M
    May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:691-692.
    PubMed    


  1045. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    PubMed    


  1046. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    PubMed    


  1047. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    PubMed     Abstract available


  1048. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    PubMed    


  1049. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    PubMed    


  1050. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    PubMed    


  1051. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    PubMed    


  1052. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    PubMed    


    April 2021
  1053. FRASER AG, Tschope C, de Boer RA
    Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
    Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
    PubMed    


  1054. BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
    Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
    PubMed    


  1055. FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
    Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
    Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
    PubMed     Abstract available


  1056. HE T, Mischak M, Clark AL, Campbell RT, et al
    Urinary peptides in heart failure: a link to molecular pathophysiology.
    Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
    PubMed     Abstract available


  1057. FINE NM, Howlett JG
    Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
    PubMed    


  1058. NASSIF M, Butler J
    Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
    PubMed    


  1059. JERING KS, Claggett B, Pfeffer MA, Granger C, et al
    Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
    Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
    PubMed     Abstract available


  1060. BAYES-GENIS A, Lupon J
    Heart failure is ejection fraction in motion.
    Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
    PubMed    


  1061. ABRAHAM WT
    Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
    Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
    PubMed    


  1062. SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
    The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
    PubMed    


  1063. FERREIRA JP
    Cognitive function assessment for personalized heart failure disease management programmes.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
    PubMed    


  1064. GIRERD N, Felker GM
    The lower is not always the better: a better understanding of loop diuretics in heart failure.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
    PubMed    


  1065. BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
    A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
    Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
    PubMed     Abstract available


  1066. PAGNESI M, Adamo M, Metra M
    April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
    Eur J Heart Fail. 2021;23:505-506.
    PubMed    


  1067. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    PubMed    


  1068. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    PubMed     Abstract available


  1069. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    PubMed    


  1070. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    PubMed     Abstract available


  1071. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    PubMed    


  1072. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    PubMed     Abstract available


  1073. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    PubMed    


  1074. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    PubMed    


    March 2021
  1075. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
    Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
    PubMed     Abstract available


  1076. HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
    Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
    PubMed     Abstract available


  1077. BARAKAT MF, Amin-Youseff G, Okonko DO
    Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
    PubMed    


  1078. UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
    Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
    PubMed     Abstract available


  1079. KALOGEROPOULOS AP, Hotelling J, Skopicki HA
    Blood Counts: Targeting Anemia in Patients with Heart Failure.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
    PubMed    


  1080. KHAN MS, Fonarow GC, Greene SJ
    SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
    PubMed    


  1081. WAN SH, Pandey A
    Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
    PubMed    


  1082. KHAN MS, Usman MS, Butler J
    Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
    PubMed    


  1083. PACKER M
    What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
    PubMed    


  1084. BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
    Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
    PubMed     Abstract available


  1085. METRA M, Coats AJS
    Why we love heart failure. An introduction to the universal definition of heart failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
    PubMed    


  1086. GUPTA P, Voors AA, Patel P, Lane D, et al
    Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
    Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
    PubMed    


  1087. CHIONCEL O, Stewart Coats AJ
    National Heart Failure Societies Summit 2020.
    Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
    PubMed    


  1088. BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
    Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
    Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
    PubMed     Abstract available


  1089. RAVERA A, Santema BT, Sama IE, Meyer S, et al
    Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
    PubMed     Abstract available


  1090. TROMP J, Bryant JA, Jin X, van Woerden G, et al
    Epicardial fat in heart failure with reduced versus preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
    PubMed    


  1091. ZIAEIAN B, Fonarow GC
    Making heart failure count.
    Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
    PubMed    


  1092. PACKER M, McMurray JJV
    Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
    PubMed     Abstract available


  1093. PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
    Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
    PubMed    


  1094. WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
    Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
    PubMed     Abstract available


  1095. WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
    Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
    PubMed     Abstract available


  1096. CARAVITA S, Senni M, Parati G
    Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
    Eur J Heart Fail. 2021;23:493-494.
    PubMed    


  1097. TOMASONI D, Petrie MC, Adamo M, Metra M, et al
    Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
    Eur J Heart Fail. 2021;23:486-488.
    PubMed    


  1098. MAHJOUB Y, Rodenstein DO, Jounieaux V
    The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
    Eur J Heart Fail. 2021;23:493.
    PubMed    


  1099. PAGNESI M, Adamo M, Metra M
    March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
    Eur J Heart Fail. 2021;23:347-349.
    PubMed    


  1100. CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
    Characterization of NT-proBNP in a large cohort of COVID-19 patients.
    Eur J Heart Fail. 2021;23:456-464.
    PubMed     Abstract available


  1101. GARG A, Seeliger B, Derda AA, Xiao K, et al
    Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
    Eur J Heart Fail. 2021;23:468-475.
    PubMed     Abstract available


  1102. SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
    Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Eur J Heart Fail. 2021;23:476-485.
    PubMed     Abstract available


  1103. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    PubMed    


  1104. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    PubMed    


  1105. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    PubMed    


  1106. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    PubMed     Abstract available


  1107. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    PubMed     Abstract available


  1108. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    PubMed    


  1109. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    PubMed    


    February 2021
  1110. DAUW J, Martens P, Tersalvi G, Schouteden J, et al
    Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
    Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
    PubMed     Abstract available


  1111. PASCUAL-FIGAL DA
    Biochemical or clinical heart failure, not so simple.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
    PubMed    


  1112. SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
    The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
    PubMed     Abstract available


  1113. VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
    Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
    PubMed     Abstract available


  1114. TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
    Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
    PubMed     Abstract available


  1115. LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
    Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
    Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
    PubMed     Abstract available


  1116. TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
    SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
    PubMed     Abstract available


  1117. BHATIA K, Jain V, Gupta K, Bansal A, et al
    Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
    PubMed     Abstract available


  1118. SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
    Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
    PubMed     Abstract available


  1119. FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
    Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
    PubMed     Abstract available


  1120. BOZKURT B, Coats A, Tsutsui H
    A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
    Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
    PubMed    


  1121. CHIONCEL O, Ambrosy AP, Maggioni AP
    Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
    PubMed    


  1122. BECHER PM, Schrage B, Ferrannini G, Benson L, et al
    Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
    PubMed     Abstract available


  1123. BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
    Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
    Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
    PubMed     Abstract available


  1124. RICHARDS AM
    Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
    PubMed    


  1125. ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
    The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
    PubMed     Abstract available


  1126. MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
    Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
    PubMed     Abstract available


  1127. ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
    Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
    PubMed     Abstract available


  1128. VOLTERRANI M, Perrone V, Degli Esposti L
    Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
    PubMed    


  1129. PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
    One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
    PubMed     Abstract available


  1130. COTTER G, Davison BA, Edwards C, Takagi K, et al
    Acute Heart Failure Treatment - A Light at The End of the Tunnel?
    Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
    PubMed    


  1131. CLERICO A, Aimo A, Passino C
    The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
    Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
    PubMed    



  1132. Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
    Eur J Heart Fail. 2021;23:345.
    PubMed    



  1133. Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
    Eur J Heart Fail. 2021;23:345.
    PubMed    


  1134. SMITH N, Tampakakis E
    COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
    Eur J Heart Fail. 2021;23:208-210.
    PubMed    


  1135. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    PubMed    


  1136. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    PubMed    


  1137. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    PubMed    


  1138. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    PubMed     Abstract available


  1139. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    PubMed    


  1140. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    PubMed    


  1141. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    PubMed    


  1142. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    PubMed    


  1143. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    PubMed     Abstract available


  1144. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    PubMed    


  1145. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    PubMed    


  1146. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    PubMed     Abstract available


  1147. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    PubMed     Abstract available


  1148. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    PubMed     Abstract available


  1149. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    PubMed     Abstract available


  1150. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    PubMed     Abstract available


    January 2021
  1151. CANEPA M, Ameri P, Lainscak M
    COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
    PubMed    


  1152. PETRIE MC, Lee MMY, Docherty KF
    Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
    PubMed    


  1153. DOCHERTY KF, Vaduganathan M
    OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
    Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
    PubMed    


  1154. SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
    Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
    PubMed     Abstract available


  1155. KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
    Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
    PubMed     Abstract available


  1156. KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
    Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
    PubMed     Abstract available


  1157. REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
    Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
    PubMed     Abstract available


  1158. KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
    Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
    PubMed     Abstract available


  1159. TOMASONI D, Adamo M, Metra M
    January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
    Eur J Heart Fail. 2021;23:1-2.
    PubMed    


  1160. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    PubMed    


  1161. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    PubMed    


  1162. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    PubMed     Abstract available


  1163. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    PubMed    


    December 2020
  1164. PABEL S, Hamdani N, Sossalla S
    A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
    Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
    PubMed    


  1165. DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
    Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
    PubMed     Abstract available


  1166. ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
    Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
    Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
    PubMed    


  1167. MORIYAMA H, Kohno T, Kohsaka S
    Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
    PubMed    


  1168. DAVISON BA, Senger S, Sama IE, Koch GG, et al
    Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
    PubMed     Abstract available


  1169. SCHNEIDER B, Ong P
    Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
    PubMed    


  1170. PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
    OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
    PubMed     Abstract available


  1171. DOCHERTY KF, McMurray JJV
    SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
    Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
    PubMed    


  1172. ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
    Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
    PubMed     Abstract available



  1173. Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
    Eur J Heart Fail. 2020;22:2399.
    PubMed    


  1174. WANG N, Cao J, Lal S
    COVID-19: getting to the heart of the matter.
    Eur J Heart Fail. 2020;22:2216-2218.
    PubMed    


  1175. TOMASONI D, Adamo M, Metra M
    December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
    Eur J Heart Fail. 2020;22:2173-2174.
    PubMed    


  1176. LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
    Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Eur J Heart Fail. 2020;22:2248-2257.
    PubMed     Abstract available


  1177. BHATT AS, Vaduganathan M
    Discovery and care innovation amidst a pandemic.
    Eur J Heart Fail. 2020;22:2202-2204.
    PubMed    


  1178. FARMAKIS D
    Is cardio-oncology a rapidly growing field of precision medicine?
    Eur J Heart Fail. 2020;22:2310-2313.
    PubMed    


  1179. KONSTAM MA
    Ventricular remodelling: an equal-opportunity prognosticator.
    Eur J Heart Fail. 2020;22:2269-2271.
    PubMed    


    November 2020
  1180. PACKER M, Butler J, Filippatos G, Zannad F, et al
    Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
    Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
    PubMed     Abstract available


  1181. GREENBERG B, Janvanishstaporn S, Feng S
    Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
    PubMed    


  1182. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
    PubMed     Abstract available


  1183. BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
    Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
    PubMed     Abstract available


  1184. ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
    Advanced cancer is also a heart failure syndrome - an hypothesis.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
    PubMed     Abstract available


  1185. MADELAIRE C, Kristensen SL
    Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
    PubMed    


  1186. D'AMARIO D, Borovac JA, Crea F
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
    PubMed    


  1187. HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
    Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
    PubMed     Abstract available


  1188. CANEPA M, Kapelios CJ, Lund LH
    Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
    PubMed    


  1189. DONAL E, Galli E, Paven E, Sade LE, et al
    Haemodynamic evaluation: a key tool for heart failure management.
    Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
    PubMed    


  1190. BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
    Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
    Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
    PubMed     Abstract available


  1191. TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
    Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
    PubMed     Abstract available


  1192. VERNOOY K, Brunner-La Rocca HP
    The importance of the electrocardiographic follow-up in heart failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
    PubMed    


  1193. DUSI V, Vitolo V, Frigerio L, Totaro R, et al
    The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
    PubMed    


  1194. STARWALT JL, Ho AF, Wang H
    Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
    PubMed    


  1195. KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
    Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
    PubMed    


  1196. KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
    In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
    Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
    PubMed     Abstract available


  1197. FABRIS E, Sinagra G, Valgimigli M
    Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
    Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
    PubMed    


  1198. VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
    Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Eur J Heart Fail. 2020;22:2049-2055.
    PubMed     Abstract available



  1199. Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
    Eur J Heart Fail. 2020;22:2172.
    PubMed    


  1200. JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
    Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
    Eur J Heart Fail. 2020;22:2047-2048.
    PubMed    


  1201. RICHARDS AM
    Beating the bushes for biomarkers.
    Eur J Heart Fail. 2020;22:2075-2077.
    PubMed    


  1202. OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
    Cancer therapy and the heart; the necessity to calibrate risk.
    Eur J Heart Fail. 2020;22:1961-1965.
    PubMed    


  1203. SEFEROVIC PM, Polovina M
    In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
    Eur J Heart Fail. 2020;22:2035-2037.
    PubMed    


  1204. KEHLER DS, Arora RC
    Frailty and the failing heart do not travel alone.
    Eur J Heart Fail. 2020;22:2120-2122.
    PubMed    


  1205. COWIE MR
    DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2020;22:2157-2159.
    PubMed    


    October 2020
  1206. KOUDSTAAL S, Den Ruijter HM, Peters SAE
    Sex Differences and Heart Failure - A Story of Two Tales.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
    PubMed    


  1207. WAGNER J, Ambrosy AP
    Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
    PubMed    


  1208. AHMED F
    Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
    PubMed    


  1209. PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
    Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
    PubMed     Abstract available


  1210. WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
    Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
    PubMed     Abstract available


  1211. KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
    Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
    PubMed     Abstract available


  1212. SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
    High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
    PubMed     Abstract available


  1213. BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
    A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
    PubMed     Abstract available


  1214. CULIC V, Velat I
    Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
    PubMed    


  1215. LABROSCIANO C, Horton D, Air T, Tavella R, et al
    Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
    PubMed     Abstract available


  1216. DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
    Common Mechanistic Pathways in Cancer and Heart Failure.
    Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
    PubMed     Abstract available


  1217. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
    Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
    PubMed     Abstract available


  1218. KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
    Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
    Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
    PubMed     Abstract available


  1219. KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
    Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
    Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
    PubMed    


  1220. SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
    Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
    PubMed     Abstract available


  1221. ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
    Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
    Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
    PubMed     Abstract available


  1222. PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
    The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
    PubMed     Abstract available


  1223. COATS AJS
    Pulmonary artery pressure monitoring, a reality for Europe?
    Eur J Heart Fail. 2020;22:1905-1906.
    PubMed    


  1224. GUSTAFSSON F, Lund LH, Metra M
    If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
    Eur J Heart Fail. 2020;22:1888-1890.
    PubMed    


  1225. PARIKH PB, Tsigkas G, Kalogeropoulos AP
    Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
    Eur J Heart Fail. 2020;22:1875-1877.
    PubMed    


  1226. ADAMO M, Metra M, Alfieri O
    Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
    Eur J Heart Fail. 2020;22:1849-1851.
    PubMed    


  1227. GRIFFIN JM, Maurer MS
    Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
    Eur J Heart Fail. 2020;22:1863-1865.
    PubMed    


  1228. SCHNEIDER M, Mascherbauer J
    Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
    Eur J Heart Fail. 2020;22:1837-1839.
    PubMed    


    September 2020
  1229. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
    Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
    PubMed     Abstract available


  1230. AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
    Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
    PubMed     Abstract available


  1231. TOMASONI D, Adamo M, Metra M
    September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
    Eur J Heart Fail. 2020;22:1493-1494.
    PubMed    


  1232. KALOGEROPOULOS AP, Simitsis P, Skopicki HA
    Secrets of spironolactone: continuing insights from TOPCAT Americas.
    Eur J Heart Fail. 2020;22:1625-1627.
    PubMed    


  1233. RITCHIE R, Galougahi KK, Figtree GA
    Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
    Eur J Heart Fail. 2020;22:1582-1585.
    PubMed    


  1234. BISTOLA V, Polyzogopoulou E, Parissis J
    A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
    Eur J Heart Fail. 2020;22:1646-1648.
    PubMed    


  1235. ZIAEIAN B, Butler J, Fonarow GC
    With great power comes great... reliability.
    Eur J Heart Fail. 2020;22:1708-1710.
    PubMed    


    August 2020
  1236. HOWLETT JG
    The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020;22:1483-1485.
    PubMed    


  1237. MONTGOMERY RA, Tang WHW
    A means to an end: the promise of tracking natriuresis with diuretic therapy.
    Eur J Heart Fail. 2020;22:1448-1450.
    PubMed    


    July 2020
  1238. VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
    Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
    PubMed     Abstract available


  1239. EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
    Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
    Eur J Heart Fail. 2020;22:1283-1284.
    PubMed    


  1240. SEFEROVIC PM, Asanin M, Polovina M
    Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
    Eur J Heart Fail. 2020;22:1122-1124.
    PubMed    


  1241. GORTER TM, van Veldhuisen DJ, Dickinson MG
    Right-sided cardiac disease: no longer the 'dark side of the heart'.
    Eur J Heart Fail. 2020;22:1226-1229.
    PubMed    


  1242. INCIARDI RM, Rossi A
    Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
    Eur J Heart Fail. 2020;22:1211-1213.
    PubMed    


  1243. SEFEROVIC PM, Polovina MM
    A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
    Eur J Heart Fail. 2020;22:1108-1110.
    PubMed    


  1244. MICHEL L, Rassaf T, Totzeck M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
    Eur J Heart Fail. 2020;22:1285-1286.
    PubMed    


  1245. AIMO A, Fabiani I, Emdin M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
    Eur J Heart Fail. 2020;22:1284-1285.
    PubMed    


  1246. TER MAATEN JM, Said F, Maass AH
    Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2020;22:1171-1173.
    PubMed    


  1247. ZWEERINK A, Allaart CP, Burri H
    Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
    Eur J Heart Fail. 2020;22:1273-1275.
    PubMed    


    June 2020
  1248. KLEIN P, Anker SD, Wechsler A, Kelle S, et al
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
    Eur J Heart Fail. 2020;22:1053-1054.
    PubMed    


  1249. FERREIRA JP
    Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
    Eur J Heart Fail. 2020;22:1006-1008.
    PubMed    


  1250. BONIOS MJ, Kogerakis N, Adamopoulos SN
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
    Eur J Heart Fail. 2020;22:1053.
    PubMed    


    May 2020
  1251. HAWKINS NM, Osmanska J, Petrie MC
    Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
    Eur J Heart Fail. 2020;22:868-870.
    PubMed    


  1252. BOLLI R, Kahlon A
    Time to end the war on cell therapy.
    Eur J Heart Fail. 2020;22:893-897.
    PubMed    


  1253. FURTADO RHM, Bergmark B
    Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
    Eur J Heart Fail. 2020;22:880-883.
    PubMed    


  1254. CHATTERJEE NA, Levy WC
    Sudden cardiac death after myocardial infarction.
    Eur J Heart Fail. 2020;22:856-858.
    PubMed    


    April 2020
  1255. DE LUCA L, Savonitto S
    Composite trends of cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2020;22:673-675.
    PubMed    


    March 2020
  1256. STEWART COATS AJ
    Validating the HFA-PEFF score - or how to define a disease?
    Eur J Heart Fail. 2020;22:428-431.
    PubMed    


  1257. WESTIN O, Fosbol E, Gustafsson F
    Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:516-518.
    PubMed    


  1258. SHEN L, Jhund P, McMurray J
    Dyslipidaemia, a factor worthy of adjustment: reply.
    Eur J Heart Fail. 2020;22:564-565.
    PubMed    


  1259. SKELIN M, Lucijanic M, Lucijanic J
    Dyslipidaemia, a factor worthy of adjustment.
    Eur J Heart Fail. 2020;22:564.
    PubMed    


    February 2020
  1260. GRODIN JL, Rao A, Zaha VG
    Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
    Eur J Heart Fail. 2020;22:347-349.
    PubMed    


  1261. MAGLIOCCA A, Omland T, Latini R
    Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
    Eur J Heart Fail. 2020;22:300-302.
    PubMed    


  1262. RAJU B, McCullough PA
    Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
    Eur J Heart Fail. 2020;22:287-289.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.